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1.1 Sweet “omics” of the 21st century
It has long been believed that the biological functions of carbohydrates were
limited to the use thereof as either structural elements (like in the case of e.g.
cellulose and chitin) or sources of energy (e.g. glycogen and starch). These have
already for more than fifty years been characterized as important biomolecules, even
if only because they are (by mass) by far the most important class of biomolecules
on Earth. In recent years, this view has been significantly broadened, as deep insight
has been gained into the many diverse roles of saccharides as bio-informative
molecules. This deepened understanding has opened the research field of glycans,
in which the term “glycan” refers to a polysaccharide or oligosaccharide, or is used to
refer to the carbohydrate portion of a glycoconjugate, such as a glycoprotein,
glycolipid, or a proteoglycan. It has become evident that glycans play a critical role in
the mediation of a great number of biological processes including neuronal
development,1 hormonal activities,2 inflammation,3 immunological response,4-6 tumor
metastasis,7 and fertilization.8 Appreciation of the complexity of these biomolecules,
combined with an increased understanding of their function, resulted at the
beginning of this century in the appearance of an important new area of research,
named “glycomics”.9, 10 Analogous to genomics and proteomics, glycomics is the
systematic elucidation of the “glycome” - the totality of glycans and their interactions
within a given cell type or organism.
The glycome is, in fact, much more complex than both the proteome and
genome. This becomes evident if one considers the complexity in oligosaccharides,
even very simple ones. Thus, glucose (1, Figure 1.1) can be connected to another
sugar molecule at any of the five hydroxyl groups, and in addition, the
stereochemistry at the anomeric position can be α or β. Both linear and branched
structures are possible for oligosaccharides, and in fact many of these combinations
are known and linked to different biological functions. In contrast, amino acids (for
example methionine 2) and nucleotides (e.g. deoxycytidine monophosphate 3) can
form only linear oligo- and polymers, as there is but one way of connection in both
cases.
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Figure 1.1 Possibilities for connectivity in biological monomers. Functional groups available
for substitution are depicted in bold.
This does not downplay the already staggering complexity obtainable with amino
acids or the genetic material, but points to the fact that glycomics compares to either
of them like chess compares to draughts. Thus, even short glycans have a
significantly greater potential for structural diversity than peptides and
oligonucleotides. It has been calculated that for six sugar monomers >1012
oligomeric structures are possible, while this number is 4096 for hexanucleotides and
6*107 for hexapeptides.11 It is not therefore surprising that nature uses carbohydrates
as more than just building blocks or biochemical fuel.
In all range of organisms, from bacteria to mammals, the information-rich
oligosaccharides generally occur in the form of glycoconjugates, like glycoproteins or
glycolipids. Most work in glycomics to date has been focused on mammalian glycans
that are built up from ten different monosaccharide units. The structures of these
building blocks are given in Figure 1.2. This Figure also presents the generally
accepted three-letter codes and the symbolic notations introduced by Ajit Varki9 and
adopted by the groups interested in presenting the databases of glycan structures
(e.g. the Consortium for functional glycomics12).
Whilst glycoproteins are the major glycoconjugates in many types of animal
tissues, glycolipids dominate the glycans of the brain and are found to a significant
extent in all other tissues.13
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Figure 1.2 Monosaccharide building blocks of mammalian glycans: glucose (Glc), galactose
(Gal),  mannose (Man), fucose (Fuc), N-acetylglucosamine (GlcNAc), N-acetylgalactosamine
(GalNAc), xylose (Xyl), glucuronic acid (GlcA), iduronic acid (IdA), N-acetylneuraminic acid
(NeuAc).
1.2 Gangliosides
Glycolipids are thus ubiquitously found in animals, plants and microorganisms,
but this class of glycoconjugates is built up in there from structurally very
heterogeneous compounds. The most important subtype of glycolipids is likely
comprised by glycosphingolipids, the conjugates of the poorly reactive hydrophobic
ceramide moiety with metabolically produced highly active (oligo-)saccharide
residues. The simplest compound of this group, galactosylceramide (Figure 1.3),
often referred to as cerebroside, is the principal glycosphingolipid in brain tissue.
Figure 1.3 The structure of a glycosphingolipid by the example of cerebroside.
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Gangliosides are more complex glycosphingolipids produced naturally by the
means of consecutive glycosylations of the ceramide. They contain at least one
molecule of sialic acid attached to a galactose or hexosamine residue. The most
convenient and frequently used nomenclature of gangliosides is the system
proposed by Svennerholm.14, 15 According to this system, the names of gangliosides
are derived from combining the letter G (as the indicator of the compound’s
belonging to the gangliosides) and one of the letters М, D, Т, Q or P that reveal the
number of sialic acid residues in the molecule (1, 2, 3, 4 or 5, respectively). To this
combination, a cipher (sometimes accompanied with a letter) is added to denote the
compound. According to this nomenclature, compound 4 (Fig. 1.4 A) is denoted as
GM1, while the IUPAC rules recommend II3-α-Neu5Ac-Gg4Cer. At present, more
than 30 different gangliosides have been identified.16 A schematic overview of
selected brain gangliosides through the scheme of biosynthesis thereof is given in
Figure 1.4 B.
Figure 1.4 Structure of the ganglioside GM1 (A), and biosynthetic pathways of brain
gangliosides (B).17 Minor brain gangliosides are depicted fainted.
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Though not (yet?) found in plants and microorganisms, gangliosides are
widespread in mammalian tissues and are particularly abundant in the plasma
membranes of neuronal cells, where they constitute ca. 6 % (mass-based) of the
total contents of lipids. Gangliosides function through molecular recognition at the
cell surfaces and modulation of the activities of membrane proteins, which is the
subject of an excellent recent review.17 Thus, they participate in the processes of cell
growth regulation, adhesion, intercellular interaction and immune response. They
may act as receptors for toxins18 (e.g. GM1 is a key part of the cholera toxin
receptor), peptide hormones, antibodies, several viruses and interferon, and it is not
unlikely that in the coming years the number of studied receptor roles of gangliosides
will continue to increase rapidly.
1.3 Molecular mimicry
Guillain-Barré Syndrome (GBS),19 is the most frequent cause of acute
neuromuscular paralysis that can be triggered by a Campylobacter jejuni infection,
e.g. following from common food poisoning. GBS is an autoimmune disease;
“autoimmune” means that the immune system by mistake attacks myelin or axons,
the nerve conduits for communication with the brain. Such a dramatic “mistaken
immune attack” is likely caused by the structural resemblance of the polysaccharides
that are present on the surface of Campylobacter jejuni to the glycoconjugates of the
human nerve tissues (Figure 1.5).20 This similarity is referred to as “molecular
mimicry”, and this is the cause of the dual recognition by the immune system of a
bacteria’s outer structure and of a host antigen. This unfortunate dual recognition
explains the mechanism by which infections trigger the formation of cross-reactive
antibodies that can lead to autoimmune diseases.21 It has been found, that GBS is a
true case of molecular mimicry between lipopolysaccharides of C. jejuni and
gangliosides (mainly GM1 and GD1a) of the human nerves.21-23
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Figure 1.5 Molecular mimicry of human gangliosides and bacterial lipopolysaccharides20
Apart from causing diseases, such ganglioside – antibody recognition events can
also be the basis for cure and diagnostics.24 Thus, the diagnostics of GBS is
currently based on determining the presence of anti-GM1 antibodies in enzyme-
linked immunosorbent assays (ELISAs) that use bovine brain-derived GM1.25
1.4 Glycochemist’s tools for glycomics
Generally speaking, the solutions of many problems are often found within the
same phenomena that cause the problem. Therefore, it is of importance to
investigate those phenomena in minute detail, and to be able to reproduce them
where relevant. Thus, to map out the interactions of a glycan in biological systems,
one should first have this glycan available, either by isolation from natural sources,
or synthetically. Of equal importance is the complete characterization of the
compound in question. As soon as a carbohydrate structure of biological interest is
elucidated, and isolated or synthesized, several tools26 to investigate its function are
available in the arsenal of glycochemists. Figure 1.6 gives an example of these tools,
including (a) multivalent conjugates (molecular scaffold- or nanoparticle based), (b)
monovalent fluorescent conjugates, (c) glycans bearing affinity tags, (d)
glycoproteins and carbohydrate vaccines, (e) surface-bound glycans for ELISA,
microarray and SPR, and (f) neoglycoconjugates that will emerge in the (near)
future.
CHAPTER 1
8
synthesis
R
questionquestion
biotin
a
b
c
d
e
f
O
HO OH
OHOH O
O NHAc
O
OH
O
O OH
OH
O
O
OH
HO2C
HO
HO
HO
AcHN
OOH
HO OH O
Ceramide
answers
answers
?
gained information
gained information
OH
Figure 1.6 Tools for glycomics. , , Δ and  represent sugar moieties added to an
oligosaccharide synthetically. Those may or may not be the authentic monosaccharide
blocks of the glycan under investigation.
1.5 Outline of the thesis
The subjects of this thesis are the analogues of human gangliosides relevant in
Guillain-Barré Syndrome and other diseases.  These are primarily viewed through
the prism of prospects of their application for detection and clearance of detrimental
proteins. Figure 1.6, being general, also reflects the flow of research done within this
framework. Thus, Chapter 2 addresses the challenge of efficient synthesis of ω-
functionalized alkyl lactosides, which are the starting compounds for preparation of
ganglioside mimics in Chapters 3 and 4. Chapters 3 and 4 present chemo-enzymatic
syntheses of several functionalized ganglioside analogues. Chapter 3 describes
alkene-, alkyne-, and azido – appended mimics of gangliosides GM3, GM2 and
GM1, and Chapter 4 deals with biotinylated analogues of GM3, GM2, GM1, GD1a
and GalNAc-GD1a. The synthesis of ganglioside analogues is followed by a
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complete NMR characterization thereof. A strategy for such characterization is
proposed in Chapter 3.
Chapter 5 presents the synthesis of divalent, tetravalent and octavalent GM2 and
GM1 gangliosides for in-solution inhibition of cholera toxin and anti-GM1 antibodies.
The inhibitory potencies of the prepared glycodendrimers are evaluated.
The potential of these ganglioside mimics to detect toxins and antibodies is
studied in Chapters 3 - 6. Chapter 3 presents results of an ELISA based on an
alkene-functionalized GM1 that is non-covalently adsorbed. In chapter 4, biotin-
appended GM1 was coated on streptavidin-modified ELISA plate and used for
detection of heat-labile E. coli toxin. Chapter 5 focuses as said on cholera and anti-
GM1 antibodies, and finally, Chapter 6 describes the proof of principle for the
detection of IgG and IgM antibodies in sera of neuropathy patients.
Chapter 7 summarizes the results presented in Chapters 2-6 and places them in
the context of contemporary research on the boundary of Chemistry and Biology.
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CHAPTER 2
Efficient Glycosylations with Sugar Perpivalates
and Trichloroacetimidate Galactosamine Donors*
Abstract – This Chapter introduces 1-O-Pivaloyl glycosides as efficient glycosyl donors, as
shown by using the perpivaloylated derivatives of lactose, galactose and glucose in the
direct ZnCl2-promoted glycosylations of various alcohols. The corresponding glycosides
were isolated in good yields and with high -selectivity. In addition, we investigated the
coupling reaction of glycosyl donors N-trichloroethoxycarbonyl-galactosamine-O-
trichloroacetimidate and N-p-nitrobenzyloxycarbonyl-galactosamine-O-trichloroacetimidate
with the 4´-OH of lactose derivates to synthesize key intermediates of asialo GM2
analogues, and found that the glycosylation yields could be increased to 90% or more in all
investigated cases.
* This chapter is based on:
- Pukin, A. V.; Zuilhof, H., SynLett 2009, 2009 (20), 3267-3270;
- Sun, B.; Pukin, A. V.; Visser, G. M.; Zuilhof, H., Tetrahedron Lett. 2006, 47 (41), 7371-7374.
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2.1 Introduction
The stereoselective formation of glycosidic bonds is a crucial process in most
oligosaccharide and glycoconjugate syntheses.1-4 A large variety of glycosylation methods
has been developed to address the challenges of an efficient (i.e. high-yielding, regio- and
stereoselective) reaction between a glycosyl donor and a glycosyl acceptor.5-17 In this
research area, the development of general and simple modes of glycosylation of lipids
(ceramide and its analogues, steroids, long-chain fatty alcohols, etc.) is of continuous
interest in view of the biological relevance of glycolipids18-23 and numerous applications
thereof, e.g. in the field of biosensing.24-30
Alkyl glycosides are most commonly prepared by the well-established Koenigs-Knorr
reaction31, 32 of O-acetyl-protected glycosyl bromides and alkanols, in the presence of
promoters such as silver or mercury salts. Alternatively, for the glycosylations of alcohols
with a lower nucleophilicity (e.g. ceramide, long-chain fatty alcohols), a variety of glycosyl
donors has been used, including glycosyl trichloroacetimidates,33 thioglycosides,34-36 glycosyl
fluorides (for both chemical37 and enzymatic38 syntheses), iodides,39 and others.40, 41 Among
the plethora of glycosyl donors, sugar peracetates are frequently seen as the benchmark,42-
48 due to their stability and the ease of preparation (one-step reaction from an unprotected
sugar). The activation of these compounds can be achieved in the presence of a Lewis acid
(such as SnCl4, BF3Et2O, ZnCl2 or TMSOTf), and the products are preferentially 1,2-trans-
glycosides, as a result of the anchimeric assistance of the C-2 acetoxy group (Scheme 2.1,
A).
However, the yields of glycosylations by sugar peracetates are frequently modest (30 –
40 %), due to the formation of orthoesters49-51 in a side reaction that is common for glycosyl
donors bearing an acetyl group at C-2 (Scheme 2.1, B). To avoid such orthoester formation,
this acetyl group is often replaced by a sterically more demanding benzoyl or pivaloyl
group.52-64
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Scheme 2.1 Glycosylation reaction with a donor bearing an acetyl group at C-2. Anchimeric
assistance of such a group leads to the formation of 1,2-trans-glycoside (route A, bold arrow (a)). At
the same time, a side reaction may lead to an orthoester, which finally results in the formation of by-
products, e.g. anomeric mixtures of 2-O-deprotected glycosides (route B, arrow (b)).
In the course of our ongoing studies on the synthesis65-67 of ganglioside analogues for
various applications on surfaces68, 69 or in solution,70, 71 a highly efficient preparation of -
functionalized alkyl lactosides was required. Such lactosides are particularly useful as
starting compounds for the chemoenzymatic syntheses of the various ganglioside structures
with a specifically designed aglycone. The functionalized aglycone allows for the attachment
of the carbohydrates onto various solid65, 68, 69 and molecular70, 71 scaffolds, while the lactose
moiety - as a structural part of the human gangliosides - represents an excellent starting
point for the enzymes to construct the target oligosaccharides.66 However, unlike in the
syntheses of e.g. glucosides and galactosides, glycosylations of fatty alcohols by fully or
partially acetylated lactose donors are largely ineffective in terms of yields and -selectivity.4,
48 In addition, the preparation of an efficient lactose donor may be laborious.72 This therefore
leaves a demand for a simple and high-yielding method.
Here we report a convenient procedure for the direct high-yield glycosylation of -
functionalized alcohols via the use of perpivaloylated sugars (including lactose) as glycosyl
donors. This procedure combines the ease of preparation of peracylated glycosyl donors
with the advantageous use of O-pivaloyl protection at C-2.63, 64 To the best of our knowledge,
this is also the first report of the use of glycosyl donors with other than acetyl/benzoyl-
derived 1-O-acyl protection.
The issue of an efficient glycosylation also comes up in the synthesis of asialo-GM2
(GA2) derivatives. This sugar is only a minor brain glycolipid (see Chapter 1, Figure 1.4), but
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it is widely involved in processes of bacterial adhesion. Thus, it is a putative adhesion
molecule for Moraxella catarrhalis - an important pathogen of respiratory and middle ear
infections,73 and several pulmonary pathogens – including Pseudomonas aeruginosa,
Haemophilus influenzae, and Staphylococcus aureus – have been shown to bind to the GA2
epitope present as part of glycolipids on the surface of lung tissue.74 In addition, GA2
displays specific binding to the cell wall of gonorrhoea bacteria. To allow the application of
this sugar, e.g. in future tests of such a sexually transmitted disease, or at the very early
stage of infection as an attractive alternative to the use of antibiotics,75 we wondered
whether we could develop a generic glycosylation reaction leading to this material, given the
substantial challenge that is the low reactivity of the lactose 4’-OH towards glycosylation.
The second part of this chapter outlines the advantageous use for this purpose of a 1-O-
trichloroacetimidate galactosamine donor, in which the amino group is protected in a form of
a carbamate (2,2,2-trichloroethyl or p-nitrobenzyl).
2.2 Results and Discussion
2.2.1 Glycosylations with anomeric pivalates
In this study, perpivaloylated derivatives of lactose, glucose and galactose were used
(Figure 2.1). -Lactose octapivalate (1) was prepared by reaction of lactose with
trimethylacetyl chloride in pyridine for 5 days at 80 °C. Shorter reaction times lead to an
incomplete pivaloylation. -Glucose pentapivalate (2a) was obtained in a similar fashion. The
formation of 2a has been reported in a triethylamine-catalyzed reaction of glucose and
trimethylacetyl chloride in CH2Cl2.58 However, in our hands that procedure primarily lead to
the isolation of the thermodynamically more stable -anomer of glucose pentapivalate (2b).
-Galactose pentapivalate (3) is commercially available.
Figure 2.1 Perpivaloylated glycosyl donors used in this study.
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Zinc chloride has been reported to be the promoter of choice for the glycosylations of -
bromoalcohols with peracetylated sugars.48 In view of this, we initially examined the zinc
chloride-promoted reaction of -lactose octapivalate (1) with commercially available 11-
bromoundecanol (4a, Scheme 1). Thus, 1 and 4a (1.3 equiv.) were dissolved in dry toluene,
and upon addition of ZnCl2 the reaction mixture was heated at 65 °C for 1 hour. No reaction
took place, thus indicating much lower reactivity of an anomeric pivalate as compared to the
corresponding acetate. Overnight heating of the reaction mixture at this temperature yielded
the expected 11-bromoundecyl lactoside 5a, but only as an inseparable mixture of - and -
anomers (~1:1 as determined by 1H NMR spectroscopy).
Nevertheless, compound 5a (as an / mixture) was isolated in an excellent overall yield
of 93 %, and no byproducts common for the glycosylations of peracetylated sugars (such as
an orthoester, 2-O-deacylated glycosides or anomeric chloride) were detected in the reaction
mixture.
Scheme 2.2 Sugar perpivalates in ZnCl2-promoted glycosylations.
Lewis acids have been shown to epimerize -glycosides to their more stable -anomers,
and we reckoned that this process was very likely to occur under the applied reaction
conditions. In order to optimize the reaction towards the synthesis of -glycosides, the
reaction between 1 and 4a was followed by NMR in C6D6. This lead to reaction conditions
with a maximum yield in combination with a high stereoselectivity. With reaction conditions of
70 °C, 1.5 equiv. of 4a and 1.5 equiv. of ZnCl2, the complete disappearance of the starting
lactose octapivalate was observed after 5.5 hours, and -lactoside 5a was formed as a
major product with only 5 % of the -anomer. With this information in hand, we performed a
series of preparative glycosylations of various alcohols (4a-f) with 1 as a glycosyl donor. As
can be seen, in all cases the -anomers of the resulting lactosides 5a-f could be isolated in
good to excellent yields (Table 1, entries 1-6).
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Entry Donor Acceptor(equiv)
ZnCl2(equiv) Time (h) /-ratioa
Yield
(%)b
1 1 4a (1.5) 1.5 6c 92%  89
2 1 4b (1.5) 1.5 5c 98%  91
3 1 4c (1.5) 1.5 5c 98%  90
4 1 4d (1.5) 1.5 5с 95%  87
5 1 4e (1.5) 1.5 6с 95%  85
6 1 4f (1.5) 1.5 6.5с 88%  79
7 2a 4a (1.3) 1.3 2d 95%  90
8 2a 4b (1.3) 1.3 1.5d 99%  93
9 2a 4d (1.3) 1.3 1.5d 98%  91
10 2a 4e (1.3) 1.3 2d 95%  89
11 3 4a (1.1) 1 1.5d only  95
12 3 4b (1.1) 1 1.5d only  99
13 3 4c (1.1) 1 1.5d only  98
14 3 4d (1.1) 1 1.5d only  98
15 3 4e (1.1) 1 1.5d only  97
16 2b 4b (1.3) 2 18e 1:1 -
a In crude product, as determined by NMR spectroscopy  (1H and HSQC data).
b Isolated yield of the -glycoside.c Reaction performed at 70 °C.d Reaction performed at 65 °C.e Temperature was raised from 65 to 90 °C.
Table 2.1 ZnCl2-promoted Glycosylations of Alcohols by Sugar Perpivalates in Toluene.
Subsequently, we explored the glycosylating properties of perpivaloylated -glucose (2a)
and -galactose (3) derivatives. As in the case of lactose 1, the optimum reaction conditions
were established by performing the glycosylations in an NMR tube in C6D6. The
monosaccharides proved to be more reactive glycosyl donors in comparison with the lactose
octapivalate: couplings involving 2a and 3 required smaller amounts of the promoter and
shorter reaction times. The relative reactivities of the studied compounds were determined to
be galactose > glucose > lactose. Thus, glycosylations of the alcohols 4a-e with the
galactose donor 3 were complete within 1.5 hours, and the corresponding galactosides 7a-e
were obtained as exclusively -anomers and isolated in nearly quantitative yields (Table 1,
entries 11-15).
From the comparison of reaction conditions applied in this study (Table 1) with those
reported for sugar peracetates48 it can be concluded that the reactivity of glycosyl pivalates
is generally lower than that of analogous 1-O-acetyl glycosides. Notwithstanding, the use of
perpivaloylated saccharides for the glycosylation of -functionalized fatty alcohols avoids
numerous complications that are characteristic for the couplings involving peracetates, such
as the formation of a mixture of anomeric C-2 deprotected glycosides or anomeric halides (in
the case of the use of a halogen containing promoter). In addition, it preserves the ease of
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preparation of peracylated sugar derivatives and the -selectivity of the coupling reaction as
a result of the anchimeric assistance of an acyl group at the C-2 position, and as such
perpivaloylation is an excellent alternative for peracetylation.
It has been shown for the glucose and galactose peracetates that the -anomers are
much more reactive than the corresponding -anomers.76, 77 Since the geometries of the
sugar rings in peracetylated and perpivaloylated glucose are very similar, an analogous
relative reactivity was expected in the case of sugar perpivalates. Indeed, the -anomer of
pentapivaloyl glucose (2b) was only poorly reactive. Glycosylations with 2b as a donor (e.g.
Table 1, entry 16) required at least 2 equiv. of ZnCl2, the complete transformation of the
starting material could be achieved only in 18 hours and the resulting glucosides were
mixtures of - and -anomers at any stage of the reaction.
A nice feature of the reaction procedure is that it does not require an aqueous work-up,
and the highly apolar product (due to a number of trimethylacetyl groups) can be easily
separated on a silica column from the excess of alcohol. Crucial in the reaction to achieve
high -selectivities are essentially anhydrous conditions (with regard to both toluene and
ZnCl2). The use of molecular sieves, however, should be avoided.
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2.2.2 Synthesis of asialo-GM2 analogues
Next, we turned our attention to the synthesis of asialo-GM2 (GA2) mimics. As indicated
in Figure 2.2, the synthesis of the key intermediates 8 of GA2 analogues was based on the
assembly of two building blocks 9 and 10. An important issue for the effectiveness of such
assembling is the proper choice of the protection of the NH2 group of galactosamine donor 9.
The phthalimido and azido groups have been the most widely used.78 Recently, p-
nitrobenzyloxycarbonyl79, 80 (PNZ) and trichloroethoxycarbonyl (Troc)81 groups were applied
in the synthesis of glycoconjugates containing 2-acetamido glycoside units.82, 83 However,
the linkage of N-phthalimido or azido halide donors and OH-4΄ lactose derivatives have been
reported to yield asialo GM2 in low to moderate yields (20 - 54%).84, 85 In our hands, Troc
and PNZ proved to be stable under the glycosylation conditions (-20 oC, in diethyl ether and
TMSOTf (0.10 equiv.) as catalyst), and both could easily and selectively be removed.82, 83
Taking into account that O-glycosyl trichloroacetimidate was shown to be superior compared
to glycosyl donors containing halides (Cl or Br) at the anomeric centre,33 we selected N-
trichloroethoxycarbonyl-galactosamine-O-trichloroacetimidate (9a) and N-p-
nitrobenzyloxycarbonyl-galactosamine-O-trichloroacetimidate (9b) as glycosyl donors to
investigate their coupling efficiency with 4´-OH lactose derivatives (Scheme 2.3).
Figure 2.2 Retrosynthesis of the key intermediates of asialo GM2 analogues.
Scheme 2.3 outlines the syntheses of these donor units. Treatment of galactosamine
hydrochloride 11 with 1 eq. of NaOMe in MeOH, followed by the addition of trichloroethyl
chloroformate or p-nitrobenzyl chloroformate (1 eq.) - TEA (1 eq.) and O-acetylation (Ac2O-
pyridine) afforded compounds 12a (92%) or 12b (92%) in good yields. Finally, regioselective
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deacetylation at O-1 with hydrazine acetate in DMF followed by treatment of the reducing
sugar with trichloroacetonitrile in the presence of DBU, produced the Troc-
trichloroacetimidate 9a (79%; overall yield from 11 is 73%). The PNZ analogue 9b was
obtained in 75% yield (overall yield from 11 is 69%).
Scheme 2.3 Synthesis of building blocks 9a and 9b. Reagents and conditions: i: NaOMe (1
eq.)/MeOH, r.t., 30 min; ii: a: trichloroethyl chloroformate (1 eq.), Et3N (1 eq.), r.t., 2 h; (b: p-
nitrobenzyl chloroformate (1 eq), Et3N (1 eq, r.t., 2 h); iii: Ac2O/Py, r.t., overnight; iv: hydrazine
acetate, DMF, 0 oC, 2 h; v: CCl3CN (10 eq.)/DBU, CH2Cl2, -10 oC, 5 h.
As stated above, the 4΄-OH lactose derivatives showed very low reactivity as glycosyl
acceptors. As benzyl ethers are able to enhance the reactivity of neighboring hydroxyl
groups in glycosylation reactions,86 we selected the benzyl group as the protecting group for
the lactose units of 10a, 10b, 10c, and 10d (Scheme 2.4).
Scheme 2.4 Synthesis of building blocks 10a-10d. i: Ac2O/NaOAc, reflux, 2 h, 77%; ii: (a) 24%
NH2NH2·H2O, CH3CN, 24 h, r.t., 86%; CH3I/Ag2O/CH3CN, r.t., 24 h, 15a, 84%; (b) 2-azidoethanol (2.5
eq.), BF3.C2H5OC2H5, CH2Cl2, 0 oC to r.t., 24 h, 15b, 80%; (c) thiophenol (2.5 eq.), BF3.C2H5OC2H5,
CH2Cl2, 0 oC to r.t., 24 h, 15c, 75%; (d) 33% HBr in AcOH, 0 oC-rt, 5 h, 72%; undec-10-en-1-ol,
AgOTf, dry toluene, -78 oC to r.t., overnight, 15d, 84%; iii: NaOMe/MeOH, IR resin (H+); iv:
PhCH(OCH3)2 / CSA / THF, reflux, 3 h; v: NaH / BnBr / DMF, overnight, r.t., 16a (50%) ; 16b (57%),
16c (54%), 16d (60%)(3 steps); vi: NaCNBH3 / HCl in Et2O / dry THF, 30 min, 10a (78%), 10b (78%),
10c (76%), 10d (77%).
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In Scheme 2.4, the synthetic route to the lactose acceptors is depicted. Heating a
mixture of lactose 13, acetic anhydride and anhydrous sodium acetate afforded peracetyl-
lactose 14 (yield: 77%).87 After treatment with hydrazine, the anomeric acetyl group in 14
was selectively deprotected, and the product was treated with CH3I and silver oxide to give
15a (72%).88 Alternatively, compound 14 was reacted with 2-azidoethanol or thiophenol in
the presence of BF3-diethyl etherate to afford 15b (80%) and 15c (75%), respectively.
Bromination of 14 with 33% (w/w) hydrogen bromide  in acetic acid at 0 oC and subsequent
coupling with undec-10-en-1-ol gave 15d (84%). Compounds 15a-d were characterized by
NMR and LC-MS. Compounds 15a-d were deacetylated using NaOMe in MeOH, followed by
selective protection of OH-4 and OH-6 with α,α-dimethoxytoluene under mild acidic
conditions in anhydrous THF. The remaining OH-groups were benzylated with NaH and
benzyl bromide in DMF to give 16a-d (50%; 57%; 54%; 60%). Selective cleavage89 of the
benzaldehyde acetal in 16a-d with NaBH3CN-HCl in dry THF afforded acceptor compounds
10a-d in good yields (76 - 78%).
Finally, the glycosyl donors 9a-b  were reacted with acceptors 10a-d at –20 oC in dry
diethyl ether in the presence of TMSOTf (0.11 eq.) to give 8a-f (Scheme 2.5). The
glycosylation yields are listed in Table 2.2.
Glycosyl donor Lactose derivative Product Isolated yield, %
9a 10a 8a 91
9b 10a 8b 69
9a 10b 8c 90
9b 10b 8d 71
9a 10c 8e 90
9a 10d 8f 90
Table 2.2 Yields of glycosylations with donors 9a-b and acceptors 10a-d (used in ratio 9/10 of 1 : 1.5)
The results in Table 2.2 clearly show that the glycosylation efficiency of glycosyl donor
N-trichloroethoxycarbonyl-galactosamine-O-trichloroacetimidate (9a) was better than that of
N-p-nitrobenzyloxycarbonyl-galactosamine-O-trichloroacetimidate (9b). Replacement of the
N-Troc group in 8a by the N-acetyl group with active Zn powder in acetic anhydride81-83
followed by deacetylation with NaOMe in MeOH and debenzylation with H2 (50 psi) and
Pd/C (10%) in MeOH at room temperature gave β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-β-D-
Glc-OMe (methyl asialo GM2, 17) in 73% yield (3 steps).
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8a R = Troc, R' = OCH38b R = PNZ, R' = OCH38c R = Troc, R' = OCH2CH2N38d R = PNZ, R' = OCH2CH2N38e R = Troc, R' = SPh8f R = Troc, R' = OCH2(CH2)8CH=CH2
i
ii, iii, iv
yield over 3 steps: 73%
9a R = Troc9b R = PNZ
OC(NH)CCl3
O
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Scheme 2.5 Synthesis of protected asialo-GM2 derivatives 8a-8f, and of fully deprotected asialo-
GM2-derivative 17. Reagents and conditions: i: TMSOTf / dry Et2O, -20 oC, 5 h; ii: active Zn powder /
Ac2O, r.t., 5 h; iii: NaOMe / MeOH, r.t.; iv: H2 (50 psi), Pd(10%) / C, r.t., 6 h.
2.3 Conclusions
We have demonstrated that 1-O-pivaloyl glycosides can be activated by a Lewis acid to
serve as glycosyl donors. An efficient glycosylation procedure was developed and
successfully applied to the stereoselective synthesis of various -functionalized alkyl 1,2-
trans-glycosides in high yields (77- 99 %). Application of a perpivalate instead of peracetate
appears to be especially beneficial in the case of lactose, given the considerably higher
yields of the lactosides presented in this study in comparison with those reported previously
(cf. e.g. 42 - 47 % for 8-bromooctyl lactoside48, 56 % for 10-undecenyl lactoside66). The
application of anomeric pivalates as glycosyl donors is thus worth to be further explored
towards the use with other promoters and glycosyl acceptors, and such investigations are
currently underway in our laboratory.
In addition, we have prepared and investigated two glycosyl donors 9a and 9b, which
efficiently could be linked to lactose acceptors 10a-d, and showed unambiguously that N-
trichloroethoxycarbonyl-galactosamine-O-trichloroacetimidate was an efficient donor with
glycosylation yields of 90% or more.
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2.4 Experimental
2.4.1 General Information
Petroleum ether of the bp 40-60 °C fraction, EtOAc and EtOH were distilled. Toluene
was distilled over Na and stored over sodium wires. Pyridine (Merck, 99%) was dried over
KOH.
Thin layer chromatography (TLC) was performed on Merck silica gel 60F254 plastic
sheets and detection was realized by charring with an aqueous solution of KMnO4. Column
chromatography was conducted by elution of a column of Merck Kieselgel silica (230-400
Mesh) using eluents as specified below. NMR spectra were recorded on a Bruker Avance
400 spectrometer.
2.4.2 General procedure for the syntheses of sugar perpivalates
β-Perpivalates. The parent sugar was dissolved in dry pyridine (10 ml of pyridine per 1 g
of sugar). Trimethylacetyl chloride (2 equiv. per OH group) was added dropwise at room
temperature. The mixture was stirred at 80 °C for 5 days. After cooling down, the reaction
mixture was diluted with ice- water and extracted three times with dichloromethane. The
combined organic phases were washed successively with 1M H2SO4, saturated sodium
bicarbonate, brine, and dried over Na2SO4. After evaporation of the solvent in vacuo the
residue was recrystallized from anhydrous ethanol.
Penta-O-pivaloyl-α-D-glucose was obtained unexpectedly from the literature procedure58
in which the formation of penta-O-pivaloyl β-D-glucose (2a) was claimed.
2.4.2.1 Octa-O-pivaloyl β-lactose (1)
1H NMR (400 MHz, C6D6)  ppm 5.61 (d, J=8.3 Hz, 1 H), 5.40 (d, J=3.0 Hz, 1 H), 5.33
(m, 2H), 5.25 (m, 1H), 5.04 (dd, J=10.3, 3.3 Hz, 1 H), 4.39 (m, 2H), 4.29 (d, J=8.0 Hz, 1 H),
4.13 (m, 1H), 3.98 (m, 1H), 3.70 (m, 1H), 3.43 (m, 2H), 1.25 (s, 9 H), 1.20 (s, 9 H), 1.15 (s, 9
H), 1.14, 1.13, 1.12 (36 H, peaks overlap), 1.07 (s, 9 H).
13C NMR (101 MHz, C6D6)  ppm 177.2, 177.1, 177.0, 176.8, 176.7, 176.3, 176.0, 175.8,
100.7, 92.1, 74.6, 74.5, 71.9, 71.8, 71.7, 71.1, 69.4, 67.0, 62.0, 61.1, 39.0 - 38.6 (8C, peaks
overlap), 27.6, 27.3 (4C, peaks overlap), 27.2, 27.1, 26.9.
2.4.2.2 Penta-O-pivaloyl β-D-glucose (2a)
1H NMR (400 MHz, C6D6)  ppm 5.64 (d, J=8.0 Hz, 1 H), 5.42 – 5.16 (m, 3H), 4.04 (m,
2H), 3.16 (m, 1H), 1.15 (s, 9 H), 1.13 (s, 9 H), 1.12 (m, 18H), 1.07 (s, 9 H).
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13C NMR (101 MHz, C6D6)  ppm 177.4, 176.9, 176.2, 176.1, 176.0, 92.3, 73.1, 72.8,
70.8, 67.8, 61.4, 38.9, 38.8, 38.78 (2C, peaks overlap), 38.74, 27.3, 27.25, 27.2, 27.1, 26.9.
2.4.2.3 Penta-O-pivaloyl α-D-glucose (2b)
1H NMR (400 MHz, C6D6)  ppm 6.52 (d, J=3.8 Hz, 1 H), 5.82 (t, J=9.8 Hz, 1 H), 5.28 (t,
J=9.9 Hz, 1 H), 5.23 (dd, J=10.0, 3.8 Hz, 1 H), 4.21 - 4.28 (m, 2 H), 4.08 - 4.14 (m, 1 H),
1.16 (s, 9 H), 1.12 (s, 9 H), 1.12 (s, 9 H), 1.09 (s, 9 H), 1.08 (s, 9 H); 13C NMR (101 MHz,
C6D6)  ppm 177.8, 177.2, 176.9, 176.8, 175.9, 89.5, 71.4, 70.5, 70.3, 68.5, 62.4, 39.4, 39.3,
39.2 (2 C, peaks overlap), 39.1, 27.7, 27.6, 27.5, 27.5, 27.4.
2.4.3 Typical procedure for the glycosylations with 1-O-pivaloyl donors
To a solution of lactose octapivalate 1 (1 g, 0.99 mmol) and 8-chlorooctan-1-ol 4b (243
l, 1.48 mmol) in anhydrous toluene (10 ml), was added ZnCl2 (0.2 g, 1.48 mmol, dried in
vacuo at 120 °C  for at least 1 h prior to use) and the resulting suspension was stirred at 70
°C for 5 h. After cooling down, the reaction mixture was diluted with EtOAc (10 ml), and solid
NaHCO3 (2 g) and water (0.5 ml) were added portionwise with stirring. After the formation of
gas stopped (~20 min), the solution was filtered over Hyflo. The precipitate was washed
thoroughly with EtOAc. The combined organic phase was evaporated in vacuo and the
residue purified by silica gel column chromatography (1:7 EtOAc-petroleum ether) to give 8-
chlorooctyl lactoside 5b (0.97 g, 0.9 mmol, 91 %) as a white foam. 1H NMR (400 MHz,
CDCl3)  ppm 5.36 (d, J=2.3 Hz, 1 H), 5.18 (t, J=9.5 Hz, 1 H), 5.09 (dd, J=10.5, 8.0 Hz, 1 H),
4.96 (dd, J=10.5, 3.5 Hz, 1 H), 4.79 (dd, J=9.7, 7.9 Hz, 1 H), 4.50 (d, J=7.8 Hz, 1 H), 4.47 -
4.56 (m, 1 H), 4.44 (d, J=8.0 Hz, 1 H), 4.18 (dd, J=12.0, 5.0 Hz, 1 H), 4.04 - 4.11 (m, 1 H),
3.95 - 4.03 (m, 1 H), 3.88 - 3.94 (m, 1 H), 3.85 (t, J=9.5 Hz, 1 H), 3.67 - 3.75 (m, 1 H), 3.47
(t, J=6.8 Hz, 2 H), 3.44 - 3.53 (m, 1 H), 3.33 - 3.41 (m, 1 H), 1.65 - 1.75 (m, 2 H), 1.48 (t,
J=6.4 Hz, 2 H), 1.32 - 1.42 (m, 2 H), 1.22 - 1.28 (m, 6 H), 1.21 (s, 9 H), 1.19 (s, 9 H), 1.17 (s,
9 H), 1.15 (s, 9 H), 1.11 (s, 9 H), 1.11 (s, 9 H), 1.05 (s, 9 H); 13C NMR (101 MHz, CDCl3) 
ppm 177.7, 177.5, 177.2, 177.0, 176.7, 176.5, 175.9, 100.7, 100.0, 73.7, 73.3, 71.7, 71.6,
71.4, 71.3, 69.6, 68.8, 66.8, 61.7, 61.3, 44.9, 38.9-38.6 (7C, peaks overlap), 32.5, 29.4,
29.0, 28.7, 27.3, 27.2, 27.1, 27.0 (3C, peaks overlap), 26.9, 26.7, 25.8.
2.4.3.1 11-Bromoundecyl Hepta-O-pivaloyl β-lactoside (5a)
1H NMR (400 MHz, CDCl3)  ppm 5.38 (d, J=2.1 Hz, 1 H), 5.18 (t, J=9.6 Hz, 1 H), 5.09
(dd, J=10.0, 8.0 Hz, 1 H), 4.96 (dd, J=10.5, 3.5 Hz, 1 H), 4.75 (dd, J=9.7, 7.9 Hz, 1 H), 4.50
(d, J=7.7 Hz, 1 H), 4.46 - 4.56 (m, 1 H), 4.40 (d, J=8.0 Hz, 1 H), 4.20 (dd, J=10.0, 5.0 Hz, 1
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H), 4.04 - 4.11 (m, 1 H), 3.95 - 4.03 (m, 1 H), , 3.88 - 3.94 (m, 1 H), 3.85 (t, J=9.6 Hz, 1 H),
3.67 - 3.75 (m, 1 H), 3.44 - 3.53 (m, 1 H), 3.37 (t, J=7.0 Hz, 2 H)3.33 - 3.41 (m, 1 H), 1.65 -
1.75 (m, 2 H), 1.48 (t, J=6.4 Hz, 2 H), 1.32 - 1.42 (m, 2 H), 1.22 - 1.28 (m, 12 H), 1.21 (s, 9
H), 1.19 (s, 9 H), 1.17 (s, 9 H), 1.15 (s, 9 H), 1.11 (s, 9 H), 1.11 (s, 9 H), 1.05 (s, 9 H);
13C NMR (101 MHz, CDCl3)  ppm 177.8, 177.5, 177.3, 177.0, 176.5, 176.3, 176.0, 101.0,
100.1, 73.7, 73.2, 71.7, 71.6, 71.4, 71.3, 69.6, 68.8, 66.8, 61.7, 61.3, 38.9-38.6 (7C, peaks
overlap), 34.0, 32.5, 29.4, 29.1, 29.0, 28.8, 28.7, 28.1, 27.4 - 27.0 (7C, peaks overlap), 26.8,
25.8.
2.4.3.2 8-Azidooctyl Hepta-O-pivaloyl β-lactoside (5c)
1H NMR (400 MHz, CDCl3)  ppm 5.35 (d, J=2.0 Hz, 1 H), 5.19 (t, J=9.5 Hz, 1 H), 5.09
(dd, J=10.5, 8.0 Hz, 1 H), 4.96 (dd, J=10.5, 3.5 Hz, 1 H), 4.79 (dd, J=9.7, 7.9 Hz, 1 H), 4.50
(d, J=7.8 Hz, 1 H), 4.47 - 4.56 (m, 1 H), 4.41 (d, J=8.0 Hz, 1 H), 4.18 (dd, J=12.0, 5.0 Hz, 1
H), 4.04 - 4.09 (m, 1 H), 3.95 - 4.03 (m, 1 H), 3.88 - 3.94 (m, 1 H), 3.85 (t, J=9.5 Hz, 1 H),
3.67 - 3.75 (m, 1 H), 3.44 - 3.53 (m, 1 H), 3.33 - 3.41 (m, 1 H), 3.27 (t, J=6.8 Hz, 2 H),1.65 -
1.75 (m, 2 H), 1.48 (t, J=6.4 Hz, 2 H), 1.32 - 1.42 (m, 2 H), 1.22 - 1.28 (m, 6 H), 1.21 (s, 9 H),
1.19 (s, 9 H), 1.17 (s, 9 H), 1.15 (s, 9 H), 1.11 (s, 9 H), 1.11 (s, 9 H), 1.05 (s, 9 H);
13C NMR (101 MHz, CDCl3)  ppm 177.7, 177.5, 177.2, 177.0, 176.7, 176.5, 175.9, 100.7,
100.0, 73.9, 73.3, 71.7, 71.6, 71.4, 71.3, 69.6, 68.8, 66.8, 61.7, 61.3, 52.5, 38.9-38.6 (7C,
peaks overlap), 32.5, 29.4, 29.0, 28.7, 27.3, 27.2, 27.1, 27.0 (3C, peaks overlap), 26.9, 26.7,
25.8.
2.4.3.3 Undec-10-enyl Hepta-O-pivaloyl β-lactoside (5d)
1H NMR (400 MHz, CDCl3)  ppm 5.91 - 5.71 (m, 1H), 5.36 (d, J=2.3 Hz, 1 H), 5.18 (t,
J=9.5 Hz, 1 H), 5.09 (dd, J=10.5, 8.0 Hz, 1 H), 5.02 – 4.91 (m, 2H), 4.96 (dd, J=10.5, 3.5 Hz,
1 H), 4.79 (dd, J=9.7, 7.9 Hz, 1 H), 4.50 (d, J=7.8 Hz, 1 H), 4.47 - 4.56 (m, 1 H), 4.44 (d,
J=8.0 Hz, 1 H), 4.18 (dd, J=12.0, 5.0 Hz, 1 H), 4.04 - 4.11 (m, 1 H), 3.95 - 4.03 (m, 1 H),
3.88 - 3.94 (m, 1 H), 3.85 (t, J=9.5 Hz, 1 H), 3.67 - 3.75 (m, 1 H), 3.47 (t, J=6.8 Hz, 2 H),
3.44 - 3.53 (m, 1 H), 3.33 - 3.41 (m, 1 H), 2.05 - 1.95 (m, 2 H), 1.32 - 1.42 (m, 4 H), 1.22 -
1.28 (m, 10 H), 1.21 (s, 9 H), 1.19 (s, 9 H), 1.17 (s, 9 H), 1.15 (s, 9 H), 1.11 (s, 9 H), 1.11 (s,
9 H), 1.05 (s, 9 H); 13C NMR (101 MHz, CDCl3)  ppm 177.7, 177.5, 177.2, 177.0, 176.7,
176.5, 175.9, 140.0. 114.0, 100.5, 99.9, 73.7, 73.3, 71.7, 71.6, 71.4, 71.3, 69.6, 68.8, 66.8,
61.6, 61.4, 38.9-38.6 (7C, peaks overlap), 32.5, 29.4, 29.0, 28.7, 27.3 - 27.0 (7C, peaks
overlap), 26.9, 25.8.
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2.4.3.4 Undec-10-ynyl Hepta-O-pivaloyl β-lactoside (5e)
1H NMR (400 MHz, CDCl3)  ppm 5.36 (d, J=2.3 Hz, 1 H), 5.15 (t, J=9.5 Hz, 1 H), 5.11
(dd, J=11, 7.9 Hz, 1 H), 4.96 (dd, J=10.5, 3.5 Hz, 1 H), 4.79 (dd, J=9.7, 7.9 Hz, 1 H), 4.50 (d,
J=7.8 Hz, 1 H), 4.47 - 4.56 (m, 1 H), 4.44 (d, J=8.0 Hz, 1 H), 4.18 (dd, J=12.0, 5.0 Hz, 1 H),
4.04 - 4.11 (m, 1 H), 3.95 - 4.03 (m, 1 H), 3.88 - 3.94 (m, 1 H), 3.85 (t, J=9.5 Hz, 1 H), 3.67 -
3.75 (m, 1 H), 3.47 (t, J=6.8 Hz, 2 H), 3.44 - 3.53 (m, 1 H), 3.33 - 3.41 (m, 1 H), 2.00 - 1.89
(m, 2 H), 1.83 (m, 1H), 1.32 - 1.42 (m, 4 H), 1.22 - 1.28 (m, 10 H), 1.21 (s, 9 H), 1.19 (s, 9
H), 1.17 (s, 9 H), 1.15 (s, 9 H), 1.11 (s, 9 H), 1.11 (s, 9 H), 1.05 (s, 9 H); 13C NMR (101 MHz,
CDCl3)  ppm 177.7, 177.5, 177.2, 177.1, 176.7, 176.4, 175.9, 101.0, 100.1, 84.5, 73.7,
73.3, 71.7, 71.6, 71.4, 71.3, 69.6, 68.8, 68.1, 66.8, 61.7, 61.3, 38.9-38.6 (7C, peaks
overlap), 29.4, 29.0, 28.9, 28.8, 28.6, 27.5 – 26.9 (7C, peaks overlap), 26.7, 25.8, 18.0.
2.4.4 Typical procedure for the glycosylations with galactosamine donors
A mixture of compound 9a (238 mg, 0.33 mmol), 10a (200 mg, 0.22 mmol) and active
powdered 4 Å molecular sieves (1.0 g) in dry diethyl ether (6 mL) was stirred for 1 h at room
temperature under N2. After cooling to –20 oC, 150 μL of TMSOTf solution (50 μL TMSOTf
dissolved in 2.0 mL dry diethyl ether) (0.0237 mmol) was injected into the reaction, and the
mixture was stirred for about 4 h at –20 oC. The reaction was monitored by TLC (3 : 7, ethyl
acetate : petroleum ether (40-60)). When acceptor 10a had almost disappeared, the reaction
was quenched with triethylamine and was filtered through Celite, washed with CH2Cl2 and
concentrated. Column chromatography (3:7, ethyl acetate : petroleum ether) gave
trisaccharide 8a (280 mg, 91%). 13C NMR (101 MHz, C6D6) δ ppm: 170.3, 170.0, 154.6,
140.0, 139.6, 139.3, 129.5, 129.2, 129.1, 129.0, 128.9, 128.8, 128.7, 128.2, 127.9, 127.8,
105.3, 103.1, 102.3, 83.2, 83.1, 82.6, 81.3, 76.2, 76.0, 75.3, 74.7, 73.9, 73.6, 71.4, 68.8,
67.2, 61.6, 60.3, 56.3, 53.8, 20.8, 20.6, 20.4.
2.4.4.1 Methyl 2,3,6,2’,3’,6’-hexabenzyl lactoside (10a)
HRMS [M+Na]+ 919.40567 (calcd 919.40333, Δ ppm = 2.54).
2.4.4.2 Methyl glycoside of asialo GM2 (17)
1H NMR (400 MHz, D2O)  ppm   4.54 (d, J = 8, 1H), 4.35 (d, J = 8, 1H), 4.33 (d, J = 8,
1H), 4.01 (d, J = 2.8, 1H), 3.90 (d, J = 12, 1H) , 3.84-3.78 (m, 2H), 3.77-3.46 (m, 15 H), 3.26
–3.29 (m, 1H), 3.24-3.18 (m, 1H), 1.97 (s, 3H). 13C NMR (101 MHz, D2O)  ppm 175.34,
103.43, 103.35, 103.05, 78.83, 76.51, 75.20, 75.15, 74.73, 74.70, 73.09, 72.78, 71.43,
71.37, 68.17, 61.42, 61.05, 60.37, 57.58, 53.03, 22.77. HRMS [M+Na]+ 582.20233 (calcd
582.20100, Δ ppm = 2.28).
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CHAPTER 3
GM3, GM2 and GM1 Mimics Designed for
Biosensing: Chemoenzymatic Synthesis, Target
Affinities and 900 MHz NMR Analysis*
Abstract – Undec-10-enyl, undec-10-ynyl and 11-azidoundecyl glycoside analogues
corresponding to the oligosaccharides of human gangliosides GM3, GM2 and GM1 were
synthesized in high yields using glycosyltransferases from Campylobacter jejuni.  Due to
poor water solubility of the substrates, the reactions were carried out in methanol-water
media, which for the first time were shown to be compatible with the C. jejuni α-(2-3)-
sialyltransferase (CST-06) and β-(1-4)-N-acetyl galactosaminyltransferase (CJL-30).
Bioequivalence of our synthetic analogues and natural gangliosides was examined by
binding to Vibrio cholerae toxin and to the B subunit of Escherichia coli heat-labile
enterotoxin. This bioequivalence was confirmed by binding to mouse and human monoclonal
antibodies to GM1 and acute phase sera containing IgM and IgG antibodies to GM1 from
patients with the immune-mediated polyneuropathy Guillain-Barré Syndrome. The
synthesized compounds were analyzed by 1-D and 2-D 900 MHz NMR spectroscopy.
TOCSY and DQF-COSY experiments in combination with 13C-1H correlation measurements
(HSQC, HMBC) were carried out for primary structural characterization and a complete
assignment of all 1H and 13C chemical shifts is presented.
* This chapter is published as:
- Pukin, A. V.; Weijers, C.; van Lagen, B.; Wechselberger, R.; Sun, B.; Gilbert, M.; Karwaski, M. F.;
Florack, D. E. A.; Jacobs, B. C.; Tio-Gillen, A. P.; van Belkum, A.; Endtz, H. P.; Visser, G. M.; Zuilhof, H.,
Carbohydr. Res. 2008, 343 (4), 636-650.
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3.1 Introduction
The development of high-affinity mimics of carbohydrates associated with important
recognition events has attracted a great deal of attention as a way to develop therapeutic
agents1-7 with good stability and synthetic availability.1-12 Particular interest is focused on
gangliosides,13,14 which are a.o. important targets for auto-antibodies causing immune-
mediated forms of polyneuropathy and for bacterial toxins that cause gastro-enteritis
including cholera and travellers diarrhoea.15 For example, Vibrio cholerae toxin (CT) binds
with high affinity to GM1-ganglioside, whereas Escherichia coli heat-labile enterotoxin (LT),
apart from binding to GM1, also binds (though to a lesser extent) to GM2 and other glycolipid
receptors.16, 17
Guillain-Barré Syndrome (GBS),18 the most frequent cause of acute neuromuscular
paralysis that can be triggered by Campylobacter jejuni infection, was shown to be a true
case of molecular mimicry:19, 20 it has its origin in molecular similarities between the
carbohydrate part of C. jejuni cell wall lipooligosaccharides and the oligosaccharide
sequence of the gangliosides in the nerve tissue.21, 22 Apart from causing diseases, such
ganglioside – antibody recognition events can also be the basis for cure and diagnostics.23
However, the success of natural carbohydrates as therapeutic agents and diagnostic tools is
presently limited. Thus, serum auto-antibodies to gangliosides in patients with GBS and
other forms of immune-mediated polyneuropathy are usually detected by ELISA-based tests.
The detection of these antibodies is, however, restricted by the use of bovine brain-derived
gangliosides in these assays, which are difficult to purify, expensive, potentially infected and
usually contaminated with other glycolipids. These drawbacks may partly explain the
variation and limited sensitivity and specificity of the current ELISA to detect the antibodies.24
Consequently, pure and structurally analogous synthetic mimics of gangliosides would
have significant advantages over their parent structures. The formation of such mimics, and
in general of compounds that are able to block glycan recognition, does however still remain
a major challenge.25 Recently, a range of synthetic GM1 mimics, in which the
oligosaccharide part was modified to make them more straightforward to be chemically
synthesized,26, 27 was examined in binding to anti-GM1 GBS-related antibodies.28 However,
in both solution inhibition and immunoadsorption studies the naturally-derived GM1
pentasaccharide (GM1 lacking the ceramide tail) was found to be greatly superior to the
investigated mimics.28 As a result, we direct our efforts towards the synthesis of mimics with
the authentic GM1 oligosaccharide moiety as the ligand for binding to cholera toxin29 and
other targets.
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The specific interactions between such GM1, GM2 and GM3 ganglioside analogues and
GBS-related antibodies open the way for biosensing as a diagnostic tool for GBS, e.g. via
semiconductor surfaces30 that have been covalently modified with specific
oligosaccharides.31,32 For the preparation of such monolayers, we developed an extremely
mild photochemical method (visible light, room temperature),33, 34 which allows for
attachment of labile bio(macro)molecules such as saccharides, DNA and proteins, if their
synthesis with appropriate linkers would be feasible. Linkers of choice for such attachments
are -alkenyl or -alkynyl tails with the length of at least 10 carbon atoms.33-39 In addition,
the -alkynyl tail is an excellent tool for attachment via cycloaddition “click” reactions.40-42
However, reported methods for the efficient preparation of sialylated ganglioside
structures are scarce,43 primarily due to synthetic problems imposed by the properties of the
glycosidic linkage involving sialic acid.44 Recently, the synthesis of a variety of biologically
relevant sialyl oligosaccharides was facilitated by a number of chemoenzymatic strategies
using bacterial glycosyltransferases.45-51 Thus, several glycosyltransferase genes from C.
jejuni have been expressed in E. coli and methods for efficient synthesis of 2-azidoethyl
glycosides corresponding to the oligosaccharides of GD3, GT3, GM2, GD2, GT2, GM1 and
GD1a were developed with a water-soluble 2-azidoethyl lactoside as starting compound.52, 53
For the application of such materials into sensing devices, attachment of other than highly
water-soluble chains would, however, be a big step forward. Given the poor water solubility
and gel-forming tendency of lactosides that have a long hydrophobic chain attached to their
anomeric oxygen this requires a better solubilizing yet still glycosyltransferase-compatible
medium.  In addition, since the literature contains mutually varying, incompatible sets of
assignments of the various NMR peaks of the natural54-57 and synthetic27, 44, 52, 58 ganglioside
structures, a detailed and unambiguous assignment of the structure of GM1 and its
precursors is desirable.
The present paper shows that in appropriate methanol/water mixtures amphiphilic
lactosides are excellent substrates for the abovementioned set of glycosyltransferases
which, in their turn, for the first time were shown to be active in methanol-water media. As a
result we subsequently report here the chemoenzymatic synthesis of -undecenyl, -
undecynyl and 11-azidoundecyl glycosides of GM3, GM2 and GM1. In addition, we show the
bioequivalence of natural GM1 ganglioside and its undec-10-enyl mimic via a series of
binding/receptor studies, which points to the potential of these mimics in sensor and related
applications. Finally, we report for the first time a complete ab initio assignment of all 1H and
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13C chemical shifts in the GM3, GM2 and GM1 oligosaccharide moieties via a series of 1-
and 2-dimensional 900 MHz NMR spectra of -undecenyl gangliosides.
3.2 Results and Discussion
3.2.1 Synthesis of GM3, GM2 and GM1 mimics with long (C11) hydrophobic tails
The chemoenzymatic synthesis of glycosides with glycosyltransferases from C. jejuni52
was explored in terms of substrate specificity (presence of a long hydrophobic chain rather
than a hydrogen atom53 or a short alkyl chain52, 59 at the aglycone end) and solvent
tolerance. Thus, undec-10-enyl β-lactoside 1, undec-10-ynyl β-lactoside 2, and 11-
azidoundecyl β-lactoside 3 (Figure 3.1) were used for the enzymatic modifications in this
study.
Figure 3.1  Compounds used for enzymatic modifications.
Lactoside 3 was synthesized as described previously.44 Synthesis of 1 and 2 was
accomplished in three steps starting from D-lactose 4 (Scheme 1).*  Lactose octaacetate 5,
prepared by acetylation of D-lactose, was glycosidated with 10-undecen-1-ol or 10-undecyn-
1-ol to give heptaacetyl undecenyl lactoside 6,60 and heptaacetyl undecynyl lactoside 7,
respectively. The peracetylated lactosides 6 and 7 after isolation were deprotected according
to the standard Zemplén procedure61 to afford heptaols 1 and 2.62 Unlike reported ~1:9
mixture of undecenyl α- and β-lactosides,63 compound 1 was a 100% β-isomer, as
characterized by NMR (vide infra). The lactosides 1 and 2 did not require a purification step
and were directly used for further transformations.
* A very efficient glycosylation method for the synthesis of lactosides with long chain alcohol-based
aglycones has been developed when this work was already done. These glycosylations are described
in Chapter 2.
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Scheme 3.1 Synthesis of heptaols 1 and 2. (a) Ac2O, NaOAc, reflux, 4 h; (b) SnCl4 in dry CH2Cl2, rt,
overnight, 56%; (c) BF3*Et2O in dry CH2Cl2, 0 C to rt, overnight, 40%; (d) NaOCH3 in MeOH, rt
(overnight), or rt to reflux (15 min), 100%.
Compounds 1-3 could be converted in a series of novel reaction steps and by a modified
procedure to the respective GM3, GM2 and GM1 mimics; the overall reaction scheme is
depicted in Scheme 2. Contrary to the previously reported 2-azidoethyl lactoside52 and other
synthetic substrates for glycosyltransferases,52, 59 compounds 1, 2 and 3 are poorly soluble
in water: they form gels, and as such are not amenable for enzymatic modification. The
solubility properties of the compound 1 appeared to be different from those described
before.63 Thus, it dissolved readily in methanol while clearly forming gels in water. To obtain
a suitable medium for the reactions with sialyltransferase, compounds 1, 2 and 3 were first
dissolved in 100% MeOH. After addition of aqueous solutions of the other components, we
obtained a mixture of methanol/water (25/75 v/v) that was compatible with CST-06, the
sialyltransferase used to add NeuAc. The mixture of respective compound 1, 2 or 3,
sialyltransferase CST-06 and CMP-NeuAc was kept at 37 °C for 1 h, after which TLC
analysis unambiguously showed that the lactoside was converted completely.  In a separate
experiment, the target GM3-mimic 8 was subsequently bound on a Sep-Pak column, which
was then washed with H2O to elute hydrophilic compounds (such as the buffer and the
nucleotide) and finally the GM3-analogue 8 was eluted with MeOH in a 92% yield (Scheme
2).
For synthesis of GM2-mimics 11, 12 and 13, we added the different components directly
to the corresponding GM3 reaction mixture which resulted in a final concentration of 10%
(v/v) of methanol. Compound 8, 9 or 10 was in this medium reacted with the in situ-
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generated UDP-GalNAc in a one-pot mixture containing UDP-GlcNAc, the UDP-GlcNAc 4'-
epimerase (CPG-13) and the -(1,4)-N-acetylgalactosaminyltransferase (CJL-30). The
corresponding product, GM2-mimic 11, 12 or 13, was bound to a Sep-Pak column as
described above for GM3-mimics and eluted with MeOH. For compounds 11, 12 and 13,
quantitative yields (from starting lactosides) were obtained.
The GM2 analogues 11, 12 and 13 were further elongated in an aqueous solution to the
GM1 mimics 14, 15 and 16, respectively. To that end, compound 11 reacted with UDP-Gal
and -(1,3)-galactosyltransferase CJL-20, while compounds 12 and 13 were converted in
one-pot mixture containing UDP-Glc, epimerase CPG-13 and -(1,3)-galactosyltransferase
CJL-137. Corresponding GM1 mimics were recovered after purification in high yields (94%
for compound 14, 99% for compound 15, and 75% for compound 16). The identity of these
GM3, GM2 and GM1 mimics was proved by a series of 900 MHz NMR experiments (vide
infra, part 2.3).
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C CH
8 : R= CH=CH2
9 : R=
10 : R= CH2CH2-N3
C CH
11 : R= CH=CH2
12 : R=
13 : R= CH2CH2-N3
C CH
14 : R= CH=CH2
15 : R=
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C CH
UDP-Glc
Epimerase CPG-13
Scheme 3.1 Enzymatic syntheses of GM3, GM2 and GM1 mimics.
CHEMOENZYMATIC SYNTHESIS / 900 MHZ NMR
37
3.2.2 Evaluation of the receptor-binding affinity of GM1 analogues
The synthesized GM1 mimic 14 has been tested for its bioequivalence to the natural
bovine brain GM1. In order to investigate this, 14 was firstly subjected to ELISA titration
studies with the B subunit of Escherichia coli heat-labile enterotoxin (LT-B). It is well known
that binding of CT and LT to gangliosides is mediated through their respective pentameric B
subunits.64 Because of the high binding affinities for gangliosides, these B subunits are ideal
tools to study structural similarities between natural and synthetic analogues.
Effectiveness of 14 in binding LT-B is demonstrated in Figure 3.2 which also indicates
that the undec-10-enyl GM1 analogue 14 appeared to be in general even better than the
bovine GM1 in this study. Thus, EC50 of LTB on ELISA plate coated with 14 was determined
to be 0.25 nM, while on the plate coated with bovine GM1 it was 0.57 nM. The undec-10-
enyl GM2 mimic 11 showed minor activity, while the GM3 analogue 8 as expected was
practically inactive, thus giving a confirmation of the specificity of binding.
0.01 0.1 1
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
1.1
 bovine GM1
 GM1 mimic 14
 GM2 mimic 11
 GM3 mimic 8
Op
tic
al d
en
sit
y (
415
 nm
)
LTB, nM
Figure 3.2 ELISA titration of the binding of B subunit of E.coli heat-labile enterotoxin (LT-B) to natural
and synthetic gangliosides coated on ELISA plates, as visualized using a monoclonal antibody
specific for LT-B-pentamer.
Subsequently, we tested the binding of the  GM1 mimic 14 to the B subunit of cholera
toxin and three monoclonal antibodies (mAbs) to GM1, specifically mouse IgG mAbs DG1
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and DG2 and human IgM mAbs SM1. The cholera toxin B-subunit and all monoclonal
antibodies displayed a similar binding to the natural and synthetic (14) GM1 gangliosides
coated on ELISA plates (Fig. 3). Moreover, both IgM and IgG antibodies from the sera of
patients with GBS recognized the synthetic GM1 analogue 14 to a similar extent as the
bovine brain derived GM1. Serum IgM and IgG from normal controls (NC) showed no activity
to this GM1 mimic, demonstrating that its structure does not aspecifically bind to
immunoglobulins.
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Figure 3.3 Binding of cholera toxin B subunit and antibodies to bovine GM1 and GM1 mimic 14.
As a result it is clear that GM1 analogue 14 can be used to detect both toxins and
antibodies involved in human diseases. Since the structure of this compound is the result of
stepwise syntheses, each of which can be controlled and modified using different building
blocks, these results encourage studies of the potential of GM1 mimics to supersede the
bovine brain-derived GM1 in diagnostic and therapeutic studies. Specifically, such mimics
can be useful when these can be applied in counteracting the physiologically detrimental
effect of several toxin- or antibody-mediated diseases, and such studies are currently
underway in our laboratories.
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3.2.3 Assignment of 1H and 13C chemical shifts in 900 MHz NMR spectra of undec-10-
enyl glycoside mimics of GM3 (8), GM2 (11) and GM1 (14)
The sugar units in 8, 11, and 14 are denoted by the pyranoside units "I" through "V"
starting from the aglycone end as shown in Figure 3.4. As the starting point, all the H - C
correlations are established using HSQC spectra.
Figure 3.4  Compounds under study, and numbering of C atoms (1-11) and saccharide rings (I to V).
The olefinic proton resonance at 5.8 ppm can be unambiguously assigned to proton 10
of the tail. The resonances for the protons in the alkyl tail up to H3 are established in DQF-
COSY spectrum, and 2D-TOCSY allows for assignment of H2 and H1 protons. All these
resonances in aglycone are confirmed by HSQC and HMBC spectra.
3.2.3.1 Assignments of 1H and 13C resonances of the glucose (I) residue
Subsequently, the 1H-NMR spectrum of GM3 mimic 8 shows two resolved anomeric
resonances at 4.46 and 4.31 ppm. Of these, the signal at 4.31 ppm is readily assigned to H1
of Glc(I), as it shows the cross peak with carbon atom C1 of the aglycone tail in the HMBC
spectrum. Starting with this anomeric resonance, the peaks for the first glucose ring to
(I)H6b are assigned in the DQF-COSY spectra as shown in Figure 3.5.
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Figure 3.5 DQF-COSY spectrum of GM3 mimic 8. Solid lines show through-bond connectivities of the
glucose ring.
In the 2D-TOCSY spectrum (Figure 3.6), the through-bond connectivity between (I)H1
and other protons in ring I can be monitored, and the accurate chemical shifts for these
hydrogen atoms can be established.
H1-H6,6`
H1-H4
H1-H3
H1-H5
H1-H2
Figure 3.6 Part of the 2D-TOCSY  spectrum of GM3 mimic 8 showing through-bond connectivities of
ring (I).
The HMBC spectrum of GM3 mimic 8 shows the (II)C1/(I)H4 coupling peak across the
glycosidic bond, which confirms the assignment of the (I)H4 resonance. Resonances of
(I)H6a and (I)H6b are accurately assigned by (I)C6/(I)H6a and (I)C6/(I)H6b cross peaks in
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the HSQC spectrum. Once the chemical shifts of the H atoms are established, the
assignments for the C atoms can be obtained using HSQC.
3.2.3.2. Assignments of 1H and 13C resonances of the galactose (II) residue
The doublet at 4.45 ppm (in 11 and 14) or 4.46 ppm (in 8) can be assigned to (II)H1, as
the signal obtained from the HSQC spectrum of the corresponding carbon atom shows a
clear correlation with (I)H4 in the HMBC spectrum (Figure 3.7).
Figure 3.7 Parts of 2D-TOCSY, HSQC and HMBC spectra of GM3 mimic 8. Red lines show C(1)-H(1)
correlation for the galactose (II) ring (left), and correlation between the anomeric carbon atom of the
galactose ring with the glucose H4 proton (right).
In the TOCSY spectrum of 8 (Figure 3.8), the spin-spin information transfer from (II)H1 to
(II)H2, (II)H3 and (II)H4 is clearly seen. The chemical shifts of (II)H5 and (II)H6 protons are
obtained from both 2D-TOCSY and HMBC spectra. In the TOCSY spectrum, through-bond
connectivity for the (II)H4 signal is not only observed to the (II)H1, (II)H2 and (II)H3 signals,
but also to two additional signals at 3.70 ppm and 3.89 ppm. Of these, the signal at 3.7 ppm
has a cross-peak correlated with the anomeric (II)C1 carbon, and is thus assigned to (II)H5.
The other signal is then assigned to (II)H6. The 13C chemical shifts are subsequently
obtainable from the HSQC spectrum. For 11 and 14, the 13C resonance of the (II)C4 atom is
shifted 10 ppm downfield, which supports the proposed linkage site of rings II and IV.
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HMBC
C1
H4
H1
-H4 -H3
C1-H5
-H2
-H2-H3-H1 -H5-H6
TOCSY
Figure 3.8 Parts of HMBC and TOCSY spectra of GM3 mimic 8 for the galactose (II) ring. The black
line shows correlation between the anomeric C atom and one of the protons, which was thus
assigned to (II)H5.
3.2.3.3. Assignments of 1H and 13C chemical shifts of the NeuAc (III) residue
In the TOCSY spectra of GM3 mimic 8, GM2 mimic 11 and GM1 mimic 14, spin-spin
information transfer from (III)H3eq to (III)H4, (III)H5, (III)H6 and (III)H7 is observed (Figure
3.9; example given for 14). The assignments can be unambiguously made by cross peaks in
DQF-COSY (for H4) and HSQC (for H5) spectra.
-H4 -H5
-H4
C5-H5
H3
H3
-H6 -H7
C5 HSQC
TOCSY
COSY
GM1
(IV)C2
Figure 3.9 Partial TOCSY, DQF-COSY and HSQC spectra for the NeuAc (III) residue in GM1 mimic
14.
For the (III)H7 signal, through-bond connectivity to the (III)H8 and (III)H9 protons are
observed in these TOCSY spectra, and HSQC allows for the assignment thereof (Figure
3.10).
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Figure 3.10 Partial TOCSY and HSQC spectra of GM1 mimic 14. The black line shows through-bond
connectivities for the (III)H7 proton of the NeuAc ring, while red lines indicate C-H correlations of the
(III)C9 carbon with the two (III)H9 protons.
3.2.3.4. Assignments of 1H and 13C chemical shifts of the GalNAc (IV) residue
Of all the anomeric hydrogen resonances, the lowest field signal in the 1H spectrum of 11
as assigned to (IV)H1 of the GalNAc (IV) residue, on the basis of the HMBC spectrum of 11
that shows the (IV)C1\(II)H4 cross peak across the glycosidic bond. Cross peak
connectivities in the DQF-COSY spectrum subsequently yield proton assignments for the
H2, H3 and H4 resonances of ring IV (Figure 3.11).
Figure 3.11 DQF-COSY spectrum of GM2 mimic 11. Red lines show through-bond connectivity of the
GalNAc (IV) ring.
H3
-H4 -H5 -H6 -H7
H3
-H7H7-H9H7-H8
C9 C9-H9C9-H9
HSQC
TOCSY
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The chemical shifts of (IV)H5 and (IV)H6 are determined analogously to those of the ring
II by the TOCSY and HSQC spectra. Thus, the TOCSY spectrum of 11 shows magnetization
transfer from (IV)H4 to signals at 3.83 and 3.78 ppm (Figure 3.12), and the cross peak with
the methylene carbon signal in HSQC spectrum allows assignment of the H6 resonances
(Figure 3.13). The carbon chemical shifts are subsequently obtainable from the HSQC
spectrum. For GM1 mimic 14, the 13C resonance of the (IV)C3 atom is shifted 9 ppm
downfield with respect to its value in 11, which thus provides additional confirmation for the
linkage site of rings IV and V.
H1
-H4 -H3-H2
H4
-H5 -H6-H1
Figure 3.12 Part of the TOCSY spectrum of GM2 mimic 11 showing correlations for the H1 and H4
protons of saccharide ring IV.
Figure 3.13 Partial TOCSY and HSQC spectra of GM2 mimic 11. The red line shows the assignment
of one of the H6 protons of ring IV based on C-H correlations.
3.2.3.5. Assignments of 1H and 13C chemical shifts of the galactose (V) residue
Finally, the remaining anomeric hydrogen signal at 4.47 ppm in spectrum of GM1 mimic
14 is assigned to (V)H1 of the terminal galactose residue. The remaining 1H chemical shifts
can then be assigned from this anomeric signal using DQF-COSY and HSQC. Similar to the
approach used for the II and IV sugar units, the chemical shifts for H atoms up to (V)H4 can
C6
H4
C6-H6 C6-H6`
-H6
-H5
HSQ
C
TOCSY
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be established using DQF-COSY, in this case of 14 (Figure 3.14). The only unassigned
CH2OH carbon signal can be assigned to the (V)C6 atom of ring V, and the (V)H6 chemical
shifts is established from HSQC cross peaks. The (V)H5 chemical shift can then finally
established by the cross peak H6\H5 in the DQF-COSY spectrum (Figure 3.15).
H1-H2 H2-H3
H3-H4
Figure 3.14 DQF-COSY spectrum of GM1 mimic 14. Red lines show through-bond connectivity of the
terminal galactose ring.
Figure 3.15 Partial HSQC and DQF-COSY spectra of GM1 mimic 14.
The complete assignment of proton and carbon resonances for the ganglioside mimics 8,
11 and 14 is summarized in Tables 3.1 and 3.2.
C6 C6-H6
H6,6`- H5
COSY
HSQC
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Chemical shift, ppmSugar unit Atomnumber GM3 mimic 8 GM2 mimic 11 GM1 mimic 14
1 104.25 104.21 104.19
2 74.75 74.77 74.75
3 76.43 76.31* 76.31*
4 81.01 81.40 81.44
5 76.38 76.39 76.38
βDGlc
6 62.04 62.01 62.01
1 105.06 104.88 104.91
2 70.86 71.08 71.07
3 77.51 76.40* 76.34*
4 69.13 79.02 79.02
5 76.87 75.57 75.58
βDGal
6 62.54 61.75 61.74
1 175.41 175.66 175.67
2 101.07 103.42 103.45
3 41.83 38.61 38.57
4 69.26 69.64* 69.67*
5 54.13 53.80 53.79
6 74.82 75.10 75.09
7 70.08 70.41 70.43
8 73.00 73.39 73.38
9 64.48 65.33 65.34
N-C=O 175.50 175.11 175.21
αDNeuAc
CH3 22.66 22.60 22.61
1 104.24 104.09
2 54.23 52.70
3 74.07 82.96
4 69.84* 69.72*
5 76.26 75.89
6 63.00 62.96
N-C=O 174.74 174.84
βDGalNAc
CH3 23.60 23.77
1 106.57
2 72.50
3 74.58
4 70.24
5 76.48
βDGal
6 62.40
*Examples of assignments that could not be determined at lower fields
Table 3.1 Assignment of 13C resonances in GM3 mimic 8, GM2 mimic 11 and GM1 mimic 14
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Chemical shiftSugar unit Atomnumber GM3 mimic 8 GM2 mimic 11 GM1 mimic 14
1 4.305 4.297 4.301
2 3.258 3.251 3.253
3 3.545 3.505 3.513
4 3.595 3.547 3.544
5 3.421 3.400 3.402
6b 3.924 3.912 3.913
βDGlc
6a 3.902 3.889 3.887
1 4.459 4.453 4.451
2 3.593 3.429 3.431
3 4.079 4.037 4.036
4 3.953 4.168 4.178
5 3.596 3.704 3.708
6b 3.792 3.888 3.891
βDGal
6a 3.694 3.704 3.709
3eq 2.889 2.760 2.758
3ax 1.778 1.925 1.929
4 3.773 3.850 3.872
5 3.732 3.695 3.701
6 3.656 3.457 3.450
7 3.527 3.419 3.417
8 3.897 3.766 3.777
9b 3.874 3.892 3.899
9a 3.654 3.572 3.570
αDNeuAc
CH3 2.044 2.036 2.040
1 4.858 4.938
2 4.009 4.176
3 3.592 3.696
4 3.797 4.046
5 3.825 3.849
6b 3.777 3.788
6a 3.717 3.722
βDGalNAc
CH3 2.036 2.017
1 4.474
2 3.551
3 3.503
4 3.868
5 3.576
6b 3.744
βDGal
6a 3.744
Table 3.2 Assignment of 1H resonances in GM3 mimic 8, GM2 mimic 11 and GM1 mimic 14
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3.3 Conclusions
We have successfully extended a chemoenzymatic method for the efficient synthesis of
glycan chains of gangliosides52 to poorly water-soluble lactosides, and showed the latter to
be excellent substrates for C.jejuni glycosyltranferases. As such an extension to
methanol/water mixtures may be rather general, this will simplify the synthesis of a wide
variety of oligosaccharides that are of interest to be attached onto solid substrates for
sensing or diagnostics purposes, as in carbohydrate arrays.65, 66 A full ab initio assignment
was made of all 1H and 13C chemical shifts in the 900 MHz NMR spectra of the synthesized
compounds GM3, GM2 and GM1 derivatives 8, 11 and 14.  This approach will also allow for
the full assignment of the sugar moieties of other (naturally occurring) glycolipids.
Binding studies GM1 analogue 14 with bacterial toxins and antibodies from the sera of
GBS patients clearly demonstrated that such GM1 mimics can be efficiently used to detect
both toxins and antibodies involved in human diseases.  This opens up their application as
valuable alternatives for bovine brain-derived GM1 in diagnostic and therapeutic studies.
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3.4 Experimental
3.4.1 General methods
NMR spectra were recorded on a Bruker Avance 900 spectrometer. All the
measurements were done at 298 K in CD3OD.  HRMS data were collected on a Q-TOF
Ultima (Waters Corporation) machine. Solvents and chemicals were purchased from Sigma
Chemical Co. Thin layer chromatography (TLC) was performed on Merck silica gel 60F254
aluminium backed plates, and detection was realized by either of the following methods: UV
(254 nm), charring with a solution of KMnO4(aq) or with 5% (v/v) sulfuric acid in ethanol and
subsequent heating.
3.4.2. Enzymes
The C. jejuni UDP-GlcNAc 4-epimerase (construct CPG-13) was expressed and purified
as described by Bernatchez et al.67 The C. jejuni Cst-I -(2,3)-sialyltransferase (construct
CST-06) was expressed as a fusion protein with the E. coli maltose-binding protein (without
the leader peptide) and purified on amylose resin according to the manufacturer's
instructions (New England Biolabs, Beverly, MA). The C. jejuni -(1,3)-galactosyltransferase
(construct CJL-20) was expressed and purified as described by Linton et al.68 The C. jejuni
-(1,4)-N-acetylgalactosaminyltransferase (construct CJL-30) was expressed as described
by Blixt et al.52 The cell extracts were prepared using an Avestin C5 Emulsiflex cell disruptor
(Avestin, Ottawa, Canada). In the case of CJL-30, we did not purify the enzyme but used an
extract that was clarified by centrifugation at 27,000 g and stored at -20 oC in 50 mM Hepes
buffer (pH 7) with 40% glycerol.
3.4.3. Undec-10-enyl β-D-galactopyranosyl-(1→4)-β-D-glucopyranoside (1)
Undec-10-enyl 2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl-(1→4)-2,3,6-tri-O-acetyl-β-D-
glucopyranoside (6) (1 g) was dissolved in anhydrous CH3OH (10 ml). A freshly prepared 1
M NaOMe solution in anhydrous CH3OH (100 µl) was added, and the mixture was stirred
overnight at room temperature. More methanol (50 ml) was added to dissolve the formed
precipitate, followed by addition of the acidic ion exchange resin Amberlite IR-120H, and the
mixture was stirred for 10 min. The resin was filtered off, washed with methanol, and the
filtrate concentrated under reduced pressure to give 0.62 g (99%) of 1 as a white powder
which was used without additional purification. Selected 1H NMR (400 MHz, CD3OD): 
5.87-5.74 (m, 1H, -CH2-CH=CH2), 5.04-4.91 (m, 2H, -CH2-CH=CH2), 4.21 (d, 1H, J 7 Hz,
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HGal-1), 4.17 (d, 1H, J 7.5 Hz, HGluc-1), 3.01 (m, 1H, HGluc-2), 2.06-1.97 (m, 2H, -CH2-
CH=CH2). 13C NMR (101 MHz, CD3OD):  139.71, 115.41, 104.78, 103.40, 81.71, 79.98,
76.43, 75.86, 75.62, 74.12, 74.00, 71.46, 69.58, 68.91, 61.44, 61.20, 34.03, 31.47, 29.85,
29.75, 29.69, 29.37, 29.13.
3.4.4. Undec-10-ynyl 2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl-(1→4)-2,3,6-tri-O-
acetyl-β-D-glucopyranoside (7)
A solution of octa-O-acetyl--lactose (5) (3.00 g, 4.42 mmol), undec-10-yn-1-ol (1.49 g,
8.84 mmol) and molecular sieves 4Å (1.0 g) in CH2Cl2 (anhydrous, 30 ml) was stirred under
nitrogen at room temperature for 30 min and then cooled on ice. Subsequently, boron
trifluoride etherate (5 mL, 35.37 mmol) was added dropwise over a period of 5 min and the
whole was stirred under nitrogen atmosphere overnight while it was slowly reaching room
temperature. The reaction mixture was poured onto ice water (50 mL) with stirring. The
organic layer was separated, washed successively with 10% aqueous KHCO3 and brine,
and dried over sodium sulfate. The solvent was evaporated in vacuo to give 4.89 g of
residue. Column chromatography (gradient of EtOAc : PE = 1 : 2 to 100% EtOAc) yielded 7
(1.37 g, 40%) as a white foam.
1H NMR (400 MHz, CDCl3):   5.18 (dd, 1H, J3’,4’ 3.4, J4’,5’ 0.8 Hz, H4’), 5.03 (t, 1H, J2,3 =
J3,4 9.0 Hz, H3), 4.93 (dd, 1H, J2’,3’ 10.5, J1’,2’ 7.9 Hz, H2’), 4.82 (dd, 1H, J2’,3’ 10.5 J3’,4’ 3.4 Hz,
H3’), 4.72 (dd, 1H, J2,3 9.0 J1,2 7.5 Hz, H2), 4.38 (d, 1H, J1’,2’ 7.9 Hz, H1’), 4.32 (d, 1H, J1,2 7.5
Hz, H1), 4.31 (m, 1H,  H6a), 4.01-3.90 (m, 3H, H6b, H6’a, H6’b), 3.79 (m, 1H, H5’), 3.68 (m, 1H, -
OCHa-), 3.66 (~t, 1H, J4,5 9.5, J3,4 9.0 Hz, H4), 3.47 (ddd, 1H, J4,5 9.5, J5, 6b 5.5, J5, 6a 2.0 Hz,
H5), 3.3 (dt, 1H, 2J 9.5, 3J 6.5 Hz, -OCHb-), 2.04-1.98 (m, 5H, -CH2-C≡CH, Ac at 1.99), 1.96
(s, 3H, Ac), 1.91 (s, 3H, Ac), 1.90-1.88 (m, 6H, 2 x Ac), 1.87 (s, 3H, Ac), 1.83 (t, 1H, -CH2-
C≡CH), 1.8 (s, 3H, Ac), 1.47-1.30 (m, 4H, -(CH2)2-), 1.27-1.08 (m, 10H, -CH2)5-). 13C NMR
(101 MHz, CDCl3):  170.0, 169.9, 169.8, 169.6, 169.4, 169.1, 168.7 (7 x C=O), 100.6 (C1’),
100.2 (C1), 84.3 (-CH2-C≡CH), 76.0 (C4), 72.5 (C3), 72.2 (C5), 71.3 (C2), 70.6 (C3’), 70.2 (C5’),
69.7 (-OCH2-), 68.8 (C2’), 68.0 (-CH2-C≡CH), 66.4 (C4’), 61.8 (C6), 60.6 (C6’), 29.0, 28.9,
28.8, 28.6, 28.3, 28.0, 25.4 (-(CH2)7-), 20.4, 20.3, 20.2, 20.1 (7 x CH3-C(O)-, peaks overlap),
18.0 (-CH2-C≡CH). QTOF-MS [M+H]+ 787.3411 (calcd 787.3388).
3.4.5. Undec-10-ynyl β-D-galactopyranosyl-(1→4)-β-D-glucopyranoside (2)
Compound 7 (1.37 g) was dissolved in anhydrous CH3OH (15 mL) and 150 µL of freshly
prepared 1M sodium methanolate in anhydrous CH3OH were added to the solution. The
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mixture was heated to reflux for 15 min. After cooling, more methanol was added to dissolve
the precipitate, followed by neutralization with Amberlite IR-120H for 10 min. The resin was
filtered off, washed with methanol, and the filtrate concentrated under reduced pressure to
give 0.91 g (100%) of 2 as a white powder which was used without further purification.
Selected 1H NMR (400 MHz, DMSO-D6):   4.20 (d, 1H, J 7 Hz, HGal-1), 4.15 (d, 1H, J 8 Hz,
HGluc-1), 3.00 (m, 1H, HGluc-2), 2.65 (t, 1H, J 2.5 Hz, -CH2-C≡CH), 2.14 (td, 2H, J 6.5 Hz, J 2.5
Hz, -CH2-C≡CH). 13C NMR (101 MHz, DMSO-D6):  104.22, 103.02, 84.98, 81.19, 75.98,
75.48, 75.24, 73.74, 73.64, 71.28, 71.07, 69.13, 68.61, 61.12, 60.86, 29.67, 29.27, 29.20,
28.81, 28.50, 28.35, 25.87, 18.08.
3.4.6. Undec-10-enyl (5-Acetamido-3,5-dideoxy-D-glycero-α-D-galacto-non-2-
ulopyranosylonic acid)-(2→3)-β-D-galactopyranosyl-(1→4)-β-D-glucopyranoside (8)
Compound 1 (100 mg, 202.4 µmol) was first dissolved in 10 ml of methanol. We then
added 30 mL of CMP-Neu5Ac (200 mg, 325.5 µmol, dissolved in water), 2.5 ml of 1 M
Hepes buffer (pH 7.5), 0.5 ml of 1 M  MgCl2 and 2.5 ml (14 U) of CST-06. The reaction was
kept at 37 °C for 1 h, after which 100% of the starting material was converted to product.
The reaction was repeated once to convert a total of 200 mg of compound 1 to compound 8.
One third of the reaction mixture was centrifuged and loaded on a Sep-Pak column
equilibrated with methanol. Hydrophilic material was washed off with water and the product
was eluted with methanol. Appropriate fractions were collected and evaporated to give 84
mg (92 %) of compound 8 as white powder. [α]D +2 (c 0.5, H2O). QTOF-MS [M+H]+
786.3794 (calcd 786.3755, Δ ppm =5.0).
3.4.7. Undec-10-enyl (5-Acetamido-3,5-dideoxy-D-glycero-α-D-galacto-non-2-
ulopyranosylonic acid)-(2→3)-[2-acetamido-2-deoxy- β-D-galactopyranosyl-(1→4)]-β-
D-galactopyranosyl-(1→4)-β-D-glucopyranoside (11)
60 ml of the previous reaction mixture containing approximately 212 mg (270 µmol) of
GM3 oligosaccharide 8 was used directly for the synthesis of the GM2 oligosaccharide (11).
We added 50 mL of  UDP-GlcNAc (260 mg, 399 µmol, dissolved in water), 1.2 ml of 1 M
MnCl2, 5 ml (23 U) of CJL-30, and 3 mL (22.5 U) of CPG-13. The reaction was kept at 37 °C
for 2 h. At that point at least 95% of the starting material was converted to product and the
reaction mixture was centrifuged and loaded on a Sep-Pak column equilibrated with
methanol. Hydrophilic material was washed off with water and the product was eluted with
methanol. Appropriate fractions were collected and evaporated to give 265 mg (268 µmol,
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99.3% yield) of compound 11 as a white powder. [α]D +12 (c 0.34, H2O). QTOF-MS [M+H]+
989.4555 (calcd 989.4549, Δ ppm =0.6).
3.4.8. General procedure for the synthesis of GM2 analogues 12-13
Lactoside 2 or 3 (300 µmol) was dissolved in methanol (20 mL). Subsequently, aqueous
solution of CMP-Neu5Ac (500 µmol), Hepes buffer (1 M, 4 mL, pH 7.5), MgCl2 (1 M, 0.8 mL)
and  CST-06 (10.5 U) were added. The total volume of the reaction mixture was brought to
80 mL with water. The reaction was kept at 37 °C for 1 h, after which 100% of the starting
material was converted to product (TLC analysis). The reaction was repeated to convert a
total of 750 mg of compound 2 and 500 mg of compound 3. The combined reaction mixtures
of each compound were centrifuged and the supernatant was used directly for the synthesis
of GM2 oligosaccharide.
To 100 mL of thus prepared solution of GM3 oligosaccharide 9 or 10, aqueous solutions
of UDP-GlcNAc (50 mM, 10 mL), MnCl2 (1 M, 2 ml), CJL-30 (6.2 U/ml, 15 mL) and CPG-13
(193.6 U/mL, 4 mL) were added. The total volume of the reaction mixture was brought to 200
mL with water and the reaction was kept at 37 °C for 2 h. The reaction mixture was
centrifuged and loaded on a Sep-Pak column equilibrated with methanol. Hydrophilic
material was washed off with water and the product was eluted with methanol. Appropriate
fractions, containing the product, were collected and evaporated to give compound 12 or 13
quantitatively.
3.4.8.1. Undec-10-ynyl (5-Acetamido-3,5-dideoxy-D-glycero-α-D-galacto-non-2-
ulopyranosylonic acid)-(2→3)-[2-acetamido-2-deoxy- β-D-galactopyranosyl-(1→4)]-β-
D-galactopyranosyl-(1→4)-β-D-glucopyranoside (12). [α]D +17 (c 0.59, H2O). Selected
1H NMR (400 MHz, CD3OD):  4.78 (d, 1H, J 8.6 Hz, HGalNAc-1), 4.43 (d, 1H, J 7.8 Hz, HGal-1),
4.24 (d, 1H, J 7.8 Hz, HGluc-1), 3.23 (m, 1H, HGluc-2), 2.66 (dd, 1H, J 4 Hz, HNeuAc-3eq).
13C NMR (101 MHz, CD3OD):  175.39, 175.00, 174.50, 104.20 (CGal-1), 103.77 (CGluc-1), 103.75
(CGalNAc-1), 102.82 (CNeuAc-2), 84.63 ( CH2-C≡CH), 80.35 (CGluc-4), 78.48 (CGal-4), 75.96 (CGluc-
5), 75.96 (CGal-3), 75.87 (CGalNAc-5), 75.57 (CGluc-3), 75.17 (CGal-5), 74.58 (CNeuAc-6), 74.36 (CGluc-
2), 73.20 (CGalNAc-3), 73.15 (CNeuAc-8), 70.91 (CGal-2), 70.37 (CH2-OCGluc1), 69.97 (CNeuAc-7),
69.23 (CGalNAc-4), 69.21 (CNeuAc-4), 68.31 ( CH2-C≡CH), 64.70 (CNeuAc-9), 62.55 (CGalNAc-6), 61.64
(CGluc-6), 61.41 (CGal-6), 54.03 (CGalNAc-2), 53.61 (CNeuAc-5), 38.77 (CNeuAc-3), 29.78 , 29.00 , 28.72
, 28.66 , 28.41 , 28.18 , 25.65 , 22.83 (CGalNAc-CH3), 22.49 (CNeuAc-CH3), 18.10 (-CH2-C≡CH).
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3.4.8.2. 10-Azidoundecyl (5-Acetamido-3,5-dideoxy-D-glycero-α-D-galacto-non-2-
ulopyranosylonic acid)-(2→3)-[2-acetamido-2-deoxy- β-D-galactopyranosyl-(1→4)]-β-
D-galactopyranosyl-(1→4)-β-D-glucopyranoside (13). [α]D +15 (c 0.3, H2O). Selected
1H NMR (400 MHz, CD3OD):   4.79 (d, 1H, J 8.6 Hz, HGalNAc-1), 4.42 (d, 1H, J 7.8 Hz, HGal-
1), 4.26 (d, 1H, J 7.8 Hz, HGluc-1), 3.27 (t, 2H, J 6.8 Hz, CH2-N3), 3.22 (m, 1H, HGluc-2), 2.66
(dd, 1H, J 4 Hz, HNeuAc-3eq). 13C NMR (101 MHz, CD3OD):  175.47, 105.11 (CGal-1), 104.26
(CGalNAc-1), 104.11 (CGluc-1), 81.46 (CGluc-4), 78.64 (CGal-4), 76.84 (CGal-3), 76.61 (CGluc-5),
76.42 (CGluc-3), 76.39 (CGalNAc-5), 75.64 (CGal-5), 75.33 (CNeuAc-6), 74.79 (CGluc-2), 74.49
(CGalNAc-3), 73 (CNeuAc-8), 70.98 (CH2-OCGluc1), 70.95 (CGal-2), 70.44 (CNeuAc-7), 69.79
(CGalNAc-4), 69.15 (CNeuAc-4), 65.43 (CNeuAc-9), 62.97 (CGalNAc-6), 62.03 (CGluc-6), 61.65 (CGal-
6), 54.65 (CGalNAc-2), 53.64 (CNeuAc-5, 52.5 (CH2-N3), 38.75 (CNeuAc-3), 30.82, 30.73, 30.66,
30.62, 30.31, 29.96, 27.87, 27.13, 23.43 (CGalNAc-CH3), 22.68 (CNeuAc-CH3).
3.4.9. Undec-10-enyl β-D-galactopyranosyl-(1→3)-2-acetamido-2-deoxy- β-D-
galactopyranosyl-(1→4) -[(5-Acetamido-3,5-dideoxy-D-glycero-α-D-galacto-non-2-
ulopyranosylonic acid)-(2→3)]-β-D-galactopyranosyl-(1→4)-β-D-glucopyranoside (14)
Compound 11 (30 mg, 30.6 µmol) and UDP-Gal (27.5 mg, 45 µmol) were dissolved in
2.4 ml of water. We then added 1 mL of 1 M Mes buffer (pH 6), 0.2 mL of 1 M MnCl2, 0.02
mL of 1 M dithiothreitol, and 16 mL of CJL-20 (3.35 units). The reaction was kept at 37 °C for
4 h. The mixture was centrifuged and loaded on a Sep-Pak column equilibrated with
methanol. Hydrophilic material was washed off with water and the product was eluted with
methanol. Appropriate fractions were collected and evaporated to give 33 mg (28.7 µmol,
93.8% yield) of compound 14 as white powder. [α]D +7.8 (c 0.26, H2O). QTOF-MS [M+H]+
1151.5054 (calcd 1151.5067, Δ ppm =-1.1).
3.4.10. General procedure for the synthesis of GM1 analogues 15-16
Compound 12 or 13 (100 mg, 101 µmol of 12 or 97 µmol of 13) and UDP-Glc (75 mg,
122 µmol) were dissolved in HEPES buffer (17.6 ml, pH 7.5). Subsequently, aqueous
solutions of MnCl2 (1 M, 0.2 mL), dithiothreitol (0.1 M, 0.2 mL), CPG-13 (0.5 mL, 270 U/mL,
135 units) and CJL-13769 (1.5 mL, 0.5 U/mL, 0.75 units) were added. The whole was
incubated at 37 °C for 2 h. The mixture was centrifuged and loaded on a Sep-Pak column
equilibrated with methanol. Hydrophilic material was washed off with water and the product
was eluted with methanol. Appropriate fractions were collected and evaporated to give GM1
oligosaccharides 15 and 16.
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3.4.10.1. Undec-10-ynyl β-D-galactopyranosyl-(1→3)-2-acetamido-2-deoxy- β-D-
galactopyranosyl-(1→4) -[(5-Acetamido-3,5-dideoxy-D-glycero-α-D-galacto-non-2-
ulopyranosylonic acid)-(2→3)]-β-D-galactopyranosyl-(1→4)-β-D-glucopyranoside (15).
[α]D +8.3 (c 0.24, H2O). Selected 1H NMR (400 MHz, CD3OD):  4.89 (HGalNAc-1), 4.46 (d, 1H,
J 7.1 Hz, HGal’-1), 4.45 (d, 1H, J 7.8 Hz, HGal-1), 4.27 (d, 1H, J 7.8 Hz, HGluc-1), 3.23 (dd, 1H,
J2,3 9.0 J1,2 7.9 Hz, HGluc-2), 2.74 (dd, 1H, J 4 Hz, HNeuAc-3eq). 13C NMR (101 MHz, CD3OD):
 175.40, 175.10, 174.60 (CNeuAc-1, CNeuAc-C(O)CH3, CGalNAc-C(O)CH3), 106.09 (CGal’-1),
104.23 (CGal-1), 103.75 (CGluc-1), 103.60 (CGalNAc-1), 102.85 (CNeuAc-2), 84.64 (-CH2-C≡CH),
82.09 (CGalNAc-3), 80.39 (CGluc-4), 78.48 (CGal-4), 76.10 (CGal’-5), 75.95 (CGluc-5), 75.89 (CGal-
3), 75.57 (CGluc-3), 75.50 (CGalNAc-5), 75.18 (CGal-5), 74.57 (CNeuAc-6), 74.34 (CGluc-2), 74.08
(CGal’-3), 73.14 (CNeuAc-8), 72.04 (CGal’-2), 70.91 (CGal-2), 70.39 (CH2-OCGluc1), 69.99 (CNeuAc-
7), 69.83 (CGal’-4), 69.24 (CNeuAc-4), 69.11 (CGalNAc-4), 68.31 (-CH2-C≡CH), 64.71 (CNeuAc-9),
62.51 (CGalNAc-6), 62.07 (CGal’-6), 61.64 (CGluc-6), 61.40 (CGal-6), 53.60 (CNeuAc-5, 52.50
(CGalNAc-2), 38.73 (CNeuAc-3), 29.34, 29.09, 29.00, 28.71, 28.40, 28.18, 25.64, 23.00 (CGalNAc-
CH3), 22.50 (CNeuAc-CH3), 18.09 (-CH2-C≡CH).
3.4.10.2. 10-Azidoundecyl β-D-galactopyranosyl-(1→3)-2-acetamido-2-deoxy- β-D-
galactopyranosyl-(1→4) -[(5-Acetamido-3,5-dideoxy-D-glycero-α-D-galacto-non-2-
ulopyranosylonic acid)-(2→3)]-β-D-galactopyranosyl-(1→4)-β-D-glucopyranoside (16).
[α]D +7.1 (c 0.23, H2O). Selected 1H NMR (400 MHz, CD3OD):  4.88 (HGalNAc-1), 4.46 (d, 1H,
J 7.1 Hz, HGal’-1), 4.45 (d, 1H, J 7.8 Hz, HGal-1), 4.27 (d, 1H, J 7.8 Hz, HGluc-1), 3.27 (t, 2H, J
6.8 Hz, CH2-N3), 3.23 (dd, 1H, J2,3 9.0 J1,2 7.9 Hz, HGluc-2), 2.73 (dd, 1H, J 4 Hz, HNeuAc-3eq),
2.02 (s, 3H, NHC(O)CH3), 2.00 (s, 3H, NHC(O)CH3), 1.90 (t, 1H, J 12 Hz, HNeuAc-3ax).
13C NMR (101 MHz, CD3OD):  175.69, 175.25, 174.99 (CNeuAc-1, CNeuAc-C(O)CH3, CGalNAc-
C(O)CH3), 106.61 (CGal’-1), 104.77 (CGal-1), 104.27 (CGluc-1), 104.21 (CGalNAc-1), 103.4
(CNeuAc-2), 82.61 (CGalNAc-3), 80.72 (CGluc-4), 79.12 (CGal-4), 76.52 (CGal’-5), 76.36 (CGluc-5),
76.33 (2 x C, CGal-3 and CGluc-3, peaks overlap), 75.85 (CGalNAc-5), 75.57 (CGal-5), 75.13
(CNeuAc-6), 74.96 (CGluc-2), 74.67 (CGal’-3), 73.43 (CNeuAc-8), 72.53 (CGal’-2), 71.25 (CGal-2),
70.98 (CH2-OCGluc1), 70.44 (CNeuAc-7), 70.24 (CGal’-4), 69.65 (2 x C, CNeuAc-4 and CGalNAc-4,
peaks overlap), 65.39 (CNeuAc-9), 62.97 (CGalNAc-6), 62.42 (CGal’-6), 61.9 (CGluc-6), 61.85 (CGal-
6), 53.82 (CNeuAc-5, 52.69 (CGalNAc-2), 52.47 (CH2-N3), 38.61 (CNeuAc-3), 30.8, 30.76, 30.71,
30.65, 30.61, 30.29, 29.94, 27.84, 27.11 (-(CH2)9-), 23.82 (CGalNAc-C(O)CH3), 22.67 (CNeuAc-
C(O)CH3).
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3.4.11. ELISA for detection of LT-B
Recombinant LT-B was produced in E.coli strain PC2923 and purified to homogeneity by
affinity chromatography on D-galactose essentially as described.70 All natural gangliosides
were from bovine brain. GM1 and asialo-GM1 were from Sigma Aldrich, St. Louis, USA
(G7641, G3018) and lyso-GM1 from Calbiochem-Novabiochem Corporation, La Jolla, USA
(345739).
Microtiter plates (PolySorp Immunoplates, Nunc) were coated with gangliosides at 5
µg/mL in phosphate buffered saline and serial two-fold dilutions of rec-LT-B were loaded
onto coated plates. Binding was measured using an LT-B specific monoclonal antibody as
described.71
3.4.12. ELISA for detection of CT-B and anti-GM1 antibodies
Bovine bran derived GM1 (Sigma Aldrich, St. Louis, USA, G7641) (200 pmol/well) and
synthetic GM1- analogue 14 (300 pmol/well) were coated on microtiter plates (MaxiSorb
Immunoplates, Nunc). Wells were incubated with peroxidase conjugated cholera toxin B
subunit (CT-B), mouse IgG monoclonal antibodies (mAbs) DG1 and DG2 (10 µg/ml), human
IgM mAbs SM1 (10 µg/ml) and serum samples (diluted 1:100 in phosphate buffered saline
buffer, pH 7.4) from a normal control (NC) and an anti-GM1 IgM and IgG positive patients
with Guillain-Barré syndrome (GBS). CT-B was incubated for at room temperature for one
hour and the monoclonal antibody and serum dilutions were incubated at 4 °C overnight. The
presence of bound mouse monoclonal antibodies, human monoclonal antibodies and serum
IgM and IgG antibodies to GM1 and synthetic GM1 analogue was detected by respectively
peroxidase-conjugated rabbit anti-mouse IgM, anti-human IgM and anti-human IgG as a
second step.21 All results are given as mean specific optical densities at 492 nm (mean OD
of in duplo coated wells minus mean OD of in duplo blanc wells).
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CHAPTER 4
Chemoenzymatic Synthesis of Biotin-Appended
Analogues of Gangliosides GM2, GM1, GD1a and
GalNAc-GD1a for Solid-Phase Applications and
Improved ELISA tests
Abstract – Biotinylated analogues of gangliosides GM2, GM1, GD1a and GalNAc-GD1a
were synthesized in high yields using glycosyltransferases from Campylobacter jejuni. The
presence of a biotin moiety in the aglycone part of these mimics allows for attachment of
these materials on various streptavidin-coated surfaces. Analysis of the interaction of biotin-
appended GM1 with the B subunit of Escherichia coli heat-labile enterotoxin performed in a
modified ELISA procedure shows the potential of this compound to replace the natural GM1
in toxin detection.
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4.1 Introduction
In recent years, the immobilization of oligosaccharides on solid supports and particles,
along with their conjugation to proteins, has received increasing attention as a valuable tool
to gain insight into the function of carbohydrates and improvement of their functionality.1-8
Consequently, there has risen a need for oligosaccharides that are suitably equipped with
functional groups designed for such studies and applications.9 Among the various
immobilization techniques,1, 10, 11 those based on the (strept-)avidin-biotin couple12-14 are
especially useful for two reasons: 1) the high and specific affinity of (strept-)avidin to biotin,15
and 2) the possibility to avoid complicated chemical treatments that would limit the scope of
applicable sugars and (or) alter their primary structure during the immobilization.
Accordingly, biotin-appended carbohydrates are of interest, and several procedures for the
incorporation of a biotin moiety in the aglycone part of mono- and oligosaccharides have
been reported,16-23 along with subsequent immobilization on a solid surface or preparation of
glycoconjugates12-14, 16, 24, 25 and glyconanoparticles.26-28
However, not the methods of biotinylation, but rather the synthetic availability of complex
carbohydrates is often the limiting factor in such (and other) studies. This is particularly
relevant in the case of gangliosides, a subclass of glycosphingolipids that all contain one or
more sialic acid residues but vary in other parts, such as the number of ring structures and
overall composition. Gangliosides are present in all mammalian cells, and are particularly
abundant in neuronal tissues. They are key signaling molecules of major cellular processes,
including cellular recognition, adhesion, receptor signal transduction, growth regulation,
differentiation and apoptosis.29-31 Apart from that, gangliosides act as receptors for bacterial
toxins including Vibrio cholerae toxin and Escherichia coli heat-labile enterotoxin that bind
with high affinity to GM1 ganglioside.32-34 In addition, gangliosides are primary targets for
auto-antibodies that cause immune-mediated forms of polyneuropathy including Guillain-
Barré Syndrome,35 in which apart from anti-GM1 antibodies, antibodies against other
gangliosides are relevant.35-38 The detection of toxins39, 40 and antibodies41 is based on the
recognition thereof in ELISA assays by bovine brain-derived gangliosides. These natural
extracts have several drawbacks, as they are limited in scope, difficult to purify, expensive,
potentially infected and usually contaminated with other glycolipids. Apart from that, active
surfaces obtained via a direct adsorption of gangliosides are not always optimal. Thus, a
benefit of using an ordered GM1 monolayer on an air-water interface rather than the
conventional GM1-adsorbed solid support for the selection of GM1-binding peptides, was
reported.42 Given the availability and wide use of streptavidin-coated ELISA plates, the
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synthesis of structurally analogous mimics of gangliosides containing biotin-appended
aglycone would thus bring advantages to the field of detection and diagnostics, as well as to
other (bio)medical applications that involve biotin-streptavidin interactions.
The difficulties associated with the introduction of the sialic acid to an oligosaccharide
core structure43 make the task of an efficient preparation of gangliosides and their analogues
particularly challenging,44 despite several successful chemical approaches to their
synthesis.45-48 Chemoenzymatic strategies, however, are able to considerably facilitate the
synthesis of sialylated compounds. Thus, a very efficient method49 for the synthesis of
gangliosides GD3, GT3, GM2, GD2, GT2, GM1 and GD1a was developed based on
glycoengineering by selected recombinant glycosyltransferases from Campylobacter jejuni.50
With this strategy, ganglioside analogues were prepared in high yields that contain a 2-
azidoethyl aglycone,49 a truncated functionalized ceramide unit,51 S-linked ganglioside
analogues,52 or a long hydrophobic chain* that also contains -functionalization for
applications in biosensing.53, 54
In the present study, we aim to combine the strength and specificity of the biotin-
(strept)avidin interaction with the flexibility and efficiency of the chemoenzymatic synthesis,
in the synthesis of  biotin-appended analogues of gangliosides GM2, GM1, GD1a and
GalNAc-GD1a via glycosyltransferases from C. jejuni. The synthesis of one of the
ganglioside structures involved, an oligosaccharide containing the structure of GalNAc-
GD1a, is, to the best of our knowledge, reported here for the first time. Subsequently, as a
first result of the exploration of usefulness of synthetic gangliosides, we demonstrate here
the advantage of the biotinylated GM1 mimic over the natural bovin brain-derived GM1 for
the detection of Escherichia coli heat-labile enterotoxin in a modified ELISA procedure.
* See Chapter 3 for the improved procedure for the enzymatic synthesis of ganglioside analogues
from poorly soluble in water lactosides with long hydrophobic aglycones. The application of these
ganglioside analogues in synthesis of multivalent GM1 and GM2 mimics (strong inhibitors of cholera
toxin) is described in Chapter 5.
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4.2 Results and Discussion
4.2.1 Synthesis of biotin-appended ganglioside analogues
In order to accomplish enzymatic syntheses of ganglioside analogues with authentic
oligosaccharide sequences, one needs a lactose moiety that is modified at the reducing end
according to the envisioned application. For the use as a starting compound in the enzymatic
modifications in this study, a biotin-appended lactoside 6 was synthesized (Scheme 4.1).
Peracetylated lactosyl  bromide 1 was glycosidated with 8-azidooctanol 3, prepared by a
substitution reaction from 8-chlorooctanol 2, to give 8-azidooctyl heptaacetyl lactoside 4 in a
moderate yield of 50%.* Although -azidoalkyl lactosides were shown by others49 and us54 to
be excellent substrates for glycosyltransferases, it is logical to further modify the aglycone
prior to enzymatic reactions with a view to both exploit the substrate acceptability of the
glycosyltransferases and to avoid additional manipulations with the final (and expensive)
ganglioside products. The azido group in 4 was reduced by hydrogenation, to give the amino
terminated lactoside 555 in a nearly quantitative yield. Coupling of 5 to biotin was
accomplished with the use of EDC activation under inert atmosphere. The subsequent
removal of acetyl groups by the classical Zemplén procedure56 required 4 days and afforded
the biotin-appended lactoside 6 in an excellent yield of 95% over two steps. The use of the
unprotected amino group in the aglycone was shown not to be practical in the enzymatic
reactions,51 therefore we did not consider intermediate 5 as a suitable (after deacetylation)
starting compound.
Scheme 4.1. Synthesis of biotin-appended lactose. Reagents and conditions: (a) NaN3, DMSO, 102
°C, overnight, quant.; (b) AgOTf, toluene, -78 °C → 10 °C, 50%; (c) Pd/C (10%), MeOH, rt, quant.; (d)
biotin (1 eq), EDC (1 eq), DMAP (1 eq), DMF, rt, N2; (e) NaOMe, MeOH, rt, 95% over 2 steps.
* For a more recently developed efficient and high-yielding glycosylation method, by which 4 can be
obtained, see Chapter 2.
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The conversion of lactoside 6 into biotinylated ganglioside analogues 8 - 11, as depicted
in Scheme 4.2, was achieved in a series of enzymatic reactions that combine the use of
recombinant glycosyltransferases from Campilobacter jejuni in well-described  procedures49,
51 with our recently published modification54 at the early steps (syntheses of GM3 and GM2).
Thus, sialylation of 6 was effected by CMP-NeuAc and catalyzed by the Cst-I α-(2-3)-
sialyltransferase (construct CST-06) in a methanol/water (25/75 v/v) medium at 37 °C for 1
h. The resulting GM3 analogue 7 was not isolated, and after complete conversion of 6, UDP-
GlcNAc, UDP-GlcNAc 4'-epimerase (CPG-13) and the CgtA -(1,4)-N-
acetylgalactosaminyltransferase (construct CJL-30) from C. jejuni were added directly to the
reaction mixture. The use of UDP-GlcNAc 4'-epimerase in one-pot mixtures with
transferases effectively addresses a major drawback of glycosylation reactions, namely the
limited availability and high cost of the necessary glycosyl donors. This allowed for the
reaction of 7 with the in-situ formed UDP-GalNAc, and after isolation on a Sep-Pak column,
the GM2 analogue 8 was obtained in a yield of 90 % (from the lactose-derivative 6). Further
elongation of GM2 analogue 8 to GM1 analogue 9 was performed in high yield (99 %) using
UDP-Gal, and the CgtB -(1,3)-galactosyltransferase (construct CJL-20).
In the family of gangliosides that act as target epitopes for the immunological response in
Guillain-Barré Syndrome, apart from GM1, an important role is also played by gangliosides
GD1a38 and GalNAc-GD1a.57 Given the possible profit of biotinylated analogues of these
gangliosides in immunological studies, GD1a mimic 10 was synthesized by sialylation of 9
using the Cst-I α-(2-3)-sialyltransferase (construct CST-06). Compound 10 was obtained in
87 % yield after isolation, and further elongated to GalNAc-GD1a analogue 11 using the
CgtA -(1,4)-N-acetylgalactosaminyltransferase (construct CJL-30). Compound 11 was
obtained in 75 % yield after isolation. To the best of our knowledge, this is the first report of a
synthesis of an oligosaccharide that contains the GalNAc-GD1a sugar moiety.
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Scheme 4.2. Enzymatic syntheses of biotinylated ganglioside analogues. Yields: 90 % for GM2
mimic 8 (for two steps), 99% for GM1 mimic 9, 87 % for GD1a mimic 10, 75% for GalNAc-GD1a
mimic 11.
BIOTIN-APPENDED GANGLIOSIDE ANALOGUES
65
4.2.2 Analysis of interaction of biotinylated GM1 with LT- B in a modified ELISA*
It is of interest to investigate whether the conjugation of a biotin moiety to a ganglioside
structure retains the recognition properties of both carbohydrate and biotin portions of the
new molecule.  In addition, it is worthwhile to test biotinylated mimics for their bioequivalence
to the natural gangliosides and to evaluate the possibility of their use in bioapplications such
as e.g. detection and diagnostics.  Therefore a comparison was made of LT-B detection by
GM1 analogue 9 on streptavidin-coated ELISA plates (indirect coating) to routinely used
bovine brain-derived GM1 on non-streptavidin-coated plates. Binding assays were
performed on Nunc MaxisorpTM plates that - prior to the experiments with biotinylated GM1 9
- were coated with streptavidin, and all incubations were done overnight at 4 °C. After
incubation of streptavidin-coated and non-streptavidin-coated plates with GM1 mimic 9 and
natural GM1 respectively, serial twofold dilutions of pure recombinant LT-B in coating buffer
were added to the wells and binding was allowed for 16 h at 4 °C. For each LT-B
concentration, experiments were done in triplicate. The results are shown in Figure 4.1 and
are given as mean specific optical densities at 415 nm.
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Figure 4.1. Binding of B subunit of E.coli heat-labile enterotoxin (LT-B) to natural and synthetic
gangliosides coated on ELISA plates, as visualized using a monoclonal antibody specific for LT-B-
pentamer.
* See also Chapter 3 for ELISAs making use of physisorption of ganglioside analogues, and Chapter 6
for covalent attachment of GM1 mimics on the surfaces of ELISA plates.
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Figure 4.1 clearly demonstrates that at all the applied toxin concentrations, assays based
on biotinylated mimic 9 are consistently higher by at least a factor of two than conventional
assays, indicating a higher affinity of the LT-B for the compound 9 in comparison with the
natural GM1 in these experiments. The EC50 of LT-B in an assay based on 9 was
determined to be 0.06 nM versus 0.10 nM determined in the bovine GM1-based ELISA.
The specificity of the LT-B binding to the biotin-appended GM1 9 was confirmed in an
experiment in which the toxin was added to the wells of a streptavidin-coated plate, to which
no ganglioside was bound (Figure 4.1). No positive reaction was obtained for any of the
tested LT-B concentrations, thus demonstrating that it does not aspecifically bind to
streptavidin under the applied conditions. Finally, the binding affinity of streptavidin for the
biotin moiety of the compound 9 was unambiguously demonstrated in assays based on non-
streptavidin-coated plates incubated with 9 and in assays based on streptavidin-coated
plates incubated with bovine brain-derived GM1. The former assay shows negligible
response to LT-B, while in the latter no positive reaction was obtained, equal to what was
seen when using a blank streptavidin-coated plate. These results indicate that 9 is not
adsorbed on plate that is not coated with streptavidin, and also that streptavidin does not
adsorb a ganglioside structure if that contains no biotin moiety. Thus, the specificity and
increased sensitivity of the assay that involves GM1 analogue 9 and a streptavidin-coated
plate is fully attributed to the specific binding of the biotin part of 9 to the surface-bound
streptavidin. As a result of this interaction, a GM1-coated surface is formed, in which the
natural conformation of GM1 is presumably presented better than in a surface derived from
direct coating with bovine GM1. Analogous studies with a wider set of biotin-appended
gangliosides and a wider variety of detrimental proteins are currently ongoing in our
laboratories.
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4.3 Conclusions
A series of biotin-appended ganglioside analogues was efficiently synthesized by a
chemoenzymatic route that involves consecutive glycosylations of biotinylated lactose using
recombinant glycosyltransferases from C. jejuni. In this manner, biotinylated glycoside
analogues corresponding to gangliosides GM2, GM1, GD1a and GalNAc-GD1a were
obtained in high yields. The synthesis of an oligosaccharide containing the GalNAc-GD1a
sugar moiety in this manner is, in fact, the first reported synthesis of this sugar moiety.
Analysis of the interaction of GM1 analogue 9 with Escherichia coli heat-labile enterotoxin
revealed that the biotinylated ganglioside surpasses the natural bovine GM1 in the detection
of certain proteins involved in human diseases.  This clearly displays the potential of such
chemoenzymatically synthesized gangliosides in the detection of detrimental proteins
(toxins/antibodies).
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4.4 Experimental
4.4.1 General Information
NMR spectra were recorded on a Bruker Avance 400 spectrometer. Solvents and
chemicals were purchased from Sigma Chemical Co. Thin layer chromatography (TLC) was
performed on Merck silica gel 60F254 aluminium backed plates, and detection was realized
by either of the following methods: UV (254 nm), charring with a solution of KMnO4(aq) or
with 5% (v/v) sulfuric acid in ethanol and subsequent heating.
4.4.2 Enzymes
The enzymes were prepared as described by Pukin et al.54 The C. jejuni UDP-GlcNAc 4-
epimerase (construct CPG-13) was expressed and purified as described by Bernatchez et
al.58 The C. jejuni Cst-I -2,3-sialyltransferase (construct CST-06) was expressed as a fusion
protein with the E. coli maltose-binding protein (without the leader peptide) and purified on
amylose resin according to the manufacturer's instructions (New England Biolabs, Beverly,
MA). The C. jejuni CgtB -1,3-galactosyltransferase (construct CJL-20) was expressed as
described by Linton et al.59 and we used a cell extract that was clarified by centrifugation at
27,000 g. The C. jejuni CgtA -1,4-N-acetylgalactosaminyltransferase (construct CJL-30)
was expressed as described by Blixt et al.49 and we used a cell extract that was clarified by
centrifugation at 27,000 g and stored at -20 °C in 50 mM Hepes buffer (pH 7) with 40%
glycerol.
4.4.3 8-biotinoylaminooctyl lactoside (6)
Hepta-O-acetyl 8-aminooctyl lactoside 555 (0.3 g, 0.4 mmol) was dissolved in dry DMF (5
ml). To this solution, biotin (0.1 g, 0.4 mmol), EDC (0.06 g, 0.4 mmol) and DMAP (0.05 g, 0.4
mmol) were added at room temperature, and the mixture was stirred for 4 hours in the inert
atmosphere. The reaction mixture was diluted with water and extracted (5 x) with ethyl
acetate. The combined organic layer was washed with brine, and dried over Na2SO4. After
evaporation of the solvent in vacuo the residue was dissolved in anhydrous methanol. A
freshly prepared 1 M NaOCH3 solution in anhydrous CH3OH (100 µl) was added, and the
mixture was stirred overnight at room temperature. More methanol was added to dissolve
the formed precipitate, followed by addition of the acidic ion exchange resin Amberlite IR-
120H, and the mixture was stirred for 10 min. The resin was filtered off, washed with
methanol, and the filtrate concentrated under reduced pressure to give 0.25 g (95 %) of 6 as
BIOTIN-APPENDED GANGLIOSIDE ANALOGUES
69
a white powder. 1H NMR (400 MHz, DMSO-d6):  7.75 – 7.7 (m, 1H), 6.51 – 6.20 (br s, 2H),
4.75 – 4.3 (br s, 7H), 4.31 (t, J=4.4 Hz, 1 H), 4.20 (d, J=7.2 Hz, 1 H), 4.17 (d, J=8.0 Hz, 1 H),
4.13 (t, J=4.4 Hz, 1 H), 3.8 - 3.32 (m, 13H), 3.15 - 2.95 (m, 4H), 2.82 (t, J=5.2 Hz, 1 H), 2.58
(d, J=12.4 Hz, 1 H), 2.09 – 2.00 (m, 2H), 1.67 – 1.20 (m, 18H). 13C NMR (101 MHz, DMSO-
d6):  172.6, 163.6, 104.7, 103.4, 81.7, 76.4, 75.9, 75.6, 74.1, 74.0, 71.4, 69.6, 69.0, 61.9,
61.4, 61.2, 60.1, 56.3, 39.2, 36.1, 30.1, 30.0, 29.8, 29.6, 29.0, 27.3, 26.4, 26.2. ESI-MS for
[M + Na]+ found 718.31846, calcd 718.31968.
4.4.4 Synthesis of GM3-biotin 7
59 mg (85 mol) of Lac-biotin was dissolved in 10 mL of methanol  (needed to heat the
sample at 60 °C to dissolve completely). The reaction was done in a final volume of 42 mL
containing  50 mM Hepes pH 7.5, 10 mM MgCl2, 155 mol of  CMP-NeuAc and 81.4 units of
the -2,3-sialyltransferase (construct CST-06). The reaction was complete after 1 h of
incubation at 37 °C, as judged by TLC analysis, and the reaction mixture was directly used
in the next step without isolation of the product.
4.4.5 Synthesis of GM2-biotin 8
40 mL of the GM3-biotin reaction (81 mol) was used directly for the synthesis of GM2-
biotin, after centrifugation for 10 min at 2,800 x g to remove a precipitate. The reaction was
done in a final volume of 80 mL containing 50 mM Hepes pH 7, 10 mM MnCl2, 5 mM MgCl2
(remaining from the GM3-biotin reaction), 200 mol of UDP-GlcNAc, 36.8 units of the -1,4-
N-acetylgalactosaminyltransferase (construct CJL-30) and 68.1 units of the UDP-GlcNAc 4-
epimerase (construct CPG-13). The reaction was complete after 3 h of incubation at 37 °C,
as judged by TLC analysis. The reaction mixture was centrifuged 10 min at 2,800 x g. The
supernatant was diluted 2-fold with water and loaded on two Sep-Pak column (5 g)
equilibrated with water. Hydrophilic material was washed off with water and the product was
eluted with methanol. Appropriate fractions were collected and evaporated to give 87.4 mg
of product (73 mol, 90 % yield). ESI-MS for [M + Na]+ found 1212.49620, calcd 1212.49447
[ = 1.4 ppm].
4.4.6 Synthesis of GM1a-biotin 9
The reaction was performed in a final volume of 32 mL and included: 38 mg (32 mol) of
GM2-biotin, 96 mol of UDP-Gal, 50 mM Mes pH 6.0, 10 mM MnCl2, 1 mM DTT and 14 units
of the -1,3-galactosyltransferase (construct CJL-20). The reaction was complete after 3 h of
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incubation at 37 °C, as judged by TLC analysis (a sample had to be purified on a small Sep
Pak column before doing the TLC analysis). The reaction mixture was diluted 6-fold with
water before being applied to a Sep-Pak column (5 g) equilibrated with water. Hydrophilic
material was washed off with water and the product was eluted with methanol. Appropriate
fractions were collected and evaporated to give 43 mg of product (31.8 mol, 99% yield).
ESI-MS for [M + Na]+ found 1374.54558, calcd 1374.54729 [ = 1.2 ppm].
4.4.7 Synthesis of GD1a-biotin 10
The reaction was performed in a final volume of  7 mL and included: 34.6 mg (25.6 mol)
of GM1a-biotin, 42 mol of CMP-NeuAc, 50 mM Hepes pH 7.5,  10 mM MgCl2, and 2 units
of the -2,3-sialyltransferase CST-06. The reaction was complete after 2 h of incubation at
37 °C, as judged by TLC analysis. The reaction mixture was diluted 5-fold with water before
being applied to a Sep-Pak column (5 g) equilibrated with water. Hydrophilic material was
washed off with water and the product was eluted with 60%  methanol. Appropriate fractions
were collected and evaporated to give 36.6 mg of product (22.3 mol, 87.1% yield). ESI-MS
for [M + Na]+ found 1665.64236, calcd 1665.64270 [ = 0.2 ppm].
4.4.8 Synthesis of GalNAc-GD1a-biotin 11
The reaction was performed in a final volume of 1 mL and included: 3.9 mg (2.4 mol) of
GD1a-biotin, 4 mol of UDP-GalNAc, 50 mM Hepes pH 7, 10 mM MnCl2 and 0.46 unit of the
-1,4-N-acetylgalactosaminyltransferase (construct CJL-30). The reaction was complete
after 1 h of incubation at 37 °C, as judged by TLC analysis. The reaction mixture was diluted
5-fold with water before being applied to a Sep-Pak column (0.36 g) equilibrated with water.
Hydrophilic material was washed off with water and the product was eluted with 60%
methanol. Appropriate fractions were collected and evaporated to give 3.3 mg of product
(1.8 mol, 75% yield). ESI-MS for [M - H]- found 1844.73101, calcd 1844.72448 [ = 3.5
ppm].
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CHAPTER 5
Synthesis of  Multivalent Ganglioside Derivatives
and their Evaluation as Inhibitors of  Toxins and
Antibodies*
Abstract – 11-Azidoundecyl glycoside analogues of gangliosides GM1 and GM2 were
linked to dendritic structures containing long spacer arms by highly efficient ‘click’ chemistry.
In this manner di-, tetra- and octa- GM2 and di-, tetra- and octa- GM1 substituted
compounds were obtained. In inhibition studies of the synthesized oligosaccharide-linked
dendrimers with cholera toxin B-subunit unprecedentedly large multivalency effects were
observed: the tetra- and octa-GM1- substituted dendrimers are 80 000 and 380 000 times
stronger, respectively, as binding ligands for the toxin than a monovalent GM1 derivative. In
addition, the tetravalent GM1 analogue showed specific and strong inhibition of anti-GM1
antibodies in sera from patients suffering from the immune-mediated neuropathy Guillain-
Barré Syndrome.
* This chapter is partially based on:
- Pukin, A. V.; Branderhorst, H. M.; Sisu, С.; Weijers, C. A. G. M.; Gilbert, M.; Liskamp, R. M. J.; Visser,
G. M.; Zuilhof, H.; Pieters, R. J., Strong Inhibition of Cholera Toxin by Multivalent GM1 Derivatives.
ChemBioChem 2007, 8 (13), 1500.
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5.1 Introduction
 Proteins often bind to their carbohydrate ligands in a multivalent manner.1-6  The cholera
toxin (CT) is a prime example of a multivalent protein, and is capable of binding
simultaneously to the carbohydrate moieties of up to five GM1 gangliosides.  The binding of
the five B subunits to GM1 molecules in the cell membrane is of critical importance for the
internalization7 and subsequent disease process of this AB5 toxin.8  The development of
strong binding agents to the toxin is of interest for the development of disease
prevention/treatment, but also for the detection of toxin in patient samples9 and in materials
suspect of terrorist origin.10  Furthermore, CT serves as a benchmark case to test multivalent
strategies.  As such, several systems have been reported that showed varying degrees of
multivalency effects.11-16 For example, a multivalent conjugated version of the GM1
oligosaccharide (GM1os) was prepared in very small quantities via reductive amination, and
found to enhance binding up to 250-fold.16  Studies of the smaller Shiga-like toxin17 and the
E. coli heat-labile enterotoxin and the CT B pentamer (CTB5), indicated that long spacers are
beneficial for strong binding.15, 18  A pentavalent version of a conjugated m-nitrophenyl -D-
galactopyranoside that contained long spacer arms, surpassed GM1os in affinity (relative
potency 2.8), although the compound was unstable in water.15  While a pentavalent
presentation of ligands seems to be sufficient for effective inhibition of AB5 toxins,
glycodendrimers with larger number of connected to the core glycosides were shown to be
more effective than pentavalent ligands.19
Contrary to the toxin-receptor bindings, the role of multivalency in antibody-antigen
interactions is unclear and, to the best of our knowledge, not documented. At the same time,
strong and specific binding species are of great medical interest, given the role of antibodies
in the clinical course of certain autoimmune diseases like, e.g. Guillain-Barré Syndrome
(GBS). GBS is the major cause of acute neuromuscular paralysis with an annual incidence
of 1.3 - 2 per 100 000 throughout the world. GBS is a typical post-infectious and immune-
mediated polyneuropathy. Recent serological investigations have revealed that 60 % of
acute-phase GBS sera had antibodies to at least one of the gangliosides, but predominantly
to the ganglioside GM1. Microorganisms of the antecedent infections of GBS sometimes are
shown to have carbohydrate structures similar to those of gangliosides. Molecular mimicry
mechanism has therefore been suggested as the mechanism of producing anti-ganglioside
antibodies. The anti-GM1 antibodies usually disappear within weeks from the serum and
only then the patients recover. Selective removal of these neurotoxic antibodies may thus
lead to a considerable improvement of treatment outcome.
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This chapter describes the synthesis of highly effective inhibitors of CTB5 - multivalent
GM1 and GM2 ganglioside derivatives (Figure 5.1) that were designed by combining the use
of 1) the authentic GM1 oligosaccharide sequence as the optimal monovalent ligand, 2)
multivalent dendritic scaffolds, and 3) elongated spacer arms of optimal length. The
evaluation of binding affinities of the synthesized tetravalent GM1 towards anti-GM1
antibodies in sera from GBS patients is also described here.
Figure 5.1 Compounds under study: mono-, di-, tetra- and octavalent analogues of the gangliosides
GM2 and GM1.
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5.2 Results and Discussion
5.2.1 Synthesis of Multivalent Analogues of GM1 and GM2 Gangliosides
Multivalent gangliosides were synthesized from the 11-azidoundecyl glycosides of GM1
(1) and GM2 (3) (Figure 5.2), as described in Chapter 3. An azido group at the end of the C11
aglycone of 1 and 3 allows for the conjugation of these ganglioside analogues to various
(molecular and material) scaffolds via [2+3] cycloaddition “click” reaction,20-22 a method that
has been shown to significantly extend the range of organic and inorganic substrates that
can be attached to oligosaccharides and other biomolecules.23-26
Figure 5.2 Ganglioside analogues used as starting for synthesis and reference.
The counterparts for the “click” reactions – alkyne-terminated dendritic scaffolds 5a, 6a,
7a and the monovalent reference compound 4a – were synthesized from known
dendrimers12, 13, 27, 28 that were functionalized by coupling to 4-pentynoic acid (Scheme 5.1).
Scheme 5.1 Synthesis of alkyne-terminated dendrimers.
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Conjugation of azido-gangliosides to alkyne-terminated dendrimers is depicted on
Scheme 5.2. To establish the best conditions for copper-catalyzed “click” cyclization, first
parallel reactions of GM2 analogue 3 were performed with the tetravalent dendrimer 6a in
50% (v/v) tBuOH-water, 50% (v/v) DMF-water and 2% (v/v) water in DMF as solvents. The
reactions were conducted at 80 C under microwave irradiation. Samples for analytical
HPLC analysis were taken after 20 min, 40 min and 60 min. In 50% (v/v) tBuOH-water the
reaction was not complete even after 1 hour of heating, with HPLC showing the peaks
corresponding to conjugation of 6a with one, two and three molecules of 3. In contrast, in
50% (v/v) DMF-water, which was found to be the best solvent for this coupling, not only full
conversion of the starting material was observed after 20 min of heating, but in a separate
experiment, analytical HPLC analysis showed the reaction between 1 and 6a to form 6b to
be, in fact, complete after 1 min!
With this information in hand, in the following step GM1-derivative 1 was reacted with the
dendrimeric alkynes 4a, 5a, 6a and 7a, respectively, in the presence of CuSO4 and sodium
ascorbate in 50% (v/v) DMF-water at 80 C under microwave irradiation for 20 min (Scheme
5.2). This provided products 4b, 5b, 6b and 7b in good isolated yields after HPLC
purification. GM2 conjugates 5c, 6c and 7c were prepared in a similar fashion.
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Scheme 5.2. Synthesis of the multivalent gangliosides.  Reagents and conditions: i) 1, CuSO4,
sodium ascorbate, DMF/H2O, 80 C, 20 min; yield: 57% for 4b, 78% for 5b, 76% for 6b, 44% for 7b.
ii) 3, CuSO4, sodium ascorbate, DMF/H2O, 80 C, 20 min; yield: 64% for 5c, 74% for 6c, 34% for 7c.
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5.2.2 Inhibition of Cholera Toxin
In order to evaluate the inhibitory efficiency of the synthesized polyvalent gangliosides,
an ELISA type assay was used.12, 29, 30  In this assay, a 96-well plate was coated with GM1
ganglioside followed by blocking of the remaining binding sites with BSA. Horseradish
peroxidase (HRP)-conjugated CTB5 was incubated with the synthetic ganglioside derivatives
in PBS solutions at room temperature for 2 hours. The remaining activity of CTB5 was
measured upon addition of the solutions to the wells and 30 min of incubation to allow
binding to the GM1-coated surface. The results were analyzed as dependence of remaining
activity of CTB5 on inhibitor concentration.
As a reference in inhibitory potency evaluation, the undec-10-enyl glycoside GM1
analogue 2, the target affinities of which are described in Chapter 3, was chosen (Figure
5.3).
Figure 5.3. Undec-10-enyl GM1 analogue, used as a reference in solution inhibition experiments.
In this assay the monovalent GM1 derivative 2 exhibited an IC50 in the micromolar range
(19 M, Table 5.1).  Since the GM1os oligosaccharide is reported to have a Kd of 43 nM,31
the high inhibitory concentration of the GM1 analogue 2 indicates that the toxin binds
strongly to the ELISA plate due to multivalent binding.  The role of the aglycon part beyond
the C11 tail was found to be negligible, since monovalent 4b showed a similar IC50 as 2, i.e. in
the micromolar range. The divalent 5b was subsequently measured, and found to have an
IC50 that was almost 4 orders of magnitude lower, i.e 2.0 nM.  The tetravalent 6b gave an
IC50 that was an additional order of magnitude lower (230 pM). Finally for the octavalent 7b
the IC50 was lower still at 50 pM.  Control experiments with non-functional dendrimers (4a,
5a and 6a) showed no measurable inhibition for all concentrations tested (up to 100 M).
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Compound valency IC50 (M)
relative potency
(per sugar)
Hill
coefficient
GM1 derivatives
2 1 1.9 (±0.6) x 10-5 1 (1) 0.5
4b 1 7 (±3) x 10-6 2,7 (2.7) 0.5
5b 2 2 (±1) x 10-9 9,500 (4,750) 1.0
6b 4 2.3 (±0.7) x 10-10 83,000 (20,750) 3.0
7b 8 5 (±1) x 10-11 380,000 (47,500) 1.7
GM2 derivatives
5c 2 2 (±1) x 10-3 1 -
6c 4 1.05 (±0.02) x 10-7 19,000 2.8
7c 8 4 (±1) x 10-7 5,000 1.4
Table 5.1. Inhibitory potency of the multivalent ganglioside derivatives towards CTB5.
The prepared compounds exhibited unprecedentedly large affinities. We attribute this to
combination of the use of the strongest known CT ligand (GM1os) with large multivalency
effects.  For tetravalent 7b, each of the GM1os moieties bound on average 47,500-fold
stronger than monovalent 2.
Experiments with GM2 were performed to confirm the multivalency effects with a similar
but weaker ligand.  Monovalent GM2 was not measured because an expected low affinity
suggested that it would take too much material to perform the assay.  However, divalent 5c
was prepared and its inhibitory potency could just be observed with an IC50 of 2 mM.  A
19 000-fold jump in binding strength was observed when moving to tetravalent 6c having an
IC50 of 100 nM. This jump was almost three orders of magnitude larger than observed for
the corresponding change from dimeric to tetrameric dendrimer in the GM1 series.  The
octavalent 7c was shown to be a weaker inhibitor than its tetravalent counterpart, while in
the GM1 series the octavalent inhibitor was still moderately better (2.3 fold per sugar).
In the assay, more information about the cooperativity of binding can be obtained from
the Hill coefficients.32 Interestingly, the monovalent compounds showed negative
cooperativity with a Hill coefficient of around 0.5: after one molecule of 2 has bound to CTB5,
subsequent molecules of 2 bind less strongly.  For the divalent 5b this value was close to 1,
but the tetravalent 6b and 6c both showed steeper inhibition curves, with Hill coefficients of
around 3 (Figure 5.4). For the octavalent compounds 7b and 7c the Hill coefficients were
lowered to ca. 1.5.
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Figure 5.4 Observed data points and fitted curves of the inhibition of the shown compounds on the
CT binding to GM1-coated plates.
Hill plots have been used as a method to assess cooperativity in binding of a multivalent
ligand to a multivalent receptor33, 34 (Hill coefficients >1 and <1 being diagnostic for positive
and negative cooperativity, respectively). Other studies, however, criticized this approach
showing that attribution of a Hill coefficient >1 to positive cooperativity is not always
justified.35, 36 Cooperativity of CT binding has previously been claimed in calorimetric
experiments.37  However, it is not fully clear whether the effects observed for these materials
are in line with such claims. The observations depicted in Figure 5.4 (high binding constants,
Hill coefficients > 1) can indicate cooperative binding of the tetravalent inhibitors to CTB5. On
the other hand, they could also be the result of increased local concentration of the ligands
due to the multivalency of the dendrimers, making binding of each following arm easier
compared to the very first.  ITC experiments are required to clarify this issue, and those are
currently in progress.*
* This work has been continued with analytical ultracentrifugation and dynamic light scattering studies
that have demonstrated that the multivalent inhibitors induce protein aggregation and the formation of
space-filling networks. See Sisu, C.; Baron, A. J.; Branderhorst, H. M.; Connel, S. D.; Weijers, C.; de
Vries, R.; Hayes, E. D.; Pukin, A. V.; Gilbert, M.; Pieters, R. J.; Zuilhof, H.; Visser, G. M.; Turnbull, W.
B., ChemBioChem 2009, 10 (2), 329-337.
CHAPTER 5
84
5.2.3 Inhibition of anti-GM1 Antibodies
Anti-GM1 ganglioside antibodies are both frequent and pathogenic in various
autoimmune neuropathies, including Guillain-Barré syndrome (GBS). The detrimental role of
these antibodies was shown to be based on the interactions thereof with ganglioside GM1
on peripheral nerves as a target antigen. Therefore, removal of these antibodies from the
blood circulation in GBS patients would be of considerable therapeutic value. One of the
strategies aimed to suppress GM1-antibody interaction would be the intracorporal
neutralisation: oral or intravenous use of soluble compounds that are able to block anti-GM1
autoantibodies. Solution inhibition studies can provide a basis for evaluation of such soluble
inhibitors as potential therapeutic agents. The results of inhibition experiments in solution
may also give an indication whether the compounds under study are suitable for application
in the construction of new diagnostic tools via e.g. attachment on various supports (ELISA
plates, diagnostic beads, etc). Recently, a range of natural and synthetic GM1-like
oligosaccharides was examined for inhibition and immunoadsorption of mouse and human
anti-GM1 antibodies,38  however, in all experiments significant amounts of inhibitors were
required and in all cases the synthetic GM1 mimics were much less active as compared to
lyso-GM1.
Inspired by the results of the experiments that revealed the great inhibitory potency of
tetravalent GM1 analogue 6b towards cholera toxin (Figure 5.4), we examined this
glycodendrimer in regard of its potential to inhibit human neuropathy-associated antibodies
in solution.* In the first experiment, 16 representative sera samples (denoted as S1 – S16) in
containing anti-GM1 immunoglobulins G and M from patients with autoimmune neuropathies
(GBS and multifocal motor neuropathy - MMN) were incubated for 2 hours with 6b at a
concentration of 250 µg/mL (35.4 µM), followed by assessment of binding in the standard
ELISA for detection of anti-GM1 antibodies.39 At this concentration of the inhibitor, full or
partial suppression of serum antibody binding to GM1 was observed for all but three
samples, the percentage of inhibition being in a good accordance with the antibody titre
(Table 5.2).
In general, better inhibition was achieved in GBS sera as compared to MMN sera.
Reference incubation experiments of 6b with two anti-GQ1b positive sera samples (one IgG,
one IgM) showed no inhibition thus giving an indication of specificity of 6b-antibody binding.
* See also Chapter 6, where the on surface binding of anti GM1 antibodies to the synthetic
gangliosides is studied by ELISA using the plates modified with covalently attached synthetic GM1
analogues.
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Serum
(dilution) MC label Diagnosis Isotype
Inhibition
by 6b, %
S1 PFKEY GBS IgG 7
S2 F102c GBS IgG 43
S3 F116a-b p GBS IgG 0
S4 F120c GBS IgG 70
S5 F152b GBS IgG 0
S6 F263c GBS IgG 99
S7 F308b GBS IgG 42
S8 F241c GBS IgG 37
S9 PFKEY GBS IgM 8
S10 F102c GBS IgM 99
S11 F228c GBS IgM 43
S12 F223a2 GBS IgM 38
S13 MMN3 MMN IgM 11
S14 MMN4 MMN IgM 0
S15 MMN7 MMN IgM 20
S16 MMN22 MMN IgM 11
Table 5.2 Results of inhibition of anti-GM1 antibodies in sera (diluted 100 x) from sixteen neuropathy
cases
Next, the samples S4 (1:100), S6 (1:400), S10 (1:100) and S11 (1:400) were subjected to
solution inhibition by 6b at concentrations varying from 0.07 µM to 35.4 µM. A clear dose-
response dependence was observed in all the four cases and the inhibitory potency of 6b (in
the form of IC50 values) was determined (Figure 5.5). The reference S17, another anti-GQ1b
positive serum sample, showed a constant decrease in the antibody activity for all applied
inhibitor concentrations.
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Figure 5.5 Inhibitory potency of 6b towards anti-GM1 antibodies.
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From these studies, we conclude that the tetravalent GM1 analogue 6b is a specific and
rather potent in vitro inhibitor of anti-GM1 antibodies (cf. results of Willison et. al.24 where
high levels of inhibition were only achieved at oligosaccharide concentrations of at least 50
µM). As such, it may represent an excellent basis for the development of soluble therapeutic
agents for oral or intravenous delivery, as well as for the design of extracorporeal depletion
techniques in treatment of GBS patients. Additional inhibition experiments with GM1
analogues of other valencies are required to elucidate whether and to which degree the
inhibitory potency may be attributable to the multivalency effects.
Finally, an experiment was conducted that aimed to deplete GM1 molecules from
surface-bound immunoglobulins on an ELISA plate. To the GM1-coated wells of an ELISA
plate, sera samples S1, S2, S6, S9, S10, and S11, each in two different dilutions, were
added and incubated overnight at 4 C. Subsequently, inhibitor 6b was added to the wells
followed by incubation at room temperature for 4 hours with shaking. After several washing
steps, the antibodies bound to the surface were detected and the result compared to that of
the reference experiment, where BSA in PBS buffer was applied instead of the inhibitor.
However, no significant effect was observed, the biggest decrease of measured antibody
presence being 30% for S10. It is not thus likely, that antibodies, once bound to the GM1 on
the surface, can be removed by administration of an inhibitor. Similar observations were
previously made in the depletion experiments of the cholera toxin bound to GM1 on ELISA
plates.29  In other words: to be clinically relevant inhibitors like 6b should bind to antibodies
in the serum prior to binding of those antibodies to membrane-bound GM1os.
5.2 Conclusions
Multivalent GM1 and GM2 analogues were successfully synthesized via efficient “click”
reaction of corresponding 11-azidoundecyl glycosides with alkyne terminated dendritic
scaffolds. The strategy in inhibitor design that consisted of employing the authentic GM1
oligosaccharide moiety together with dendrimers of various valencies and long spacer arms
led to inhibitors that were up to 380,000-fold stronger as binding ligands for the cholera toxin
than a monovalent GM1 derivative. The tetravalent GM1 analogue was evaluated as an
inhibitor of anti-GM1 antibodies in several neuropathy cases and showed specific and strong
binding to the abovementioned antibodies. These binding studies clearly demonstrate the
potential of multivalent GM1 mimics in e.g. the development of very sensitive sensor
applications, such as also relevant for other oligosaccharide-related medical problems.
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5.3 Experimental
5.3.1 General Information
Unless stated otherwise, chemicals were obtained from commercial sources and used
without further purification. Solvents were purchased from Biosolve (Valkenswaard, The
Netherlands). Microwave reactions were carried out in a dedicated Biotage Initiator
microwave oven. The microwave power was limited by temperature control once the desired
temperature was reached. A sealed vessel of 2 – 5 mL was used. Analytical HPLC runs
were performed on a Shimadzu automated HPLC system with a reversed phase column
(Alltech, Adsorbosphere C8, 90 Å, 5 m, 250 x 4.6 mm) equipped with an evaporative light
scattering detector (PL-ELS 1000, Polymer Laboratories) and a UV/VIS detector operating at
220 and 254 nm. Preparative HPLC runs were performed on a Applied Biosystems
workstation. Elution was effected using a gradient of 5% MeCN and 0.1% TFA in H2O to 5%
H2O and 0.1% TFA in MeCN. 1H NMR (300 MHz) and 13C NMR (75.5 MHz) were performed
on a Varian G-300 spectrometer. 1H NMR (400 MHz) and 13C NMR (101 MHz) were
performed on a Bruker DPX 400 spectrometer. Mass spectra were measured by
nanoelectrospray time-of-flight mass spectrometry on a Micromass LC ToF mass
spectrometer at a resolution of 5000 fwhm. Gold-coated capillaries were loaded with 1 L of
sample (concentration 2 M) dissolved in a 1:1 (v/v) mixture of CH3CN-H2O with 0.1% formic
acid. NaI or poly(ethylene glycol) (PEG) was added as internal standard. The capillary
voltage was set between 1100 and 1350 V, and the cone voltage was set at 30 V. Matrix
Assisted Laser Desorption Ionization Time of Flight (MALDI ToF) MS were recorded on a
Shimadzu Axima-CFR with -cyano-4-hydroxycinnamic acid or sinapic acid as a matrix.
Insulin and adrenocorticotropin fragment 18-39 (Acth) were used for calibration.
5.3.2 Synthesis of ganglioside – dendrimers conjugates
5.3.2.1 Monovalent GM1 compound
A solution of 4a (10 mg, 16.8 mol), pentasaccharide 1 (30 mg, 25 mol), CuSO4.5H2O (4.2
mg, 16.8 mol) and sodium ascorbate (3.3 mg, 16.8 mol) in H2O/DMF (1/1, v/v, 4 mL) was
heated under microwave irradiation at 80 C for 20 min. Analytical HPLC showed the full
conversion of the monovalent compound to a new peak. The reaction mixture was
concentrated and subjected to preparative HPLC purification. The product was obtained
after lyophilization as a glass (17 mg, 57 %).
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1H NMR (H2O/D2O, 9/1, v/v, 400 MHz)  8.41 (1H, t, C(O)NH), 8.17 (1H, t, C(O)NH), 8.06
(1H, d, NHAc), 7.84 (1H, t, C(O)NH), 7.66 (1H, s, CHtriazole), 7.59 (1H, d, NHAc), 7.50 (1H, m,
CHarom-2), 7.46 (1H, d, CHarom-6), 7.40 (1H, t, CHarom-5), 7.19 (1H, dd, CHarom-4), 4.49 (1H, d,
HGal’-1), 4.47 (1H, d, HGal-1), 4.39 (1H, d, HGlc-1), 4.27 (2H, t), 4.17 (2H, t), 4.11 (2H, m), 4.05
and 3.99 (2 x 2H, 2 x s, OCH2C(O)), 3.87 (3H, s, C(O)OCH3), 3.33 - 3.29 (3H, m), 3.24 -
3.21 (3H, m), 3.11 - 3.07 and 2.94 - 2.90 (2 x 2H, 2 x m, CH2CH2Ctriazole), 2.61 (1H, dd,
HNeuAc-3), 2.51 (2H, t), 1.99 and 1.96 (2 x 3H, 2 x s, NHC(O)CH3), 1.89 (1H, m, HNeuAc-3),
1.78 - 1.67 (4H, m, OCH2CH2CH2NH), 1.60 - 1.49 and 1.23 - 1.08 (4H and 14H, 2 x m,
CH2CH2CH2). 13C NMR (H2O/D2O, 9/1, v/v, 101 MHz):  175.5, 175.2, 174.9, 174.3, 172.1
and 171.6 (COOH and C(O)NH), 168.5 (C(O)OCH3), 158.5 (Carom-3), 146.3  (Ctriazole-4),
131.2 (Carom-1), 130.5 (CHarom-5), 123.6 (Ctriazole-5), 122.9 (CHarom-6), 120.7 (CHarom-4), 115.4
(CHarom-2), 105.1 (CGal’-1), 102.9  (CGal-1), 102.8 (CGalNAc-1), 102.4 (CGluc-1), 101.8 (CNeuAc-2),
80.6 (CGalNAc-3), 79.0 (CGluc-4), 77.4 (CGal-4), 75.2 (CGal’-5), 75.1 (CGluc-5), 74.8 (CGal-3), 74.72
(CGluc-3), 74.70 (CGalNAc-5), 74.4 (CGal-5), 73.4 (CNeuAc-6), 73.1 (CGluc-2), 72.8 (CGal’-3), 72.5
(CNeuAc-7), 71.0 (CGal’-2), 70.9 (CH2OCGluc-1), 70.3 (CNeuAc-8), 70.2 (OCH2), 70.0 (OCH2), 69.8
(OCH2), 69.1, 69.0 (CGal-2 and CNeuAc-7), 68.9 (OCH2), 68.7 (OCH2), 68.4 (CGalNAc-4), 68.2
(CNeuAc-4), 67.1 (OCH2CH2NH), 63.1 (CNeuAc-9), 61.4 (CGalNAc-6), 61.3 (CGal’-6), 60.9 (CGluc-6),
60.5 (CGal-6), 53.2 (C(O)OCH3), 51.9 (CGalNAc-2), 51.5 (CNeuAc-5), 50.7 (CH2Ntriazole), 38.9
(CNeuAc-3), 37.3 and 36.7 (OCH2CH2NH and CH2NHC(O)) 35.5 (CH2CH2Ctriazole), 29.7, 29.2,
29.12, 29.06, 29.0, 28.97, 28.6, 28.5, 25.9 and 25.5 (CH2CH2CH2), 22.9 (CGalNAc-
NHC(O)CH3), 22.4 (CNeuAc-NHC(O)CH3) and 21.3 (CH2CH2Ctriazole). HRMS for C77H126N8O39
(M, 1786.8122) [M - H]- found 1785.722, calcd 1785.804.
5.3.2.2 Divalent GM1 dendrimer 5b
A solution of 5a (3.8 mg, 3.6 mol), pentasaccharide 1 (13 mg, 10.8 µmol), CuSO4.5H2O
(1.8 mg, 7.2 mol) and sodium ascorbate (1.4 mg, 7.2 µmol) in H2O/DMF (1/1, v/v, 2 mL)
was heated under microwave irradiation at 80 C for 20 min. Analytical HPLC showed the
full conversion of the dendrimer to a new peak. The reaction mixture was concentrated and
subjected to preparative HPLC purification. The product was obtained after lyophilization as
a white fluffy compound (9.8 mg, 78 %).
1H NMR (H2O/D2O, 9/1, v/v, 400 MHz):  8.45 (2H, t, C(O)NH), 8.22 (2H, t, C(O)NH), 8.08
(2H, d, NHAc), 7.87 (2H, t, C(O)NH), 7.73 (2H, s, CHtriazole), 7.47 (2H, d, CH3C(O)NH), 7.17
(2H, d, CHarom-2,6), 6.78 (1H, m, CHarom-4), 4.54 (2H, d, HGal’-1), 4.52 (2H, d, HGal-1), 4.43
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(2H, d, HGlc-1), 4.32 (4H, t), 4.10 and 4.06 (2 x 4H, 2 x s, OCH2C(O)), 3.41 - 3.34 (6H, m),
3.30 - 3.25 (6H, m), 3.14 and 2.97 (2 x 4H, 2 x t, CH2CH2Ctriazole), 2.66 (2H, dd, HNeuAc-3),
2.56 (4H, t), 2.03 and 2.00 (2 x 6H, 2 x s, NHC(O)CH3), 1.94 (2H, m, HNeuAc-3), 1.80 - 1.73
(8H, m, OCH2CH2CH2NH), 1.66 - 1.52 and 1.30 - 1.08 (8H and 28H,   2 x m, CH2CH2CH2).
13C NMR (H2O/D2O, 9/1, v/v, 101 MHz):  175.5, 175.2, 174.9, 174.3, 172.1 and 171.6
(COOH and C(O)NH), 168.5 (C(O)OCH3), 159.9 (Carom-3,5), 146.4 (Ctriazole-4), 132.0 (Carom-
1), 123.6 (Ctriazole-5), 108.8 (CHarom-2,6), 107.1 (CHarom-4), 105.1 (CGal’-1), 102.9 (CGal-1),
102.8 (CGalNAc-1), 102.4 (CGluc-1), 101.8 (CNeuAc-2), 80.6 (CGalNAc-3), 79.0 (CGluc-4), 77.4 (CGal-
4), 75.2 (CGal’-5), 75.1 (CGluc-5), 74.8 (CGal-3), 74.72 (CGluc-3), 74.70 (CGalNAc-5), 74.4 (CGal-5),
73.4 (CNeuAc-6), 73.1 (CGluc-2), 72.8 (CGal’-3), 72.5 (CNeuAc-7), 71.0 (CGal’-2), 70.9 (CH2OCGluc-
1), 70.3 (CNeuAc-8), 70.2 (OCH2), 70.0 (OCH2), 69.8 (OCH2), 69.0 (CGal-2), 68.9 (OCH2), 68.7
(OCH2), 68.4 (CGalNAc-4), 68.2 (CNeuAc-4), 67.1 (OCH2CH2NH), 63.1 (CNeuAc-9), 61.4 (CGalNAc-
6), 61.3 (CGal’-6), 60.9 (CGluc-6), 60.5 (CGal-6), 53.2 (C(O)OCH3), 51.9 (CGalNAc-2), 51.5 (CNeuAc-
5), 50.7 (CH2Ntriazole), 38.9 (CNeuAc-3), 37.3 and 36.7 (OCH2CH2NH and CH2NHC(O)) 35.5
(CH2CH2Ctriazole),  29.7, 29.2, 29.12, 29.06, 29.0, 28.97, 28.6, 28.5, 25.9 and 25.5
(CH2CH2CH2), 22.9 (CGalNAc-NHC(O)CH3), 22.4 (CNeuAc-NHC(O)CH3) and 21.3
(CH2CH2Ctriazole). ESI-MS for C146H244N16O76 (M, 3437.572) [M + 3H]3+ found 1147.27, calcd
1146.86.
5.3.2.3 Divalent GM2 dendrimer 5c
A solution of 5a (9.5 mg, 9.0 mol), tetrasaccharide 3 (28.8 mg, 28.0 mol), CuSO4.5H2O
(2.3 mg, 9.0 mol) and sodium ascorbate (1.8 mg, 9.0 mol) in H2O/DMF (1/1, v/v, 2 mL)
was heated under microwave irradiation at 80 C for 20 min. Analytical HPLC showed the
full conversion of the dendrimer to a new peak. The reaction mixture was concentrated and
subjected to preparative HPLC purification. The product was obtained after lyophilization as
a white fluffy compound (19.0 mg, 68 %).
1H NMR (H2O/D2O, 9/1, v/v, 400 MHz):  8.44 (2H, t, C(O)NH), 8.23 (2H, t, C(O)NH), 8.08
(2H, d, NHAc), 7.87 (2H, t, C(O)NH), 7.71 (2H, s, CHtriazole), 7.36 (2H, d, NHAc), 7.16 (2H, d,
CHarom-2,6), 6.78 (1H, m, CHarom-4), 4.52 (2H, d, HGal-1), 4.43 (2H, d, HGlc-1), 4.31 (4H, t),
4.11 and 4.07 (2 x 4H, 2 x s, OCH2C(O)), 3.39 - 3.34 (6H, m), 3.31 - 3.26 (6H, m), 3.17 -
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3.12 and 2.98 - 2.95 (2 x 4H, 2 x m, CH2CH2Ctriazole), 2.66 (2H, dd, HNeuAc-3), 2.55 (4H, t),
2.03 and 2.01 (2 x 6H, 2 x s, NHC(O)CH3), 1.92 (2H, m, HNeuAc-3), 1.79 - 1.74 (8H, m,
OCH2CH2CH2NH), 1.66 - 1.51 and 1.35 - 1.04 (8H and 28H, 2 x m, CH2CH2CH2).
13C NMR (H2O/D2O, 9/1, v/v, 101 MHz):  175.5, 175.2, 174.9, 174.3, 172.1 and 171.6
(COOH and C(O)NH), 168.5 (C(O)OCH3), 159.9 (Carom-3,5), 146.4  (Ctriazole-4), 132.0 (Carom-
1), 123.5 (Ctriazole-5), 108.9 (CHarom-2,6), 107.2 (CHarom-4), 103.1 (CGal-1), 103.0 (CGalNAc-1),
102.5 (CGluc-1), 101.9 (CNeuAc-2), 79.0 (CGluc-4), 77.5 (CGal-4), 75.1 (CGal-3), 75.0 (CGluc-5),
74.8 (CGluc-3), 74.4 (CGalNAc-5), 73.5 (CGal-5), 73.3 (CNeuAc-6), 72.7 (CGluc-2), 71.8 (CGalNAc-3),
71.0 (CH2OCGluc-1), 70.5 (CNeuAc-8), 70.3 (OCH2), 70.0 (OCH2), 69.8 (OCH2), 69.1 (2C,
CNeuAc-7 and CGal-2), 68.9 (OCH2), 68.7 (OCH2), 68.5 (CGalNAc-4), 68.3 (CNeuAc-4), 67.2
(OCH2CH2NH), 63.4 (CNeuAc-9), 61.6 (CGalNAc-6), 61.0 (CGluc-6), 60.6 (CGal-6), 53.3
(C(O)OCH3), 52.8 (CGalNAc-2), 52.1 (CNeuAc-5), 50.7 (CH2Ntriazole), 39.0 (CNeuAc-3), 37.4 and
36.8 (OCH2CH2NH and CH2NHC(O)), 35.6 (CH2CH2Ctriazole), 29.8, 29.3, 29.2, 29.1, 29.0,
28.9, 28.7, 28.5, 26.0 and 25.5 (CH2CH2CH2), 23.1 (CGalNAc-NHC(O)CH3), 22.5 (CNeuAc-
NHC(O)CH3) and 21.4 (CH2CH2Ctriazole).
5.3.2.4 Tetravalent GM1 dendrimer 6b
A solution of 6a (4.1 mg, 1.8 mol), pentasaccharide 1 (13.0 mg, 10.8 mol), CuSO4.5H2O
(1.8 mg, 7.2 mol) and sodium ascorbate (1.4 mg, 7.2 mol) in H2O/DMF (1/1, v/v, 2 mL)
was heated under microwave irradiation at 80 C for 20 min. Analytical HPLC showed the
full conversion of the dendrimer to a new peak. The reaction mixture was concentrated and
subjected to preparative HPLC purification. The product was obtained after lyophilization as
a white fluffy compound (9.7 mg, 76 %).
1H NMR (H2O/D2O, 9/1, v/v, 400 MHz):  8.56 (2H, t, C(O)NH), 8.41 (4H, t, C(O)NH), 8.21
(4H, t, C(O)NH), 8.07 (4H, d, NHAc), 7.87 (4H, t, C(O)NH), 7.70 (4H, s, CHtriazole), 7.48 (4H,
d, NHAc), 7.05 (2H, m, CHarom-2,6), 6.93 (4H, m, CHarom-2’,6’), 6.66 (3H, m, CHarom-4, 4’),
4.52 (4H, d, HGal’-1), 4.49 (4H, d, HGal-1), 4.39 (4H, d, HGlc-1),  4.24 (8H, t), 4.07 and 4.03 (2 x
8H, 2 x s, OCH2C(O)), 3.39 - 3.33 (12H, m), 3.29 - 3.22 (12H, m), 3.17 - 3.10 and 2.95 - 2.90
(2 x 8H, 2 x m, CH2CH2Ctriazole), 2.65 (4H, dd, HNeuAc-3), 2.53 (8H, t), 2.01 and 1.99 (2 x 12H,
2 x s, NHC(O)CH3), 1.93 (4H, m, HNeuAc-3), 1.76 - 1.68 (16H, m, OCH2CH2CH2NH), 1.64 -
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1.59, 1.53 - 1.45 and 1.22 - 0.95 (8H, 8H and 56H, 3 x m, CH2CH2CH2). 13C NMR (H2O/D2O,
9/1, v/v, 101 MHz):  175.5, 175.2, 174.9, 174.3, 172.1 and 171.6 (COOH and C(O)NH),
168.5 (C(O)OCH3), 159.9 (Carom-3,5), 146.4 (Ctriazole-4), 132.0 (Carom-1), 123.6 (Ctriazole-5),
108.8 (CHarom-2,6), 107.1 (CHarom-4), 105.1 (CGal’-1), 102.9 (CGal-1), 102.8 (CGalNAc-1), 102.4
(CGluc-1), 101.8 (CNeuAc-2), 80.6 (CGalNAc-3), 79.0 (CGluc-4), 77.4 (CGal-4), 75.2 (CGal’-5), 75.1
(CGluc-5), 74.8 (CGal-3), 74.72 (CGluc-3), 74.70 (CGalNAc-5), 74.4 (CGal-5), 73.4 (CNeuAc-6), 73.1
(CGluc-2), 72.8 (CGal’-3), 72.5 (CNeuAc-7), 71.0 (CGal’-2), 70.9 (CH2OCGluc-1), 70.3 (CNeuAc-8),
70.2 (OCH2), 70.0 (OCH2), 69.8 (OCH2), 69.0 (CGal-2 and CNeuAc-7), 68.9 (OCH2), 68.7
(OCH2), 68.4 (CGalNAc-4), 68.2 (CNeuAc-4), 67.1 (OCH2CH2NH), 63.1 (CNeuAc-9), 61.4 (CGalNAc-
6), 61.3 (CGal’-6), 60.9 (CGluc-6), 60.5 (CGal-6), 53.2 (C(O)OCH3), 51.9 (CGalNAc-2), 51.5 (CNeuAc-
5), 50.7 (CH2Ntriazole), 38.9 (CNeuAc-3), 37.3 and 36.7 (OCH2CH2NH and CH2NHC(O)) 35.5
(CH2CH2Ctriazole),  29.7, 29.2, 29.12, 29.06, 29.0 and 28.9 (CH2CH2CH2), 22.9 (CGalNAc-
NHC(O)CH3), 22.4 (CNeuAc-NHC(O)CH3) and 21.3 (CH2CH2Ctriazole). ESI-MS for
C302H498N34O154 (M, 7065.2182) [M + 4H + 2Na]6+ found 1185.64, calcd 1185.87.
5.3.2.5 Tetravalent GM2 dendrimer 6c
A solution of 6a (7.4 mg, 3.2 mol), tetrasaccharide 3 (20 mg, 19.4 mol), CuSO4.5H2O (3.2
mg, 12.8 mol) and sodium ascorbate (2.5 mg, 12.8 mol) in H2O/DMF (1/1, v/v, 2 mL) was
heated under microwave irradiation at 80 C for 20 min. Analytical HPLC showed the full
conversion of the dendrimer to a new peak. The reaction mixture was concentrated and
subjected to preparative HPLC purification. The product was obtained after lyophilization as
a white fluffy compound (7.6 mg, 37 %).
1H NMR (H2O/D2O, 9/1, v/v, 400 MHz):  8.57 (2H, t, C(O)NH), 8.41 (4H, t, C(O)NH), 8.22
(4H, t, C(O)NH), 8.07 (4H, d, NHAc), 7.88 (4H, t, C(O)NH), 7.71 (4H, s, CHtriazole), 7.37 (4H,
d, NHAc), 7.04 (2H, m, CHarom-2,6), 6.95 (4H, m, CHarom-2’,6’), 6.66 (3H, m, CHarom-4, 4’),
4.51 (4H, d, HGal-1), 4.40 (4H, d, HGlc-1), 4.25 (8H, t), 4.08 and 4.04 (2 x 8H, 2 x s,
OCH2C(O)), 3.39 - 3.35 (12H, m), 3.30 - 3.24 (12H, m),   3.17 - 3.12 and 2.97 - 2.94 (2 x 8H,
2 x m, CH2CH2Ctriazole), 2.67 (4H, dd, HNeuAc-3), 2.55 (8H, t), 2.03 and 2.01 (2 x 12H, 2 x s,
NHC(O)CH3), 1.94 (4H, m, HNeuAc-3), 1.76 - 1.67 (16H, m, OCH2CH2CH2NH), 1.64 - 1.60,
1.52 - 1.48 and 1.23 - 0.96 (8H, 8H and 56H, 3 x m, CH2CH2CH2). 13C NMR (H2O/D2O, 9/1,
CHAPTER 5
92
v/v, 101 MHz):  175.4, 175.2, 174.6, 174.0, 172.0 and 171.4 (COOH and C(O)NH), 168.9
(C(O)OCH3), 160.0 (Carom-3,5), 146.4 (Ctriazole-4), 131.8 (Carom-1), 123.5 (Ctriazole-5), 115.2
(CHarom-2,6), 106.8 (CHarom-4), 103.1 (CGal-1), 103.0 (CGalNAc-1), 102.6 (CGluc-1), 101.6
(CNeuAc-2), 79.0 (CGluc-4), 77.3 (CGal-4), 75.1 (CGal-3), 75.0 (CGluc-5), 74.9 (CGluc-3), 74.4
(CGalNAc-5), 73.5 (CGal-5), 73.3 (CNeuAc-6), 72.6 (CGluc-2), 71.8 (CGalNAc-3), 70.9 (CH2-OCGluc1),
70.4 (CNeuAc-8), 70.3 (OCH2), 70.0 (OCH2), 69.8 (OCH2), 69.1 (CGal-2), 69.0 (CNeuAc-7), 68.9
(OCH2), 68.7 (OCH2), 68.5 (CGalNAc-4), 68.3 (CNeuAc-4), 67.0 (OCH2CH2NH), 63.4 (CNeuAc-9),
61.6 (CGalNAc-6), 61.0 (CGluc-6), 60.6 (CGal-6), 53.2 (C(O)OCH3), 52.9 (CGalNAc-2), 52.1 (CNeuAc-
5), 50.8 (CH2Ntriazole), 38.9 (CNeuAc-3), 37.4, 36.9 and 36.8 (OCH2CH2NH and CH2NHC(O)),
35.5 (CH2CH2Ctriazole), 29.9, 29.4, 29.3, 29.2, 29.1, 28.8, 26.1 and 25.7 (CH2CH2CH2), 23.1
(CGalNAc-NHC(O)CH3), 22.5 (CNeuAc-NHC(O)CH3) and 21.4 (CH2CH2Ctriazole). ESI-MS for
C278H458N34O134 (M, 6417.0069) [M + 5H]5+ found 1184.90, calcd 1184.41.
5.3.2.6 Octavalent GM1 dendrimer 7b
A solution of 7a (6.6 mg, 1.4 mol), pentasaccharide 1 (20.0 mg, 16.6 mol), CuSO4.5H2O
(5.5 mg, 22.0 mol) and sodium ascorbate (4.6 mg, 23.0 mol) in H2O/DMF (1/1, v/v, 3 mL)
was heated under microwave irradiation at 80 C for 40 min. Analytical HPLC showed the
full conversion of the dendrimer to a new peak. The reaction mixture was concentrated and
subjected to preparative HPLC purification. The product was obtained after lyophilization as
a white fluffy compound (8.5 mg, 44%).
1H NMR (H2O/D2O, 9/1, v/v, 400 MHz):  8.44 (6H, bs, C(O)NH), 8.30 (8H, bs, C(O)NH),
8.09 (8H, bs, NHAc), 7.96 (8H, d, C(O)NH), 7.75 (8H, s, CHtriazole), 7.53 (bs, C(O)NH), 7.34
(8H, d, NHAc), 6.92, 6.81 and 6.52 (m, CHarom) 4.41, 4.29, 3.23 (16H, m), 3.13 (16H, m),
3.02 (16H, m), 2.81 (16H, m),  2.54 (8H, m, HNeuAc-3), 2.40 (16H, m), 1.91 and 1.88 (each
24H, s, NHC(O)CH3), 1.60, 1.50, 1.37 and 0.90 (16H,16H, 16H and 112H, 4 x m,
CH2CH2CH2). 13C NMR (H2O/D2O, 9/1, v/v, 101 MHz):  175.4, 175.1, 174.6, 174.4, 171.9,
171.4 (COOH and C(O)NH),168.5 (C(O)OCH3),160.0 (Carom-3,5),146.5 (Ctriazole-4), 136.1 and
126.3 (Carom), 123.2 (Ctriazole-5), 106.7 (Carom), 105.1 (CGal’-1), 103.0 (CGal-1), 102.9 (CGalNAc-1),
102.6 (CGluc-1), 102.0 (CNeuAc-2), 80.8 (CGalNAc-3), 79.1 (CGluc-4), 77.6 (CGal-4), 75.3 (CGal’-5),
75.1 (CGluc-5), 75.0 (CGluc-5, 74.8 (CGal-3), 74.5 (CGal-5), 73.5 (CNeuAc-6), 73.3 (CGluc-2), 73.0,
72.8 (CGal’-3), 71.2 ,70.9 (CH2-OCGluc1), 70.5 (CNeuAc-8), 70.3 (OCH2), 70.0 (OCH2), 69.8
(OCH2), 69.2 (CGal-2 and CNeuAc-7), 69.1, 68.9 and 68.7 (OCH2), 68.5, 68.4 and 66.9
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(OCH2CH2NH), 63.4 (CNeuAc-9), 61.6 (CGalNAc-6), 61.4 (CGal’-6), 61.1 (CGluc-6), 60.7 (CGal-6),
52.1 (CGalNAc-2), 51.6 (CNeuAc-5), 50.5 (CH2Ntriazole), 39.0 (CNeuAc-3), 37.3, 36.9 and 36.8
(OCH2CH2NH and CH2NHC(O)), 35.7 (CH2CH2Ctriazole),  29.9, 29.4, 29.3, 29.2, 28.8, 26.2
and 25.7 (CH2CH2CH2), 23.1 (CGalNAc-NHC(O)CH3), 22.5 (CNeuAc-NH(O)CH3) and 21.6
(CH2CH2Ctriazole).
5.3.3 CTB5 inhibition assay
A 96-well plate (F96 MaxisorpTM, Nunc) was coated with a 100 L solution of GM1 (2 g/mL)
(Sigma-Aldrich) in PBS at 37 C for 16 h. Unattached ganglioside was removed by washing
with PBS (2 x 450 L), after which remaining binding sites were blocked by incubation with
100 L 1% (w/v) BSA in PBS for 30 min at 37 C. Subsequently, the plate was washed with
PBS (3 x 450 L). Samples of Cholera Toxin B Subunit horseradish peroxidase conjugate
(Sigma-Aldrich) and inhibitor in 0.1% BSA, 0.05 % Tween 20 in PBS were incubated at r.t.
for 2 h, and were then transferred to the coated plate. After 30 min incubation the solution
was removed followed by washing steps with 0.1 % BSA, 0.05 % Tween-20 in PBS (3 x 450
L). To identify toxin binding to surface-bound GM1 the wells were treated with a freshly
prepared o-phenylenediamine (OPD) solution (100 L) (25 mg OPD.2HCl, 7.5 mL 0.1 M
citric acid, 7.5 mL 0.1 M sodium citrate and 6 L of a 30% H2O2 solution) and the color-
forming reaction was quenched after 15 min with H2SO4 (50 L) (2.5 M). The absorbance at
490 nm was measured by a Quant plate reader.
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CHAPTER 6
Detection of Antibodies in Neuropathy Patients by
Synthetic GM1 Mimics
Abstract – Antibodies to the ganglioside GM1 are associated with various forms of acute
and chronic immune-mediated neuropathy, including Guillain-Barré syndrome (GBS) and
multifocal motor neuropathy (MMN). In diagnostics and research these antibodies are
usually detected by GM1 preparations derived from bovine brain tissue, which are non-
covalently attached to solid carriers such as ELISA plates. Such brain-derived GM1
preparations are potentially contaminated with other glycolipids. In the current study
uncontaminated mono- and divalent synthetic analogues of the ganglioside GM1 were
successfully attached via covalent bonds onto the surface of ELISA plates. The resulting
modified diagnostic tool showed strong affinities and good specificities for binding of
monoclonal mouse and human anti-GM1 antibodies and cholera toxin, as well as for the
anti-GM1 antibodies in serum samples from neuropathy patients.
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6.1 Introduction 
The presence of serum antibodies to the ganglioside GM1 is associated with various 
forms of immune-mediated neuropathy, including the Guillain-Barré Syndrome (GBS), 
multifocal motor neuropathy (MMN) and monoclonal gammopathy and polyneuropathy.1 
GBS is the most common form of acute neuromuscular paresis, and 10 to 40% of GBS 
patients have serum anti-GM1 antibodies, depending on the geographical region of the 
patients and the techniques used to detect these antibodies. Anti-GM1 antibodies in GBS 
are predominantly of the IgG subclass and associated with a severe and motor variant of the 
disease.2 In GBS these antibodies are primarily raised to microbial carbohydrate antigens 
and produced during a preceding infection.3 Due to molecular mimicry4 between these 
microbial carbohydrates and the pentasaccharide unit of GM1 these antibodies can cross-
react to native GM1 in peripheral nerve membranes, where they induce complement-
dependent nerve dysfunction.5 These antibodies usually disappear within weeks from the 
serum, after which the then surviving GBS patients recover. MMN is a chronic form of 
neuropathy in which 30 - 50 % of the patients have serum anti-GM1 antibodies, 
predominantly of the IgM subclass, and the presence of these antibodies is associated with 
a severe form of the disease.6-10 Similar to GBS, the anti-GM1 antibodies in patients with 
MMN are neurotoxic in animal models. Patients with GBS and MMN show a partial response 
to treatment with intravenous immunoglobulins (IVIg). At present there is no specific 
treatment focused on anti-GM1 antibodies, although they likely have a dominant contribution 
to the peripheral nerve damaging.   
Antibodies to GM1 are diagnostic markers11 for GBS, MMN and other forms of immune-
mediated neuropathy and a possible target for future specific treatment. A number of 
protocols for enzyme-linked immunosorbent assays (ELISAs) for measuring serum anti-GM1 
antibodies have been described,12-14 as well as a standardized INCAT-ELISA15, 16 protocol 
aimed to facilitate the comparison of results from different laboratories. The detection of anti-
GM1 antibodies in these protocols is, however, restricted by the use of bovine brain-derived 
gangliosides, which are difficult to purify, expensive, potentially infected, and usually 
contaminated with other glycolipids. These drawbacks may partly explain the variation and 
limited sensitivity and specificity of currently used ELISAs to detect the antibodies. 
Development of a specific treatment based on selective removal of anti-GM1 antibodies from 
the blood of the patients by immunoabsorption would require covalent attachment of the 
GM1 to a surface carrier at the aglycone part, thus leaving accessible the carbohydrate 
moiety of GM1 to which the antibodies are directed. Bovine brain-derived GM1, however, 
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can not be used for this purpose considering its impurity, potential risk of infection and 
unsuitability of the ceramide tail for the covalent attachment. Only fully pure GM1 ganglioside 
(or its mimics) would be required to solve these problems. Moreover, depletion from the 
serum may also be hampered by the relatively low affinity of the anti-GM1 antibodies.  
In recent years there is a rapidly increasing interest in a new class of neuropathy-
associated autoantibodies. These antibodies only bind to complexes of gangliosides and 
have no affinity to either ganglioside individually.17-33 Direct evidences for the existence of 
ganglioside complexes in nature have been provided,34, 35 and of considerable interest is the 
development of new methods for the assessment of serum antibody reactivity to ganglioside 
complexes in patients. Thus, in addition to more traditional ELISA and thin-layer 
chromatography with immuno-overlay,21 an automated glycoarray-based combinatorial 
system for the analysis of interactions of proteins with ganglioside complexes has been 
recently proposed.36 It is clear that the purity of the gangliosides applied in these techniques 
is crucial for their specificity and sensitivity, and therefore the demand for the individual 
uncontaminated compounds, rather than bovine brain-derived ganglioside fractions, is high. 
Application of synthetic ganglioside mimics may circumvent these limitations of bovine 
GM1 fractions. First, these synthetic analogues can be produced in completely pure form, 
preventing the binding of antibodies to contaminants. Second, GM1 mimics can be 
synthesized with an identical to GM1 carbohydrate group but with alternative apolar tails 
tailor-made for covalent binding to scaffolds. This covalent attachment also takes care of 
attachment of the GM1 sugar onto the biosensor in only one orientation. Third, polyvalent 
ganglioside analogues can be synthesized to increase the binding of the low-affinity37 
antibodies. These polyvalent gangliosides can be designed to contain either two or more 
identical carbohydrate groups,38 or the oligosaccharide parts of different gangliosides linked 
to one dendrimeric scaffold. This would allow binding of antibodies that are reactive against 
ganglioside complexes. Thus, such structurally analogous and completely pure ganglioside 
mimics are able to be specifically recognized by the same antibodies, while at the same time 
they are equipped with functional groups that allow chemical tuning of the properties and 
composition of the diagnostic tools. These innovations therefore have the potential for 
significant advantages over currently employed methods for antibody binding.  
In the present study we investigated the proof-of-principle of whether covalently attached 
pure synthetic mono- and divalent analogues of GM1 can bind to anti-GM1 antibodies. 
These analogues were covalently attached to Nunc Immobilizer™ Amino ELISA plates and 
tested for binding with cholera toxin and mouse and human monoclonal anti-GM1 
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antibodies. In addition, sera from patients with GBS, MMN and monoclonal gammopathy and 
polyneuropathy were screened for the presence of anti-GM1 antibodies using these 
synthetic GM1 analogues. 
 
 
6.2 Results 
 
6.2.1. Attachment of ganglioside analogues on the surfaces of ELISA plates 
In the present study, Nunc Immobilizer™ Amino ELISA plates were used for 
modifications with the GM1 analogues. These plates are specifically designed for covalent 
attachment of peptides and proteins via the reaction of free amino or thiol groups thereof. 
 
 
Figure 6.1. GM1 analogues used for covalent attachment onto the surfaces of the ELISA plates. 
 
The immobilization of the synthetic monovalent GM1 analogue 1 (Figure 6.1) was 
achieved in two steps. First, plates were incubated with propargylamine (HC≡C-CH2-NH2) 
under the recommended conditions for protein immobilization via amino groups. The 
protocol for such an immobilization is provided with the plates by the manufacturer. No 
auxiliary reagent was needed for the attachment onto the plate surfaces. Alkyne-coated 
surfaces formed in this way were incubated at the next step with 1 in the presence of CuSO4 
and sodium ascorbate. During this incubation, the Huisgen-Meldal-Sharpless cycloaddition 
“click” reaction39 between alkyne moieties on the surface and the azido group of 1 occurred 
under very mild conditions, thus resulting in diagnostic tools functionalized with this 
covalently attached GM1 analogue. The attachment of dimer 2 on the ELISA plates was 
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performed in one step following the recommended protocol for peptide immobilization via 
amino groups. 
 
6.2.2 Detection of cholera toxin and monoclonal anti-GM1 antibodies in ELISA using 
the modified plates. 
In order to establish general principles, we first examined five monoclonal antibodies 
(mAbs) and the cholera toxin B subunit (CT-B) in respect of their binding to bovine GM1 
(coated on the Maxisorp plates) and covalently immobilized synthetic GM1 analogues. 
Among the mAbs used in this study, two mouse antibodies (DG-1 and DG-2) and one 
human antibody (Sm-1) recognize GM1; DG1 is monospecific for GM1, while DG2 has been 
shown to bind, apart from GM1, also GA1 and GD1b.34, 40 The GM1-negative mouse mAb 
EG-1 and the human mAbs L were tested as negative controls.  
The ganglioside-binding characteristics of the anti-GM1 mouse mAbs DG-1 DG-2 and 
human mAb Sm-1 are presented in Figure 6.2 (A-C).  As can be observed, GM1-positive 
mouse mAbs bind to the synthetic GM1 analogues in a slightly different manner as 
compared to their binding to the bovine GM1. Thus, DG-1 reacts with the bovine GM1 with a 
half-maximal binding value of 0.45 µg/ml, while analysis of its binding to 1 and 2 gives 1.54 
and 2.14 µg/ml, respectively. At the same time, for the synthetic gangliosides the saturation 
of the binding is reached at a much higher concentration of DG-1 antibodies. Thus, for this 
antibody the sensitivity of the assay with natural GM1 is higher than the assay with synthetic 
analogues, but the potential to discriminate between samples of different concentrations 
increases upon use of covalently attached GM1.  
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Figue 6.2. Ganglioside-binding characteristics of the anti GM1 antibodies and CT-B.  - binding to 
natural GM1;  - binding to monovalent GM1 analogue 1;  - binding to divalent GM1 analogue 2. 
 
For the DG-2 mAbs (Figure 6.2B), the half-maximum binding value of 0.85 µg/ml for 
binding to natural GM1 is decreased to 0.4 µg/ml in the case of 2 and even lower to 0.2 
µg/ml for the GM1 analogue 1, while the maximum signal is reached at similar 
concentrations for all the three gangliosides. In other words: the synthetic GM1 display a 
higher sensitivity than the natural GM1 towards DG-2.  
The human anti-GM1 mAbs Sm-1 reacted with synthetic GM1 analogues with both the 
half-binding values and the saturation points similar to those observed for the binding to 
GM1 (Figure 6.2C), thus indicating 1 and 2 to be very good mimics of natural GM1 with 
respect to the binding to the human mAbs. 
The performance of the ELISAs based on the natural and synthetic gangliosides in the 
detection of cholera toxin is demonstrated in Figure 6.2D.  As can be clearly seen, for both 
mono- and divalent GM1 analogues, the saturation of the binding is reached at significantly 
lower concentrations of the toxin as compared to this value for the bovine GM1. The 
calculated half-maximum binding values for the synthetic gangliosides are also considerably 
[DG-1], g/ml
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lower than for the natural GM1, showing that synthetic GM1 is in this case far superior over 
natural GM1.  
The ganglioside-binding characteristics were also studied for the negative-to-GM1 mAbs 
EG-1 and L, as controls for nonspecific binding. These monoclonal antibodies did not bind to 
any of the gangliosides, thus giving a proof of the specificity of the observed binding of the 
anti-GM1 mAbs. 
 
6.2.3 Detection of anti-GM1 antibodies in serum from neuropathy patients. 
Next, the performances of the routine ELISA (based on the bovine brain GM1 non-
covalently adsorbed on Nunc MaxisorpTM ELISA plates) and of the ELISAs based on the 
plates modified by covalent attachment of monomeric 1 and dimeric 2 GM1 analogues were 
compared in detecting IgM and IgG antibodies in serum from normal controls and patients 
with neuropathies. After coating of the plates, the same validated INCAT protocol2, 15, 16 was 
used in all the types of ELISAs. Sera from a series of 33 neuropathy patients strongly 
positive for anti-GM1 antibodies in routine INCAT ELISA (15 GBS patients, 15 MMN 
patients, 3 monoclonal gammopathy and polyneuropathy patients), as well as 5 healthy 
control sera were examined for antibody reactivity to the synthetic GM1 mimics covalently 
bound in an ELISA. The comparison with the routine INCAT and monovalent GM1-based 
assays is presented in Figure 6.3. The GBS patients were selected on the basis that they 
displayed a strong IgG antibody activity in INCAT ELISA (in practice: 1.1  0.2), which for 
bovine GM1 maxes out at ca. 1.3 (see Figure 6.3A). The MMN patients and monoclonal 
gammopathy with polyneuropathy patients were selected for their IgM antibody activity in 
INCAT ELISA (1.15  0.25 with the maximum at ca. 1.4) 
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Figue 6.3. Comparison of ELISAs with covalently bound monovalent pure GM1 analogue 1 versus  
non-covalently bound bovine impure GM1 with respect to detecting IgM and IgG antibodies in serum 
from neuropathy patients and healthy controls. The values on the axes represent d-OD in the assays 
obtained by subtracting the OD in the blanc wells from the OD in the GM1 (analogue) coated wells.  
 
The figure demonstrates that within the tested sera variations, both IgG and IgM 
antibodies behave very similar in the modified ELISAs and the standardized INCAT-ELISA. 
Indeed, statistical analysis of the data using the Spearman rank correlation shows that the 
relationship between the OD values in these two assays is significant (Spearman’s  = 0.75, 
P = 2 x 10-7). The high value of  indicates the strong correlation between the affinity of the 
antibodies towards natural GM1 and their affinity to the synthetic analogues, clearly pointing 
to the potential of the synthetic analogues in diagnostic detection of the anti-GM1 antibodies 
in sera.  
Significant attention has been directed recently to study the antibodies to ganglioside 
complexes.17-33 Such antibodies bind much stronger, if not exclusively, the mixtures of 
gangliosides (e.g. GM1/GD1a mixture) rather than single gangliosides, and therefore it is 
likely, that multivalent interactions are important in the recognition of ganglioside complexes. 
In order to establish whether the multivalency based on the identical ganglioside structures 
plays a role in the antibody binding, the ELISAs based on the monovalent (1) and divalent 
(2) GM1 analogues were compared (Figure 6.4) in the detection of the anti-GM1 antibodies 
in the same set of serum samples as mentioned above.  
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Figue 6.4. Comparison of ELISAs based on the covalently bound monovalent GM1 analogue 1 and 
divalent GM1 analogue 2, respectively, for detecting IgM and IgG antibodies in serum from 
neuropathy patients and healthy controls. The values on the axes represent d-OD in the assays 
obtained by subtracting the OD in the blanc wells from the OD in the GM1 (analogue) coated wells.  
  
Figure 6.4 shows the relative performance of the assays based on the synthetic 
gangliosides 1 and 2. As can be clearly seen, for both IgG and IgM antibodies the majority of 
the tested samples showed virtually the same d-OD in both assays. 
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6.3 Discussion 
Identification of anti-GM1 antibodies in serum from patients with immune-mediated 
neuropathies is complicated by the natural origin of the bovine GM1 fractions used to detect 
these antibodies. It is almost impossible to obtain 100% pure gangliosides from natural 
sources, and the contaminants are – due  to the way these compounds are isolated – likely 
to be other glycolipids that could interfere with the determination of the specificity of the anti-
ganglioside antibodies. Several studies have shown that the commercially available bovine 
GM1 fractions are contaminated with other gangliosides, which may also bind antibodies in 
serum from the patients. Moreover, the binding of serum antibodies to GM1 may be 
enhanced or diminished by the presence of other gangliosides. Some patients with GBS 
may even have antibodies to combinations of gangliosides, the so-called gangliosides 
complexes, instead of to single gangliosides.17-33 Recognition of the fine specificity of these 
antibodies is relevant because of the distinct association between the antibody specificity 
and defined clinical subgroups in GBS and MMN.1 Pure ganglioside preparations are 
therefore essential to determine antibody specificities, including ganglioside complexes, 
especially when techniques like ELISA and arrays are used.  
 In the current study antibodies were detected by ELISAs using synthetic GM1 
analogues with the same terminal pentasaccharide as in the natural GM1. These synthetic 
mono- and divalent GM1 mimics contained one or two of these carbohydrate moieties. By 
way of comparison of the performance of the mono- and divalent GM1 analogues, a primary 
assessment of the role of multivalency in antibody binding could be made. For the 
attachment of the ganglioside analogues, the ELISA plates designed for the attachment of 
proteins were used successfully. Since this worked unproblematically, this indicates a 
broader scope for the application of these plates, in particular, the possibility to attach 
smaller molecules.  The current experimental data even show that multistep chemical 
transformations are compatible with low-noise ELISAs. Thus, the attachment of the azide-
terminated GM1 analogue 1 required a two-step process with application of a copper salt at 
the second step. Performing this reaction sequence did not result in any loss of performance 
of the ELISA plates. 
Importantly, the synthetic GM1 analogues were completely pure individual compounds. 
Binding studies with cholera toxin and specific mouse and human monoclonal antibodies to 
GM1 demonstrated that the targets for antibody binding in the test systems were preserved. 
Moreover, the cholera toxin B subunit showed considerably stronger binding to the synthetic 
gangliosides than to bovine GM1, which implies that the synthetic ganglioside-based ELISA 
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would be a much more sensitive tool for the detection of cholera toxin. The sensitivity of the 
ELISA with synthetic GM1 mimics to detect the presence of monoclonal antibodies was in 
general very similar to that of the routine ELISA using the bovine GM1 preparation. Mouse 
and human control monoclonals showed no binding, excluding the possibility of aspecific 
binding. These results delivered a proof of principle that synthetic GM1 mimics can be used 
as a sensitive and specific target to demonstrate anti-ganglioside antibodies by ELISA.  
 Next we aimed to detect anti-GM1 antibodies in serum from patients with immune-
mediated neuropathies using the mono- and divalent synthetic GM1 analogues and 
compared the results to those using the bovine GM1. Serum IgM antibodies were tested in 
healthy controls, MMN and monoclonal gammopathy patients, and serum IgG antibodies in 
healthy controls and acute stage GBS patients. A high correlation between the serum IgM 
and IgG activity to the synthetic GM1 mimics and to the native bovine GM1 was found. This 
correlation was demonstrated by Spearman rank correlation calculations, which 
unequivocally show a correlation between antibody activities to bovine GM1 and 1 
(Spearman’s  = 0.75; P = 2 x 10-7). The ELISA with the synthetic GM1 mimic demonstrated 
IgM antibody activity in the majority of MMN patients and IgG activity in the majority of GBS 
patients, while the healthy controls were usually negative. These data show the potential of 
these synthetic GM1 mimics to be used in ELISA to detect IgM and IgG antibodies in serum 
from patients with both MMN and GBS. It seems that the application for this purpose of a 
dimeric GM1 analogue with two identical carbohydrate units is not really beneficial over the 
monomeric one. Thus, the mono- and divalent GM1 mimics showed highly comparable 
results (Figure 6.4), indicating that the divalency does not improve the detection system for 
patient sera. This may indicate that multivalency is of little to no importance in the antibody 
binding, i.e. binding of serum anti-GM1 antibodies does not depend on the presence of 
multivalent targets, or that the density of the monovalent GM1 mimics on the surface is 
sufficient to provide multivalent interactions. 
Although the results with the ELISAs with bovine GM1 preparation and synthetic 
ganglioside mimics were highly correlated, a significant difference in the assay outcomes of 
natural and synthetic GM1 is the scatter of the data observed for the synthetic GM1s. This is 
most clearly seen for the negative controls, which are expected to give a result close to zero 
for all 5 data points from healthy patients, but this is only seen for the bovine-derived GM1 
assay. This is not caused by experimental scatter (“noise”), as e.g. plots of the responses of 
the synthetic GM1’s 1 and 2 display a correlation with little noise (Figure 6.4). Apparently, 
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aspecific interactions are present in the assays with synthetic GM1s, which would hamper 
accurate quantification of the antibody concentration in sera. 
For the sera from patients, to this undesired scatter also a positive aspect needs to be 
considered, as the scatter here can partly be explained by the manner in which the samples 
were selected for this study. Thus, for the comparison of the routine and modified ELISAs, 
sera samples were chosen that previously not only tested positive in the traditional ELISA, 
but also showed d-OD values close to the experimentally found maximum of 1.3. As a result 
of the highly desirable higher dynamic range of the synthetic GM1-based tests, the plateau 
corresponding to the binding saturation therein is reflected in higher d-OD values than those 
in the routine ELISA, and thus the differences in activities of the antibodies with high 
affinities can be observed better. This, of course, may give rise to observed variations (with 
d-OD sometimes significantly > 1.3) with the synthetic GM1 for cases where bovine GM1 
gives a near-constant response. 
A subgroup of MMN and GBS patients was clearly positive only for reactivity to the 
bovine GM1 preparation (Figure 6.3), giving remarkably low signals in the synthetic GM1-
based assays. This subgroup with serum reactivity preferentially to bovine GM1, consisted of 
a heterogeneous group of patients with MMN or GBS with various preceding infections, 
clinical features and outcome and titers to bovine GM1. This subgroup did not differ 
significantly from the other MMN and GBS patients regarding these features. Interpretation 
of this finding is hampered by the absence of a golden standard for the detection of anti-
GM1 antibodies. Previous results with other techniques12-16 have shown that the binding of 
anti-GM1 antibodies is highly influenced by the type of ELISA plates, presence of Tween, 
temperature and other test characteristics. In addition, cross-reactivity of these antibodies 
with other gangliosides (possibly present as contaminants) may also yield positive results for 
the bovine-derived GM1 that are absent in pure, synthetic GM1 derivatives. Further studies 
with application of a 100% pure natural GM1 in ELISA (which in our view may become a 
golden standard) are needed to clarify this situation.  
The synthetic GM1 ELISA may be less sensitive than the bovine GM1 ELISA for 
detecting serum antibodies in these particular cases, e.g. because the random orientation of 
the glycan part of non-covalently attached bovine GM1 sugars and their flexibility in a rather 
disorganized layer may allow orientations that are optimally suited to interact with an 
(comparatively large) antibody (see Figure 6.5A for a simplified depiction of this hypothesis). 
In comparison, the better ordered layer of covalently attached GM1 may in fact be packed 
too densely, which diminishes the orientations with which the oligosaccharide part may 
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present itself to the antibody, and thereby making the oligosaccharide moiety topologically
less available for the antibody binding (Figure 6.5B).
Figue 6.5. Tentative schematic representation for the observed sensitivity differences between non-
covalently attached bovine GM1 and covalently attached synthetic GM1. The flexibility of positioning
of the non-covalently adsorbed GM1 (A) allows for interaction with a more sterically demanding
antibody, which can not access the binding targets of GM1 in a well-ordered layer (B).
Alternatively, the antibodies binding to the bovine GM1 preparation may partly bind to
contaminants or to complexes21, 27, 29, 31, 32 between GM1 and these contaminants. The higher
dynamic range of synthetic GM1 – as was observed for mouse antibody DG-1 (see Figure
6.2a) – could actually point to differences in affinities of different antibodies that do not
clearly show up in the current ELISAs due to their limited dynamic range. Clearly, while
these data show a proof of principle, more research is needed to minimize the aspecific
response and to determine the value of the synthetic GM1 mimics in clinical practice.
Although the direct response of the synthetic GM1-based ELISA test is lower in the case of
several serum samples, availability of completely pure ganglioside analogues allows the
controlled formation of a stable layer of the covalently bound antigen, which is attractive for
the investigation of the fine specificity of antibodies to both individual gangliosides and
ganglioside complexes. Future studies with GM1 derivatives need to be directed to variation
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of the spacers (length and polarity) between the substrate and the oligosaccharide moiety 
and, and to the density of GM1 molecules on the surface.  With tailor-made syntheses both 
can, in principle, be controlled to a very high degree. This could enhance a major advantage 
of using the synthetic GM1 mimics compared to bovine-derived products, namely the highly 
defined circumstances under which the antibody binding can be studied.   
 
6.4 Conclusions 
We have successfully performed the covalent attachment of mono- and divalent GM1 
analogues onto Nunc Immobilizer™ Amino ELISA plates. Thus obtained diagnostic tools 
have shown strong affinities to the cholera toxin B subunit and monoclonal mouse and 
human anti-GM1 antibodies. Detection of the anti-GM1 IgG and IgM antibodies in sera from 
neuropathy patients demonstrated that natural GM1 and synthetic mimics bind analogously 
to these antibodies, which shows the potential of the synthetic GM1 analogues in practical 
anti-GM1 antibody detection. The main differences are the increased scatter observed with 
these synthetic analogues, and the higher dynamic range obtainable with these synthetic 
sugars. These differences in binding behavior between natural and synthetic 
oligosaccharides show the necessity of more detailed studies. In general, these proof-of-
principle experiments reveal the potential to obtain selective and sensitive diagnostics based 
on synthetic ganglioside mimics, and to provide a valuable alternative to the currently used 
methods. 
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6.5 Experimental 
 
6.5.1 General Information 
Nunc Immobilizer™ Amino 96-well ELISA plates were used for the coatings with 
synthetic GM1 analogues. The ganglioside GM1 was obtained from Sigma and coated on 
the 96-well Nunc MaxiSorp™ ELISA plates as previously described.2, 15 The ganglioside 
analogues 1 and 2 were synthesized during the design of inhibitors of cholera toxin.38, 41 
6.5.2 Human serum samples 
Human serum samples were obtained from patients with acute and chronic 
neuropathies, and controls. The study included patients with GBS (n = 15), MMN (n = 15), 
monoclonal gammopathy and polyneuropathy (n = 3), and healthy controls (n= 5). 
6.5.3 Attachment of the monovalent GM1 analogue onto ELISA plate 
To the wells of a Nunc Immobilizer Amino ELISA plate, a 10 mM solution of 
propargylamine in 0.1 M sodium carbonate buffer (pH 9) was added (200 µl per well). The 
plate was incubated at room temperature for 4 hours with shaking. The solution was 
discarded by flicking and the wells were washed 3 times with water (each time 400 µl per 
well). After that, the following solutions were added to each well in the following order: 6 µM 
solution of copper (II) sulfate in water (50 µl per well),  3 µM solution of the ganglioside 
analogue 1 in water (100 µl per well), 12 µM solution of sodium ascorbate in water (50 µl per 
well). The plate was incubated overnight at room temperature with shaking. The wells were 
emptied by flicking and washed 3 times with water (each time 400 µl per well). 
 
6.5.4 Attachment of the divalent GM1 analogue onto ELISA plate 
To the wells of a Nunc Immobilizer Amino ELISA plate, 0.75 µM solution of the 
ganglioside analogue 2 in 0.1 M sodium carbonate buffer (pH 9) was added (200 µl per 
well). The plate was incubated overnight at room temperature with shaking. The wells were 
emptied by flicking and washed 3 times with water (each time 400 µl per well). 
6.5.5 Enzyme-Linked Immunosorbent Assay (ELISA) 
Serum IgM and IgG anti-GM1 ganglioside antibodies were determined by ELISA 
according to the method previously described2 and standardized by the INCAT group.15, 16 
To determine anti-GM1 reactivity, the mean difference of optical densities (d-OD) of two 
GM1-coated wells and two reference wells were used. 
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CHAPTER 7
Antithesis. Synthesis.
Abstract – This chapter gives a summary of the research results described in chapters 2-6
through the prism of their place in contemporary science. “Antithesis” denotes the main body
of work done in the research field to which our own results belong. “Synthesis” is meant to
show that the results obtained within the framework of this thesis are coherent with the
current goals in this research field, strengthen these and provide a basis for further studies
beyond the scope of this dissertation.
"It was the best of times, it was the worst of
times, it was the age of wisdom, it was the age
of foolishness, it was the epoch of belief, it was
the epoch of incredulity, it was the season of
Light, it was the season of Darkness, it was the
spring of hope, it was the winter of despair, we
had everything before us, we had nothing before
us, we were all going direct to Heaven, we were
all going direct the other way."
(Charles Dickens, A Tale of Two Cities)
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7.1 Introduction
The interaction of chemistry and biology offers new dimensions to the research field of
carbohydrates in general, and gangliosides in particular. The constantly growing
understanding of the biological role and significance of gangliosides determines the
increasing demand in having these compounds available, both in the authentic form and as
(a part of) modified structures. The complications associated with the chemical synthesis of
gangliosides impede the biological investigations thereof.  This, at the same time, provides a
significant motive for the development of new strategies that would allow to overcome these
challenges. Indeed, in the last two decades great progress has been made in the chemistry
of glycolipid synthesis, which makes almost any compound of almost any structural
complexity potentially available synthetically. Such an availability of gangliosides and
especially of structural analogues thereof initiates, in its turn, an even wider interest for
biological studies and applications. And of course, the achievements in the synthesis of
carbohydrates would not be full-fledged without the input from so-called nature-inspired
approaches, viz. enzymatic methods that are considered nowadays as much a part of the
oligosaccharide construction toolbox as chemical glycosylations.
Figure 7.1 The gangliosides through a schematic representation of interdisciplinary interactions. ,
, Δ and  represent sugar moieties added to an oligosaccharide synthetically,  denotes a moiety
by which the synthetic sugar can be used for various manipulations.
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The general principles of the interdisciplinary interactions of chemistry, biology and
chemical biology, schematically depicted in Figure 7.1, are in full measure applicable to
gangliosides, and, as a consequence, to the research presented in this thesis.
7.2 Chemical Solutions of Chemical Problems: Glycosylation Reactions for
the Synthesis of Asialo-Gangliosides and NMR Analysis of Ganglioside Mimics
7.2.1 Thesis
In Chapter 2, we addressed the challenge of glycosylations of the fatty alcohols by
lactose donors. Our endeavours resulted in the presentation of 1-O-pivaloyl saccharides as
promising glycosyl donors that can be simply activated by a Lewis acid. We also developed
a convenient procedure for the direct high-yield glycosylation of ω-functionalized alcohols via
the use of the perpivaloylated donors that in addition possess the highly desired β-directing
properties due to the presence of an acyl group at the C-2 position. Application of such a
donor in the case of lactose is especially beneficial, as considerably higher yields were
obtained compared to earlier reported syntheses of analogous lactosides.
Chapter 2 also describes the comparison of trichloroacetimidate galactosamine donors
bearing two different N-protection groups in the glycosylation of 4´-OH lactose acceptors.
This reaction provides the oligosaccharide backbone of the asialo-GM2 ganglioside. By
combining the trichloroethoxycarbonyl protection of the amino group of galactosamine with
the trichloroacetimidate donor approach, we were able to achieve higher than previously
published yields of asialo-GM2 derivatives.
A strategy for a full assignment of all 1H and 13C chemical shifts in the 900 MHz NMR
spectra of the gangliosides GM3, GM2 and GM1 is presented in Chapter 3 by the example
of undec-10-enyl glycosides of these gangliosides. The approach described therein will also
allow the full assignment of the sugar moieties of other (naturally occurring) glycolipids.
7.2.2 Antithesis
The application of the protection of sugar alcohol moieties by the pivaloyl group instead
of the acetyl group at the C-2 position of glycosyl donors was pioneered by Kunz in 1982.1 It
has been shown that the use of 2,3,4,6-tetra-O-pivaloyl-α-D-glucopyranosyl bromide in the
Koenigs-Knorr glycosylations of benzyl alcohol and cholesterol avoids the (undesired)
formation of orthoesters, which often complicate the glycosylations starting from the
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analogous tetraacetate. The results of glycosylations with these two donors were compared
and the reason for the suppression of formation of an orthoester was proposed. Since then,
the application of glycosyl donors derived from the perpivaloylated sugars became
ubiquitous; the most recent examples include syntheses of Gb3 and iGb3 glycosphingolipids
using the perpivaloylated 1-O-trichloroacetimidate donors for the glycosylation of ceramide
at the key steps.2 The activation of pentapivaloyl galactose by SnCl4 towards reaction with
trimethylsilyl azide with the formation of 1-azido-1-deoxy-2,3,4,6-tetrapivaloyl galactose, was
also described.3
7.2.3 Synthesis
Confronted by the enormous amount of effective, creative and efficient glycosylation
methods emerged in last decades,4-6 one may have an impression that oligosaccharide
chemistry has already had its peak, that it is either easy or done. However, the potential for
both small and great discoveries in this area is high and will not cease in near future, as do
not cease the efforts of glycochemists to develop a general method that would be applicable
to a selective formation of all and any of the glycosidic linkages needed. In this thesis, the
perpivaloylated sugars were used not as precursors for the effective glycosyl donors, but
instead were applied themselves as glycosyl donors, thus combining the well-known
advantages of the stereodirecting effect of the pivaloyl group1 with the challenge of the
activation of a 1-O-pivaloyl donor towards reactions with O-nucleophiles. This combination is
promising, as shown in Chapter 2, and further exploitation of anomeric pivalates as glycosyl
donors is worth to be explored.
7.3 Biological Tools in Organic Chemistry
7.3.1 Thesis
Chapters 3 and 4 describe the use of recombinant glycosyltransferases from
Campylobacter jejuni in an efficient chemo-enzymatic synthesis of ω-functionalized alkyl
glycoside analogues of human gangliosides.  These analogues are of interest to be attached
onto solid and soluble scaffolds for sensing and/or diagnostics purposes. The chosen
synthetic route (Figure 7.2) involves consecutive enzymatic glycosylations of chemically
synthesized undec-10-enyl, undec-10-ynyl, 11-azidoundecyl (Chapter 3) and N-biotin-
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appended 8-aminooctyl (Chapter 4) lactosides. The mentioned lactosides are poorly soluble
in water, and the reactions were performed in water-methanol media.
Figure 7.2 Chemo-enzymatic synthesis of ganglioside mimics (Chapters 3 and 4).
In this manner, analogues of gangliosides GM3, GM2, and GM1 with authentic
oligosaccharide moieties and any of the four mentioned aglycones were obtained in high
yields. For the biotin-appended gangliosides, the series was extended to analogues of
gangliosides GD1a and GalNAc-GD1a.
7.3.2 Antithesis
A number of chemoenzymatic strategies using bacterial glycosyltransferases has been
described for the synthesis of a variety of biologically relevant sialyl oligosaccharides7-13 and
the applications of glycosyltransferases have been reviewed.14 The use of an enzyme
outwits the necessity of elaborate protecting groups manipulations. This is particularly
important for the preparation of sialylated oligosaccharide structures, primarily due to
synthetic limitations imposed by the properties of the glycosidic linkage involving sialic
acid.15 Indeed, the methods using sialyltransferases are superior to any chemical sialylation
technique. Thus, methods for the efficient synthesis of 2-azidoethyl glycosides
corresponding to the oligosaccharides of GD3, GT3, GM2, GD2, GT2, GM1 and GD1a were
developed using the glycosyltransferases from C. jejuni.16
CHAPTER 7
118
7.3.3 Synthesis
The success of an enzyme application in preparative organic synthesis depends inter
alia on the substrate specificity of the enzyme and on the conditions under which the
operation of an enzyme is possible. Therefore, both of these aspects require exploration in
terms of broadening the scope. This thesis describes the (a priori unlikely!) successful
application of the known glycosyltransferases from C. jejuni in water-methanol media, with
as much as 25% methanol in the reactions involving sialyltransferases. Incorporated in the
on-going research on glycosyltransferases, this extension to methanol/water mixtures will
simplify the synthesis of a wide variety of oligosaccharides that are of interest to be attached
onto solid substrates for sensing and/or diagnostics purposes.  It also provides another
example of how organic and biological chemistry can be merged to reach a goal
unattainable without this multidisciplinairy approach.
7.4 Organic Chemistry for Biology: functionalization of solid and soluble
scaffolds
7.4.1 Thesis
Synthesized ganglioside analogues (vide supra) were applied for the modification of a
number of scaffolds, both soluble and solid-phase. Thus, Chapter 5 presents the synthesis
of multivalent GM1 (see Figure 7.3 for an example) and GM2 analogues for solution-based
inhibition of bacterial toxins and antiganglioside antibodies. These glycodendrimers were
obtained via the “click” reaction of corresponding 11-azidoundecyl glycosides with alkyne-
terminated dendritic scaffolds that contain long spacer arms. Di-, tetra- and octa- GM2 and
di-, tetra- and octa- GM1 substituted compounds were obtained in good yields and purity and
fully characterized.  These dendrimeric gangliosides proved to be a very valuable tool to
study multivalency effects (see chapter 5 and section 7.5 below).
GENERAL DISCUSSION
119
Figure 7.3 Tetravalent GM1 analogue (Chapter 5): a very strong inhibitor of cholera toxin.
Functionalization of the surfaces of various ELISA plates was the next step in the
application of our ganglioside mimics. Here we made use of three different approaches.
Thus, 11-undecenyl glycosides of GM3 GM2 and GM1 were attached onto classical
polystyrene plates by means of non-covalent adsorption (Chapter 3). The phenomenon of
biotin-avidin affinity interactions made for successful attachment of the biotin-appended GM1
analogue onto streptavidine-coated plates (Chapter 4). Finally, as described in Chapter 6,
Immobilizer AminoTM plates – which are specifically designed for covalent, amine-linked
attachment of peptides and proteins – were  subject to a two-step modification: attachment
of propargylamine followed by modification of the thus obtained alkyne-terminated surface
by 11-azidoundecyl GM1 via the copper-catalyzed “click” reaction. All three approaches
(physisorption, biotin-avidin directed and ‘clicked’) lead to formation of GM1-modified
surfaces that showed good sensitivity and selectivity in detecting detrimental proteins (vide
infra).
7.4.2 Antithesis
The variety of scaffolds to which bio-molecules can be attached grows constantly. In
recent years, nanoparticles have become the subject of increasing attention of scientists, as
they are full of promises for electronic, optical, and (bio)medical applications. Among the
biomolecules to functionalize nanoparticles, carbohydrates are not an exception, and since
the first report in 2001,17 the interest in glyconanoparticles is continuously rising.18-23 The
CHAPTER 7
120
overwhelming majority is formed by gold glyconanoparticles,21 although biocompatible
magnetic iron nanoparticles24 and fluorescent nanoparticles prepared by
photopolymerization of the vesicles of diacetylene-containing glycolipids25 are also well-
known. Recently, a non-covalent functionalization of carbon nano-tubes with glycosides has
been reported.26
7.4.3 Synthesis
While the number and variation of surfaces for biomedical application are constantly
growing and developing, the amount of applicable glycans that are both biologically active
and suitable for attachments is still limited. The ganglioside analogues presented in this
thesis have been shown to be hihgly suitable for non-covalent (Chapter 3), affinity-based
(Chapter 4) or covalent (Chapter 6) attachments on various types of surfaces without loosing
their biological properties upon attachment. The integration of the results presented here
with the advantages of known and developing (like silicon nanoparticles27) active surface
investigations will likely lead to new achievements in the field of biosensing.
7.5 Organic Chemistry for Biology: Ganglioside Analogues for (Bio)medical
applications
7.5.1 Thesis
The multivalent GM1 and GM2 analogues were evaluated as cholera toxin inhibitors
(Chapter 5). In these inhibition studies, conducted with cholera toxin B-subunit, the
ganglioside dendrimers showed unprecedentedly large multivalency effects. Thus, the tetra-
and octa-GM1- substituted dendrimers are 80 000 and  380 000 times stronger, respectively,
as binding ligands for the toxin than a monovalent GM1 derivative. In addition, as also
described in Chapter 5, the tetravalent GM1 analogue showed specific and strong inhibition
of anti-GM1 antibodies in sera from neuropathy patients.
The diagnostic tools obtained by the attachment of GM1 analogues onto various ELISA
plates were tested in binding toxins, viz. the B subunit of Escherichia coli heat-labile
enterotoxin (LT-B, Chapters 3 and 4) and the B subunit of Vibrio cholerae toxin (CT-B,
Chapter 6), as well as the anti-GM1 antibodies, both monoclonal (Chapters 3 and 6) and
from the sera of neuropathy patients (Chapter 6). The binding studies described in Chapters
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3, 4 and 6 reveal that a synthetic GM1 analogue attached onto an appropriately modified
ELISA plate surpasses the natural bovine GM1 in the detection of the toxins.
The sensitivity of the ELISAs with synthetic GM1 mimics to detect the presence of
monoclonal antibodies (see Chapter 3 for a single instance and Chapter 6 for a detailed
study) was in general very similar to that of the routine ELISA using the bovine GM1
preparation, and the specificity of the synthetic GM1-based assays was demonstrated.
A third evaluation of the synthetic GM1 mimics was provided via the detection of anti-
GM1 antibodies in sera from neuropathy patients. For such an evaluation, the binding
characteristics of both IgG and IgM antibodies in sera samples from patients with Guillain-
Barré Syndrome (GBS, n = 15), multifocal motor neuropathy (MMN, n = 15) and monoclonal
gammopathy and polyneuropathy (n = 3) were studied. Results described in Chapter 6
demonstrate the strong correlation between the affinity of these antibodies towards natural
GM1 and to the synthetic analogues. These proof-of-principle experiments reveal the
potential to obtain selective and sensitive diagnostics based on synthetic ganglioside
mimics, and to provide a valuable alternative to the currently used methods.
7.5.2 Antithesis
Recently, a range of synthetic GM1 mimics, in which the oligosaccharide part was
modified to make them more straightforward to be chemically synthesized,28, 29 was
examined in binding to anti-GM1 GBS-related antibodies.30 In both solution inhibition and
immunoadsorption studies the naturally derived GM1 pentasaccharide (GM1 lacking the
ceramide tail) was found to be greatly superior to the investigated mimics.30
An automated glycoarray-based combinatorial system for the analysis of interactions of
proteins with ganglioside complexes has been recently proposed.31 This array can be probed
with much smaller quantities of reagents than would be required using existing techniques
such as ELISA and thin-layer chromatography with immuno-overlay.32
7.5.3 Synthesis
The interest in and demand for mimics of gangliosides for various medical applications
related to diagnostics and cure of neuropathies, is high. Thus, the prospect of the use of
ganglioside mimics as soluble inhibitors of antiganglioside antibodies in therapy may arise
from detailed in vitro solution-inhibition studies of these mimics. The results shown in
Chapter 5 for the inhibitions with the tetravalent GM1 analogue are a significant step forward
in these studies, as compared to e.g. the results reported by Willison et. al.30 of in vitro
CHAPTER 7
122
antibody inhibition by other types of GM1 mimics. Application of GM1 analogues of other
valencies may further improve on the strength of such inhibition.
Another potential therapeutic use of the GM1 analogues is their application in
extracorporeal immunoadsorption. Such a strategy has been successfully applied for
carbohydrate antigens that mediate transplant rejection.33-35 The ganglioside mimics
described in this thesis may form a basis for the development of an analogous approach for
the cure of neuropathies. Thus, we have shown that these compounds can be covalently
attached to various solid supports and preserve upon attachment the specificity and high
affinity of the binding to anti-GM1 antibodies and toxins. Moreover, in all the studied cases
for the detection or inhibition of cholera toxin and related heat-labile E.coli  toxin, our
synthetic GM1 analogues have revealed unprecedented affinities, and without exception
were significantly better that the natural GM1.
Similarly, new diagnostic tools, like e.g. high throughput microarrays and multiplex
Luminex36 diagnostics may use the advantages of the ganglioside analogues presented
here. In fact, studies on the modification of Luminex beads with the azido-terminated GM1
analogue and application of the resulting diagnostic tool are underway.
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Summary
The development of high-affinity mimics of carbohydrates associated with important
recognition events has attracted a great deal of attention as a way to develop therapeutic
agents with good stability and synthetic availability. Particular interest is focused on
gangliosides, a subclass of glycosphingolipids that all contain one or more sialic acid
residues but vary in other parts, such as the number of ring structures and overall
composition. Gangliosides are present in all mammalian cells, and are particularly abundant
in neuronal tissues. They are a.o. important targets for auto-antibodies causing immune-
mediated forms of polyneuropathy and for bacterial toxins that cause gastro-enteritis
including cholera and travellers diarrhoea. For example, Vibrio cholerae toxin binds with high
affinity to GM1-ganglioside, whereas Escherichia coli heat-labile enterotoxin, apart from
binding to GM1, also binds (though to a lesser extent) to GM2 and other glycolipid receptors.
This thesis describes the synthesis of analogues of human gangliosides and applications
thereof for the detection and inhibition of bacterial toxins and antibodies. An efficient
glycosylation method was developed for the synthesis of ω-functionalized alkyl lactosides
(Chapter 2). These lactosides were further used as starting compounds in chemo-enzymatic
syntheses of analogues of human gangliosides GM3, GM2, GM1, GD1a and GalNAc-GD1a
(Chapters 3 and 4). In addition, divalent, tetravalent and octavalent GM2 and GM1
gangliosides were obtained (Chapter 5). A complete NMR characterization of the
synthesized compounds was performed (Chapter 3).
The potential of these ganglioside mimics to detect toxins and antibodies was shown in a
variety of diagnostic tests:
- in inhibition studies of the synthesized oligosaccharide-linked dendrimers with the
cholera toxin B-subunit (Chapter 5) unprecedentedly large multivalency effects were
observed: the tetra- and octa- GM1-substituted dendrimers are, respectively, 80 000 and
380 000 times stronger than a monovalent GM1 derivative as binding ligands for the toxin;
- in various modified ELISAs the synthetic ganglioside analogues were used to modify
the plates (Chapters 3, 4 and 6) and thus tested for their performance in the detection of the
cholera toxin B-subunit and the B subunit of E. coli heat-labile enterotoxin;
- for the detection of IgG and IgM antibodies in serum samples from neuropathy patients
by the covalently attached ganglioside analogues a proof of principle was demonstrated
(Chapter 6).
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Synthetische analogen van gangliosiden voor nauwkeurige biosensing:
verbeterde detectie moleculen voor antilichamen en bacteriële toxinen
(Samenvatting)
De ontwikkeling van synthetische koolhydraatanalogen met een hoge affiniteit die
betrokken zijn bij belangrijke biologische herkenningsprocessen heeft veel aandacht
gekregen als methode om medicijnen te ontwikkelen met een goede stabiliteit en
synthetische beschikbaarheid. De focus ligt met name op gangliosiden, een subklasse van
glycosfingolipiden die alle één of meer siaalzuurgroepen bevatten maar kunnen variëren in
het aantal suiker units en de algehele samenstelling. Gangliosiden zijn aanwezig in alle
zoogdiercellen en voornamelijk in zenuwweefsel. Het zijn o.a. belangrijke aangrijpingpunten
voor auto-antilichamen die immuun-gemedieerde vormen van polyneuropathie veroorzaken
en voor bacteriële toxinen die buikgriep veroorzaken zoals cholera en reizigersdiarree.
Bijvoorbeeld, het Vibrio cholerae toxine bindt met hoge affiniteit aan het GM1-ganglioside,
terwijl het hittelabiele Escherichia coli enterotoxine, behalve aan GM1 ook aan GM2 (hoewel
in minder mate) en andere glycolipidereceptoren bindt.
Dit proefschrift beschrijft de synthese van analogen van menselijke gangliosiden en
toepassingen daarvan voor de detectie en remming van bacteriële toxinen en antilichamen.
Er werd een efficiënte glycosyleringsmethode ontwikkeld voor de synthese van ω-
gefunctionaliseerde alkyllactosiden (Hoofdstuk 2). Deze lactosiden werden verder gebruikt
als uitgangsstof in chemo-enzymatische synthesen van analogen van de menselijke
gangliosiden GM3, GM2, GM1, GalNAc-GD1a (Hoofdstukken 3 en 4). Bovendien werden
ook divalente, tetravalente en octavalente GM2 en GM1 gangliosiden gesynthetiseerd
(Hoofdstuk 5). Tevens werd een volledige NMR-karakterisering van de synthetische
verbindingen uitgevoerd (Hoofdstuk 3).
Het potentieel van deze synthetische ganglioside-analogen om toxinen en antilichamen
te detecteren werd aangetoond in verschillende diagnostische tests:
- in remmingsstudies werden voor de gesynthetiseerde oligosaccharide-gekoppelde
dendrimeren met de B-subunit van het choleratoxine (Hoofdstuk 5) aanzienlijk grote
multivalente effecten waargenomen: tetra- en octa- GM1-gesubstitueerde dendrimeren
bleken, respectievelijk, 80 000 en 380 000 keer sterkere bindingsliganden voor het toxine
dan een monovalent GM1 derivaat;
- in diverse gemodificeerde ELISAs werden de synthetische ganglioside analogen
gebruikt om de ELISA platen te modificeren (Hoofdstukken 3, 4 en 6) en aldus getest op hun
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bruikbaarheid in de detectie van de B-subunit van het choleratoxine en de B-subunit van het
hittelabiele Escherichia coli enterotoxine;
- voor de detectie van IgG en IgM antilichamen in serummonsters van
neuropathiepatiënten door de covalent gebonden ganglioside-analogen werd een ‘proof of
principle’ verkregen (Hoofdstuk 6).
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